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Abstract 
Multiple sclerosis (MS) is the most common autoimmune inflammatory demyelinating 
disorder of the human nervous system affecting nearly 1 million people worldwide every 
year. Current treatments for first-line nontoxic therapy of the relapsing-remitting form of 
the disease are two forms of recombinant IFN(3, Ia and 1(3 andglatiramèr acetate. The 
pathogenesis of MS is highlighted by an inflammatory response and myelin destruction. 
Several recent studies have reported alterations in immune variables such as cytokine 
concentrations, immune-related molecules such as MHC and adhesion molecules and 
chemokines; which may contribute to an imbalance between Thi and Th2 T cell-
mediated immune response. 
The aims of the present study were to characterize the cytokinetic profile of MS 
patients through investigating the secretion of the main pro and anti-inflammatory 
cytokines from peripheral blood mononuclear cells of MS patients compared to controls, 
and to investigate cytokine receptor expression levels in T and NK cells. In addition, the 
induction of apoptosis and the involvement of adhesion molecules and metalloproteinases 
in oligodendrocyte destruction are examined. Finally, the effect of IFN(3 treatment on 
cytokine secretion levels as well as on the aforementioned immunoregulatory molecules 
was evaluated. 
The study population consisted of 60 MS patients (20 untreated, 20 treated with 
IFNf3-lcz and 20 treated with IFN(3-1(3) in parallel with 25 controls. Serumlplasma 
samples and peripheral blood mononuclear cells (PBMCs) were isolated from each 
participant. Using the enzyme linked immunospot (ELISPOT) assay the numbers of 
cytokine-secreting PBMCs were measured for the following cytokines: IFN-y, TNF-a, 
IL- 12, IL- 10 and IL-4. The expression levels of the cytokine receptors IL- 1 2R(3 1, IFN-y, 
IL- 1 OR, TNFaR were estimated in the surface of lymphocytes using flow cytometry and 
serum levels of soluble CD95, ICAM- 1, VCAM-1, metalloproteinase-9 (MMP-9) and the 
tissue inhibitor, metalloproteinase-1 (TIMP-1) were evaluated in all samples. 
The ELISPOT assay proved a very sensitive and valuable tool for characterisation 
of the cytokine profile of MS patients. Decreased numbers of PBMCs secreting IL-b 0 and 
IL-4, and increased numbers of PBMCs secreting TNF-a, IL-12 and IFN-y were observed 
in MS patients compared to healthy controls. Treatment with IFN(3 elevated IL-IO and 
IL-4 levels, and decreased TNF-a, IL-12 and IFN-y levels in these patients. IFN(3/lci was 
more efficient in decreasing IL-12 secreting cells and IFN(3/1(3 in decreasing IFN-y, and 
TNF-a secreting cells and elevating IL-4 and IL- 10 secreting cells 
Increased expression of IL-12Rj31 and TNF-aR was observed in NK cells and decreased 
expression of WN-7R and IL-I OR was shown in T cells of MS patients compared to 
controls. IFNf3 therapy reduced IL-12R(3l levels in I and NK cells (IFNf3-la was more 
effective), and TNF-uR levels in I cells (IFNj3- 1(3 was more effective), but it increased 
IFN-1R and IL-1OR in T and NK cells of MS patients. 
Increased levels of the soluble CD95 apoptosis marker were observed in serum of MS 
patients compared to controls, which further increased after IFN(3 treatment (IFN(3-10 
was more efficient). 
Increased levels of soluble ICAM-1 and VCAM-1 were observed in serum of MS 
patients compared to controls, which were further increased after treatment with IFN(3 
(IFN-1a was more efficient in increasing sICAM-1 and IFNI3-113 in increasing sVCAM-
1 levels) 
Increased levels of MMP-9, decreased levels of TIMP- 1, and increased MMP-9ITIMP- I 
ratio was found in serum of MS patients compared to controls, and treatment with IFN 
decreased MMP-9 levels, increased TIMP-1 levels and decreased MMP-9/TIMP-1 levels 
ITCXTII 1.. 
	
4'P + tss i,p s a ,lvaS it"j*.. 
These results indicate an over expression of Thi type cytokines in MS accompanied by a 
concomitant suppression of Th2 type immune response as well as by alterations in the 
expression of cytokine receptors. A consequent activation of other immunoregulatory 
elements (sCD95, adhesion molecules, metalloproteinases) was also observed which was 
partly modified by IFNI3 treatment. 
This study provides important evidence on the role of cytokines and of other 
inflammatory molecules in MS pathogenesis and highlights possible mechanisms of 
action of IFNI3 treatment, offering new perspectives for novel, more efficient, diagnostic, 
and therapeutical approaches for the disease. 
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CHAPTER 1: INTRODUCTION 
1.1. General introduction 
Multiple sclerosis (MS) is the most common inflammatory demyelinating disorder of the 
human central nervous system (CNS), and the leading cause of non-traumatic 
neurological disability in young adults in Europe and North America. It affects nearly 1 
million people worldwide every year. Neurologic disability generally increases over the 
course of, the disease, which runs over a 10-20 year period (Kumar and Clark 2002). 
Thus, MS has a major personal and social impact on those afflicted with the illness 
(Gytten and Maseide 2006). 
.Unlike type-i diabetes which becomes clinically evident once the majority of islet cell 
damage has occurred, the initial presentation in MS occurs when there is reversible 
clinical disability and minimal nervous system damage (Phadke, 1990; Miller et al., 
2005). Thus the opportunity exists to prevent CNS damage and disability by early 
intervention, followed by more aggressive immunotherapy if the disease continues to be 
active. The future therapy for MS is to identify the exact mediators of inflammatory 
damage (like cytokines) investigate their cell signaling pathways and find compounds 
that can be given early in the course of the disease to allow an aggressive treatment. 
The present thesis focuses on the investigation of inflammatory cytokines associated with 
MS pathogenesis, aiming to identify their mechanisms of actions as well as their 
regulation in the peripheral tissues of MS patients. Furthermore, a specific cytokine 
(IFNf3) has been selected as a therapeutic modality for these patients at an early disease 
stage and its effects in the immunopathology of these patients are clearly presented. 
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1.2. Multiple sclerosis 
Multiple sclerosis has begun to be studied from the beginning of the 
	 century, but was 
established as a particular neurological disease by the famous French neurologist Charcot 
(1868), who systematized the clinical and pathological features and moreover proposed 
the first diagnostic tests (Charcot's "three"), by which the disease was separated from 
other diseases like hysteria and tabes (Compston et al., 1998). Since then, many 
investigators have studied its etiopathogenesis, which remains enigmatic and 
indeterminable. It is generally believed, that it is a disease of multifactorial etiology, and 
not a single disease. That is that what is described today as multiple sclerosis with aspects 
rare insome, and common, or more common in other patients. 
In multiple sclerosis, the white matter of the CNS is more often affected than the gray 
matter. The peripheral nerves and roots affected only in particular cases (Lublin and 
Reingold, 1996). 
The more typical features of the disease are: firstly, the disseminated development of 
demyelinated areas of the CNS, a fact which explains the great diversity of its clinical 
features, and secondly, it is a process of relapses, i.e. it shows characteristic exacerbations 
and remittances of the clinical features. Another characteristic feature of the disease is the 
apparent finding at necrotomies of a higher number of demyelinating areas than those 
shown clinically or in the laboratory (provoked dynamics, imaging methods). It is 
possible that those clinically silent areas are responsible for some of the inexplicable or 
unstudied symptoms of the disease, such as observed psychomental disorders, which will 
be described later (Keegan and Noseworthy, 2002). 
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1.2.1 Clinical features 
Multiple sclerosis as mentioned earlier is characterized by demyelinating lesions in the 
white matter of the CNS (the gray matter is rarely affected) and can be broadly defined 
clinically into relapsing/remitting and progressive forms. Although there are mixed 
patterns and two different classifications of the progressive disease, it is generally the 
progressive form that leads to disability (Hope et aL, 1993). Another distinction used in 
the . past by some authors according to the underlying symptomatology, defines the 
disease as MS of brain, MS of brain stem, MS of cerebellum, MS of cortex-spinal tract, 
MS of posterior columns. However, this classification is without practical importance, 
because in most cases with progressive time there is a mixture and a combination of the 
symptoms. Further classifications refer to 'disseminated' and 'spinal' forms according to 
disease characteristics. 
Different immunologic mechanisms may be linked to the different stages of the illness, 
and treatment may also differ depending on the stage of the disease. Most commonly, MS 
begins as a relapsing-remitting illness, with an average age of onset of 28-30 years. At 
this stage, the patient experiences discrete neurologic attacks, with full or partial recovery 
and lack of progression between relapses. The relapse rate tends to decline with time, 
with an average rate of 1.2-1.8 relapses per person/year at the first year from diagnosis, to 
0.8-1.0 in the 5" year and 0.5-0.9 in the l0 year (Rich et aL, 2001). 
A large percentage (at least half) of patients with the relapsing-remitting form, enter a 
stage in which the disease becomes progressive (secondary progressive stage). At this 
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time the clinical course is continuously progressive, with no or only occasional relapses. 
Another progressive form is termed primary progressive, in which there is continuous 
progression from the onset. The primary progressive form is different, pathologically and 
perhaps etiologically from the relapsing-remitting and secondary progressive forms. In 
10-15% of cases there is minimal accumulation of disability over a 10-15-year period, 
and the MS is classified as benign (Ramsaransing and de Keyser, 2006). In rare instances 
MS may be an acute fulminating illness or may present primarily as a cognitive disorder. 
The course of the disease is usually unpredictable. Sometimes the relapses follow 
infections, puerperium, trauma, stress, increase of the body temperature. After each 
relapse the 'disease leaves additional neurological damage and at the last stages, the 
patient remains in bed susceptible to respiratory or urinary infections (Hope et al., 1993; 
Rich et al., 2001). 
The clinical features of MS depend mainly on the site of the lesions in the CNS, and 
although there are no typical symptoms or signs related to the onset or the course of the 
disease, some regions tend to be more affected than others. These include the optical 
tract, the brain stem, the cerebellum, and the cortex - spinal tract and the posterior 
columns (Kumar and Clark, 2002). 
Optical disturbances are frequently associated with the disease, and include dazzling of 
vision, decrease or complete loss of vision (usually unilateral), and disturbances of the 
optical fields i.e. central scotoma and more rarely homonymous hemianopia. These 
disturbances are of acute or subacute onset, and the color conception declines earlier and 
more intensively. 
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The optic neuritis which is responsible for these signs is thought to be a common feature 
and a classic form of onset for MS (Cerovski et at, 2005). It involves an inflammation of 
the optical nerve accompanied by demyelination of the nervous fibres and swelling of 
tissues around the area. This is demonstrated clinically by the acute establishment of 
unilateral dazzling of vision and of pain within or behind the bulb caused by the eyes' 
motion. The vision of the affected eye decreases acutely and importantly, at the optic 
field appears central or paracentral scotoma, since the fundus of the eye appears normal 
at • 
 the funduscopesis. After few days the pain declines, and after 1-2 weeks vision begins 
to impréwe, and retuth to normal after few weeks (Merle et at, 2005; Mc Donald and 
Ron, 1999). When the area of demyelination develops at the head of the optical nerve, a 
swelling of the papilla occurs (mamillitis), which is distinguished from the swelling from 
posture of the endocranium hypertension, by its small graduation, and from the beginning 
of decreased vision. Optic neuritis in some people appears independently of MS, but in 
the majority of cases it's combined with the rest of the symptoms of MS. Since optic 
neuritis cannot be caused by anything other than MS, the etiology of MS in the patient 
has always to be investigated extensively (Swanton et al. 2006). 
Concerning the disturbances of the eye's pupil in MS, the more usual is irregularity of 
shape, and especially the irregular reaction of the pupil of the affected side in the 
photomotor reflex, called the Marcus Gunn reaction. 
Diplopia may be caused by one single nerve being affected but is often also caused by 
damage to the median elongated bundle, and in this case is caused by nuclear 
opthalmoplegia. Binuclear opthalrnoplegia is connected, in a great number of patients, to 
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MS, and especially double binuclear opthalmoplegia is believed to be an almost 
pathognomonical finding (Cerovski et al., 2005). 
Another common feature of the disease especially in women is the development of 
numbness in the legs, which extends to the buttocks and the perineum, perinatal 
insensibility and loss of the normal sense of uresis (Hope et al., 1993). These symptoms 
are retained for long, and because they often are not accompanied by motor disturbances 
or by important modification of the reflexes, they're underestimated. 
Paresthesia symptoms are usual and.persistent subjective disturbances, which appear in 
extensive or restricted areas of the body (i.e. - face hand firigers) and compromise 
numbness and pricking pains. The Lhermitte's sign also belongs to them and is 
demonstrated as a feeling of "electric evacuation" to the back or to the ends, during the 
passive or the active bending of the head of patients. It is attributed to an irritation of the 
posterior roots and columns of the neck, and is not an exclusive feature of MS. Motor 
disturbances involve the affection of the pyramidal way and of the cerebellum as well as 
other further connections. The effect on the pyramidal way is one of the more usual 
manifestations of the disease. Often onset appears as a development of weakness and 
motor disturbances, mainly in the form of monoparesis, paraparesis or hemiparesis. These 
weaknesses can sometimes be sudden and severe whilst others are mild, leading to 
diagnostic problems. At the late onset of the disease, weakness in most of the cases 
appears from the beginning, as a slowly establishing spastic paraplegia, which is 
combined to numbness or disturbances of the proprioceptional sensitivity and sphincter 
disturbances. These motor disturbances are caused by damage to the cortex-spinal 
pyramidal way and are expressed by the analogous symptomatology and semeiography. 
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The cerebellum is also often affected, resulting in dysarthria, walking ataxia, tremor at 
voluntary motions, asynergy, and nystagmous. Tremors from cerebellar cause may also 
appear in the head, giving a characteristic retrogression movement. Dysarthria is one of 
the characteristic features of the disease, expressed as "stumbled speech". As the disease 
progresses where pseudopromecic paralysis and dyskataposia coexist, the speech is also 
affected by the damage to the cortex-spinal pathway. Ataxia is a serious and common 
symptom for the progress of the patient. 
Disturbances of uresis during the onset or the progress of the disease, take the form of 
imperative uresis or urine loss. They are the result of defective or non-existent control of 
bladder function, and these symptoms must be distinguished from those attributed to 
urine infection or other local cause before an exact diagnosis of the disease is done. 
Sexual disturbances may be present in both sexes (incapability of erection or orgasm, 
libido loss) and may have an organic cause (Compston et at, 1998). 
The possible expressions from the cranial nerves compromise: effect on the V nerve, 
which is often accompanied by a neuralgic type pain, similar to that of idiopathic 
neuralgia, usually distinguished by the fact that MS patients are young and idiopathic 
neuralgia patients are old. 
Affection of the VII nerve is usually expressed as a paresis of central type myokymia or 
hemispasm, and finally vertigo which usually comes from around the IV ventricle, is 
usually intense, associated with vomiting and appears similar to posterior cranial 
depression syndrome (Racke et aL, 2004). 
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The variable symptoms of the disease sometimes appear together from the beginning so 
that the clinical status is integrated at once, whilst in other cases they may arise as 
distinguished incidents, consisting of one or more symptoms. One can say unreservedly, 
that MS, at least in the beginning may mimic any other neurological disease. 
The named seizure symptoms of MS (pain of the V nerve, dystonia attacks, paresthesias, 
myokymias or hemispasmus of the face, seizure dysarthria or ataxia), constitute a special 
group of brief, but especially painful symptoms. The most common of them are the pain 
of the V nerve and dystonia attacks, which appear like local tetanus and are induced 
automaticilly or by a voluntary motion (Nardocci et at, 1995). With regard to epileptic 
seizures, which according to some authors are classified in this group of symptoms, it 
should be noted that they are relatively rare, since in MS, white matter of the CNS is 
mainly affected. The pathogenesis of these seizures is not completely known, but is 
believed to be associated with the disturbed transmission in the demyelinated fibers 
(tangent transmission), or with the creation of ectopic irritations in partly demyelinated 
fibers (Nyquist et at, 2001; Poser and Brinar, 2003). 
During the initial stages of the disease, pychomental functions remain normal but during 
the progress of the disease, changes in emotion and disturbance to the superior 
intellectual functions (memory, attention, concentration, poverty of ideas) occur leading 
to intellectual decline (dementia) (Kumar and Clark, 2002; Hope et at, 1993; Feinstein, 
2006). The percentage in intellectual decline at the initial stages of the disease is low 
(2%), but at the end, may be as high as 50% (Leyhe et at, 2005). It is a form of 
subcortical dementia connected to the degree of affection of the interlobar and to the 
interruption of the connections of the reticulum system of the brain stem to the cortex, or 
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to the subcortical areas, or of the connections of the frontal lobe to the posterior cortex 
areas. 
Psychiatric disorders range from unimportant deviations in the patients behavior to the 
psychosis. Euphoria has been believed, for a long time, to be the most characteristic 
psychiatric disorder (Euphoria Sclerotica), and its occurrence ranges between 10-18% 
(Fishman et al., 2004; Papageorgiou et a/l, 1993). Cheerfulness and excessive optimism 
shown by the patients often are opposite to their serious physical disability, and laughter 
usually alternates with crying. Expression of emotional instability has an organic 
background and is aitributed to the deficient control of the pyramidal system at the 
mimetic muscles (pseudopromecic syndrome). 
Depression in MS appears usually as the reactive form, as well as sometimes psychotic 
(Gold and Irwin, 2006). It is more usual in the brain rather than the spinal form of the 
disease, and occurs with a frequency of about 18-20%. The incidence of suicide in these 
patients is high, and is an important reason for the development of a direct and systematic 
therapy. Bipolar emotional psychosis (depression-mania) is rare and schizophrenic-type 
symptoms are very rare. 
Finally, hysteric symptoms may coexist in MS patients usually as an excess or 
exaggeration of existing symptoms e.g. the patient's fingers become numb and he/she 
maintains that the whole hand is numb. It has, however, to be emphasized that after an 
increase in the patients' body temperature (hot bath, fever) some temporary symptoms 
may appear which are not hysteric (Uhthoff phenomenon, Guthrie and Nelson, 1995). 
21 
Prognosis is very difficult to accurately predict. However, the majority of patients follow 
the usual path, described earlier, and only a few have unimportant symptoms lifelong, or 
a very serious disability from the beginning. Proportional to pfogress and to the severity 
of development, the following forms of the disease may be distinguished: a) Benign: with 
mild and rare relapses, complete or almost complete restoration and little or no disability, 
20% of the patients. b) Relapsing-remitting form: with more often relapses at the start, 
imperfect restoration, long remitting periods but always with some degree of disability, 
25% of the patients. c) Chronic relapsing-remitting form: with less remitts and 
continously increasing disability. It concerns 40% of patients, and finally d) Chronic 
progressive form: with unclear onset, stable and progressive worsening of the symptoms, 
15% of patients. 
Today, life expectancy of the patient is significantly increased when compared to the 
past, because of better care. Death usually comes from co-existing non-controlled 
infections of the respiratory or of the urinary system, or from infection of wounds from 
bedlying, and rarely directly from the disease (Compston et al., 1998). 
Certain factors have been associated with a better prognosis. Most studies show that 
female gender, early age of onset (Tremlett and Devonshire, 2006), onset of a relapsing-
remitting course as opposed to a primary progressive course, complete recovery from the 
first attack, low frequency of attacks in the early course, and a long period of time to 
moderate disability is associated with a better outcome. In addition, the type of sign or 
symptom at the onset may have some predictive value, as patients with optic neuritis or 
sensory symptoms at onset have a better prognosis (Rich et at, 2001). 
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1.2.2 Diagnosis and laboratory findings 
Although there is no pathognómonic test for the disease, diagnosis is generally based on 
clinical presentation, examination of cerebrospinal fluid (CSF), performance of 
electrophysiological methods, and magnetic resonance imaging (MRI) examinations 
(Freedman etal., 2005; Hope et at, 1993; Kumar and Clark, 2002). 
The preference for demyelinating areas to develop in the brain's white matter around the 
veuitricles and area around the spinal tubemakes CSF cornpSition an important source of 
information for the underlying disease. Usually five parameters are measured in CSF 
samples; the number of the white cells is usually increased in CSF (more than 40 cells per 
mm3 in about 30% of the patients). This increase is taken as an index of the clinical 
activity of the disease, but the substantial importance of the test remains unclear, since it 
has not been elucidated which exact subgroup of leucocytes is increased in CSF during 
the relapse and for what reason (Rich et at, 2001). 
A mild increase in total protein concentration of CSF is found in about 40% of the 
patients. However, a large increase in protein concentration (much more than 100 mgr/ 
%) although not excluded, is not usual, and may create doubts about the appropriate 
diagnosis. 
IgG is often increased and consists of more than 25% of the total protein of CSF in 60-
80% of the patients. This percentage of IgG is much higher than the normal upper limit 
(12-16%). Smaller increases are observed in the first years and in the milder types of the 
disease, whereas higher values are present in more serious and chronic cases. Clinically, 
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it is believed that the estimation of the y-globulin index and not total percentage is more 
useful. 
This index is estimated from the ratio: 
y-globulin of CSF x serum albumin x CSF albumin [normal values less than 0.7] 
y-globulin of serum 
An increase in the y-globulin index, indicates an increased composition of IgG globulin 
in CNS, which can also occur in other inflammatory diseases of the CNS, in addition to 
MS. 
During the electrophoresis of nonnal CSF in agar, homogenous staining of IgG is 
observed. In most MS patients, a heterogeneous staining is observed which appears in the 
form of several zones, clearly separated, known as oligoclonal bands. These zones may 
appear even when the total y-globulin in CSF is not increased, and occurs in many 
patients with recent onset of the disease and mild symptoms (Rich et al., 2001). This is a 
most important point since it enforces the diagnosis of a clinical uncertain form of the 
disease. The oligoclonal bands of IgG are found in about 87% of patients with the 
progressive form of the disease and serious disability and in 73% of the patients with 
mild symptoms. In practice this indicates that most MS patients have IgG oligóclonal 
bands in the CSF. 
These quantitative and qualitative alterations to IgO globulin are not unique and specific 
to MS, since they are observed in many other diseases, such as acute and chronic diseases 
of the CNS and peripheral neuropathies, where the blood-brain barrier (BBB) is disrupted 
(Yenari el at, 2006; Sellner and Leib, 2006). 
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The estimation of myelin basic protein (MBP) and of its antibodies has been used by 
some investigators for the definition of identity and of clinical activity of the disease 
(Rauer et al., 2006). However, the false positive results found in other diseases have 
reduced initial optimism, so that this test has now ceased to be considered as specific for 
MS. 
Electrophysiological tests include provoked potentials, electroencephalography, and 
electronystagmography. 
The registration of provoked responses from the brain cortex by the use of optical, 
hearing, and somatosensory irritations has proved valuable in the discovery of clinical 
asymptomatic focuses (Persson and Sachs, 1978). Optical provoked potentials are a great 
help in clinically uncertain cases because they often reveal subclinical affects of the 
optical tract (2 1-83% depending on the form of the disease) (Sisto etal., 2005). Provoked 
potentials of hearing give less, but important, information for subclinical damage, 
especially for the brain stem whereas somatosensory provoked dynamics provide 
evidence for the existence of damage to the spinal cord (Lublin and Reingold, 1996). 
Electroencephalographic abnormalities are found in about 35% of patients with MS, 
especially in the acute phase of the disease but are rarer in the remitting phase. They are 
mainly of slow wave type and are believed to express a non- specific brain reaction to the 
pathologic process of the acute phase of the disease (Lublin and Reingold, 1996). 
Electronystagmography contributes to the better study of binuclear opthalmoplegia, of 
the divisioned nystagmous and for the investigation of vestibular function, peripheral or 
central, which is often affected in MS. It has been confirmed that proper 
electronystagmography testing contributes to the safer diagnosis of patients with only 
25 
spinal symptoms of the disease, as effectively as provoked dynamics (Lublin and 
Reingold, 1996; Papageorgiou et aL, 1993). 
The most valuable diagnostic aid for MS is magnetic resonance imaging (MRI), which is 
a very sensitive method for the identification of multiple white matter lesions in more 
than 90% of patients (Mills et aL, 2006; Racke et al., 2001; Stone et aL, 1995). A 
characteristic distribution and morphology of plaques in T2-weighted MRI are associated 
with MS (Meier & Guttmann, 2006). MS plaques are found in the white matter in a 
periventricular distribution, the posterior poles of the lateral ventricles and the area of the 
centrum semiovale being more frequently involved (Vaneckova, 2001; Papageorgiou et 
aL, 1993). The most common appearance is of homogeneously hyperintense lesions 
whereas less commonly, rings or cystic lesions may occur. Non specific white matter 
abnormalities may be confusedwith MS, particularly in patients older than 50 years with 
encephalopathies or other CNS disorders. An alternative method is electronic counting 
brain tomography (CT); but this has a major disadvantage in being unable to identify 
small affected regions (Rich et al., 2001). 
Diagnosis of MS continues to remain mainly clinical and it does not usually reveal 
specific difficulties (Table 1). The disease has a characteristic clinical picture, procesi 
and symptoms of the CNS, from anatomically unconnected areas, which cannot be 
attributed to other diseases. 
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Table 1-1. Clinical forms of multiple sclerosis and their diagnostic criteria according to 
Rose (Papageorgiou et aL, 1993): 
Diagnosis of MS Criteria 
I. Clinically certain form of MS a)  Relapsing-remitting progress and at least 
two affects with time spaced at least one 
month between each other. 
b)  Stow or graduated progress taking more 
than 6 months. 
c)  Proved neurological signs attributed to 
more than one affected area of the white 
matter of the CNS. 
d)  Onset of the symptoms usually begins in 
patients of age 10-50 years. 
e)  No better explanation of the neurological 
symptoms. 
II. Possible form of MS a)  Relapsing-remitting history of symptoms 
and 	 clinical 	 picture 	 with 	 only 	 one 
neurological sign usual for MS. 
b)  Proved presence of symptoms with signs 
of multifocus disease of white matter. 
c)  No belier explanation for the neurological 
symptoms. 
III. Probable form of MS a)  Relapsing-remitting history of symptoms 
without proved signs. 
b)  Objective neurological signs insufficient 
to determine more than one affected area 
of white matter of the CNS. 
c)  No belier explanation for the neurological 
symptoms. 
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Conditions that may be confused with MS include acute disseminated encephalomyelitis, 
Lyme disease, Friedrich's ataxia, sarcoidosis, Behcet's syndrome, ElY or HTLV-I 
myelopathy, Arnold-Chiari dysplasia, spinal-cerebellar degenerations, angiomas and 
especially gliomas of the brain stem with a relapsing/remitting progression and CNS 
vasculitis (Hope et aL,. 1993; Kumar and Clark, 2002; Rich et al., 2001). 
1.2.3 Epidemiology and genetics 
The epidemiological characteristics of the disease are very interesting. MS has not a 
uniform geographical distribution through the world and the geographical latitude is 
believed to be a major distribution index for the disease. Someother external factors used 
to interpret this peculiar distribution (climatology conditions, diet, way of living, 
sunshine, geographical longitude) have not proved useful (Hogancamp et al., 1997). 
Disease frequency is considered 'high', when, at a given time period, more than 30 
patients per 100,000 people are affected, 'mild' when 5-25 patients are found, and 'low' 
when less than 5 patients are observed (Compston et al., 1998). 
Near the equator, MS practically does not exist, but further away, the frequency increases 
significantly and in some countries of the North such as the Shetland Islands and Orkney 
(north of Scotland); it considerably exceeds 150 per 100,000 people (Delasnerie-
Lauprertre and Alperovitch, 1991; Poskanzer et al., 1980). Countries with a high 
frequency of the disease in the Northern hemisphere are: Northern Europe, Northern 
states of USA and Southern Canada. In the Southern hemisphere, New Zealand and 
South Australia have a high incidence (Kurtzke, 1975). Southern Europe, Southern states 
of USA and the larger part of Australia have a medium frequency, and Asia and Africa, 
generally independent of geographical latitude, are areas of low frequency, with the 
unique exception of regions of South Africa inhabited by whites (Prange et al., 1986; 
Weinshenker ci at, 1989; Andersen ci al., 1993). 
MS is approximately twice as common in females as in males and prevalence and 
incidence appears to increase with distance from the equator. It affects all races, except 
very rare cases such as the Bantu race of Africa, where no indication of MS has been 
found (Papageorgiou ci al., 1993). It is not incidental that all those areas with increased 
or medium frequency of the disease are inhabited by Caucasians, and, moreover, that 
between veterans of the 2nd World War, and between several minorities in the USA 
(Japanese, Chinese) there exists an unequal distribution and tolerance to the disease, even 
in those areas with increased risk of the disease (Weinshenker ci at, 1989). 
The disease affects 1-1.8 people per 1000, resulting in a prevalence of 250,000 — 350,000 
cases in the United States. MS is unusual before adolescence, and then steadily rises in 
incidence from teens to 35 years of age, gradually declining thereafter (Filippi ci al., 
2001; Smith ci at, 1999). 
Epidemiological studies support both genetic and environmental components of 
susceptibility. Reports of clusters, small epidemics, geographical variation in prevalence 
and alteration of MS susceptibility after migration supports an environmental factor or 
factors (Poser, 2006). The higher risk of MS in Europeans and in relatives of patients, 
especially in monozygotic versus dizygotic twins, adoption studies and the existence of 
MS-resistant ethnic groups supports a genetic predisposition (Hansen ci al., 2005). In MS 
patients of European descent, a strong association occurs for HLA-DR2, the extended 
haplotype of HLA-DRB 3 * 150 1IDQA 1*01  02/DQB  1*0602  (Holmes et al., 2005). Also 
several chromosomal regions have been identified as having a mild to moderate influence 
on genetic risk for MS, among them the major histocompatibility region on chromosome 
6. The results support a multifactorial etiology, including environmental factors and 
multiple genes of a moderate effect (de Jong et al., 2002;. Zipp et al., 1995; Oksenberg, 
2001). 
There is no evidence for a single or unique environmental agent in MS although 
correlation has been found between upper respiratory tract viral infections and 
exacerbations of relapsing-remitting MS (Sibley et aL, 1985; Andersen et al., 1993). 
After a rational relationship between frequency of disease and geographical latitude, was 
proposed important information for disease risk came from studies of emigrants from 
South Africa, and, later Israel (Limburg, 1950). Data have shown that the crucial age for 
getting the disease was about 15 years of age (Papageorgiou et al., 1993). Conclusively, 
the contribution of several external factors are implicated: 1) the peculiar worldwide 
distribution of the disease, 2) the modification of the disease risk by emigration before 15 
years of age and, 3) the existence of clusters and the appearence of the disease in the form 
of epidemics. Internal factors are indicated by reports of: 1) the complete absence of the 
disease in some African races (i.e. Bantu) and its relative rareness in others (i.e. Asians), 
2) the increased consequence of the disease between members of patients' families, with 
respect to the closeness of the relationship, 3) the studies of pairs of twins, which show 
that the disease risk of the other member of the pair is 50% for monoozygotic twins and 
17% for dyoozygotic ones and 4) studies of the histocompatibility system (HLA antigens) 
(Compston etal., 1998; Hogancamp et aL, 1997; Lublin and Reingold, 1996). 
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1.2.4 Pathology 
The external surface of the brain and the spinal cord appear to be in general, normal. 
Macroscopic pathological findings consist sometimes of atrophy of the brain helixes, 
expansion of the ventricles, gray formations in the white matter, especially around 
ventricles which represent demyelination regions, spinal cord atrophy or intumesbences 
with dem)/elination regions clearer those in the brain's, and atrophy of the optic nerve 
(Dutta and Trapp 2006; Papageorgiou et al., 1993). It is evident that the most 
characteristic pathological findings of the disease are the demyelination regions (sclerosis 
plaques) which are spread in different parts of the white matter of the CNS and appear as 
gray or red-gray spots, of various shape and magnitude. They are often found around the 
ventricle network, in the semi oviform center, the brainstem, the cerebellum, and the 
spinal cord. The number of plaques depends on time, number of impulses and gravity of 
the disease, since their position determines the pattern and the severity of the clinical 
symptoms. In postmortem material the earlier plaques appear softer and red-colored, and 
the older ones gray-colored and hard. The distribution of sclerosis plaques is not uniform, 
nor determinate. Plaque sclerosis arises from the hypertrophy of astrocytes and the 
creation of projections, whilst deficient hematosis may cause necrosis and cystic 
degeneration into the plaque (Chesik et aL, 2006; Frohman et aL, 2006; Papageorgiou et 
al., 1993). Axons remain always in good condition, and rarely display swelling and 
vacuum degeneration. The whole process of gliosis produces a characteristic sclerosis in 
the earlier plaques, and gives a name to the disease (Hope et aL, 1993; Kumar and Clark, 
2002; Luccinetti et aL, 2000). 
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The main histo-pathological appearance of MS lesions includes perivascular infiltration 
of monocytes, destruction of the myelin sheath (demyelination), axonal damage, loss of 
oligodendrocytes, astrocytic hypertrophy and increased expression of MHC Class land II 
proteins (Butinx ci at, 2002; Ayers ci at, 2004) . The inflammatoryinfiltration in the MS 
lesion is composed of T lymphocytes, small numbers of B cells and plasma cells, and 
activated microglia and macrophages (Benevista, 1997; Raine, 1991) which interact with 
the myelin sheath and are actively engaged in the demyelinating process (Lassmann, 
2004, Pouly and Antel, 1999). In addition, there is a local production or expression of 
immune-related molecules such as MHC molecules, adhesion molecules, cytokines and 
chemokines (Rich ci al., 2001). In brain biopsies the myelin sheath appears thin, fragile, 
and swollen caused by the continuing destruction by the macrophages (Papageorgiou ci 
al., 1993). 
Neuropathology of the MS lesion is heterogeneous. There is a selective destruction of the 
myelin sheath and relative sparing of axons. However, axonal destruction does occur 
from the beginning of MS, isthore pronounced in progressive MS patients and correlates 
with the permanent neurological deficit. In the early stages of the disease there is also 
partial remyelination after the inflammation subsides. 
Trends of remyelination are observed, but usually the remye!inated axons are associated 
with the dense tissues of the developing glia, they are abnormal in shape and diameter, 
and may cause secondary consequences in clinical symptomatology of the disease 
whithout the creation of new foci. Generally little is known of the effect of remyelination 
in MS. It is frequently impossible to determine if remyelination is in developement or in a 
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phase of restoration. It is possible' that myelin loss is not the only cause of creation of the 
clinical symptoms of the disease, since other factors have been identified that —at least in 
vivo- inhibit synaptic transmission, but this area remains under investigation (Wegner et 
al., 2006). 
Lassmann and colleagues have classified MS into different neuropathological categories: 
(1) demyelination with no or minor oligodendrocyte loss; (2) demyelination with 
concomitant destruction of oligodendrocytes; (3) primary demyelination with secondary 
loss of oligodendrocytes in inactive plaque areas; (4) primary oligodendrocyte destruction 
with secondary demyelination. These categories correspond to different mechanisms of 
demyelination (Lassmann, 1998). 
1.2.5 Innnunopathogenesis 
The pathogenesis of the disease remains largely unknown. The most commonly believed 
theory involves an infection during childhood (e.g. viral) that may trigger exacerbations 
or influence the immune system and lead, through a series of events (B-cell activation, 
destruction of the oligodendrocyte's membrane, modification of the blood-brain barrier, 
production of antibodies against the basic myelin protein), to the appearance of the 
disease later in life (Lovvet-Racke and Racke, 2006; Pannitsch, 1994; Poser, 1993; Sibley 
et at, 1985; Prat & Antel,2005). 
Several lines of evidence suggest that an immune mediated mechanism plays a role in 
MS (Bar-Or et at, 1999; Barnett and Sutton, 2006; Compston, 2004; Grigoriadis et al., 
2006; Hemmer et at, 2002; Hemmer et at, 2006; Martinet at, 1992; Reder et at, 1985; 
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Traugott, 1990). Laboratory findings show a considerable decrease in the number of 
CD8 suppressor T-lymphocytes in the blood and CSF of MS patients, and an increase in 
the relative and absolute number of CD4 T-helper lymphocytes, as well as a correlation 
of increased antibody titer against several viruses and against the myelin basic membrane 
(MBP), with disease progression (Haase and Faustmann, 2004; Soderstrom et aL, 1993). 
Furthermore, the putative immunological events that lead to the pathology of MS are 
based on animal experiments in experimental autoimmune encephalomyelitis (EAE) and 
observations in human MS. Autoreactive T cells specific for myelin and other antigens of 
the CNS pre-exist in the normal immune system of both animals and human. These 
clones have escaped deletion by thymic negative selection and are normally controlled by 
one of the modes of peripheral tolerance, such as the maintenance of immunological 
ignorance, clonal inactivation or active suppression by regulatory cells. In MS these 
autoreactive clones undergo activation outside the CNS (Sun, 1991; Ratts ci al., 2006). 
There are several possibilities for such activation, one being molecular mimicry of a viral 
or bacterial antigen and cross-stimulation of autoantigen-specific T cells. Upon 
activation, autoreactive T cells express chemokine receptors and adhesion molecules that 
enable them to migrate into the brain tissue. Upon entering the brain, the autoantigen-
specific T cells encounter autoantigen through its presentation by MHC Class II 
molecules expressed by microglia and macrophages. Cytokines such as interferon-y, 
lymphotoxin and TNF-a produced by the entering CD4 T cells (Thl-type cells), as well 
as by activated local antigen-presenting cells, induce an up-regulation of MHC Class II 
expression. Once the inflammatory reaction begins, there is an increased production of 
inflammatory mediators, leading to a change in the BBB and to additional inflammatory 
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cells entering the brain (Kermode et al., 1990). These mediators also activate astrocytes, 
endothelium and pericytes, resulting in an increased expression of MHC Class II 
molecules and: therefore, perpetuation of the autoimmune response (Brosnan and Raine, 
1996). 
Different autoantigens, other than myelin basic protein are encephalitogenic in animal 
models; these include proteolipid protein, myelin oligodendrocyte glycoprotein, SlOOb, 
alpha-B crystalline, transaldolase oligodendrocyte myelin glycoprotein and 2'3'-cyclic 
nucleotide 3'-phosphodiestaras6 (Kuchroo et al, 2002; von Budingen et al., 2001; 
Schmidt, 1999). Different autoantigens and different epitopes of a particular autoantigen 
may be targeted by the autoimmune response during different stages of the disease (Rich 
etaL, 2001; Sunetat, 1991). 
The humoral immune system also participates in pathogenesis, as there is an 
- overproduction of IgG in the CSF and antibodies are detected in the lesions. B cells are 
usually found in MS plaques and their number relative to T cells, increases as the lesion 
becomes chronic (Qin and Duguette, 2003). There is evidence that after binding to the 
myelin surface, demyelinating autoantibodies activate complement and attract 
macrophage/microglia. Glial cells presumably also contribute to myelin damage, as 
reactive astrocytes in the MS plaques contain NADH diaphorase activity which reflects 
inducible nitric oxide synthase (iNOS). High expression of iNOS has also been detected 
in macrophages in the region of active demyelination in MS (Acar et al., 2003; Merill et 
at, 1993;Bo et at, 1994; Sarchielli et at, 1997). 
Oligodendrocyte destruction in MS lesions may be either due to direct lysis mediated by 
T-cytotoxic lymphocytes or through an indirect mechanism in which activated T cells 
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induce toxic cytokine production (e.g. nitric oxide, TNF) by accessory cells. T cell 
produced cytokines may also be involved in the damage to oligodendrocytes (Brosnan ci 
al., 1988; Ruddle ci at, 1990; Traugott and Lebon, 1988). Studies have demonstrated that 
cytotoxicity mediated by cytotoxic T cells may be secondary to the secretion of electronL 
dense cytoplasmic granules (perforin and serine esterase granzyme B) or a non-secretory 
pathway based on the interaction of Fas ligand with Fas (CD95) on target cells and the 
induction of apoptosis (Dowling ci at, 1997). 
Recent data indicate that the apoptotic process, mediated by the Cb95/Fas cell sutface 
receptor, is impaired in activated lymphocytes of patients with relapsing remitting 
multiple sclerosis (Bilinska ci al., 2002; Giusiani ci al., 1998; Ichikawa ci at, 1996; 
Macchi ci at, 1999; Pender, 1998; Sharief and Semra, 2001; Zip ci at, 1999; Gomes ci 
at 2003). CD95/CD95L interaction results in activation-induced apoptosis, thereby 
regulating clonal expansion of T cells outside the thymus (Bilinska cial., 2001; Dhein ci 
at, 1995; Gold ci at, 1997; Hong ci at, 2004; Papoff ei at, 1996; Zurak, 1997). 
More specifically there is data that shows that, being homozygotic for the G allele of 
CD95 5'(-670)A-->G SNP and for the C allele of CD95 E7(74)C-- >T SNP increased 
suspectibility in MS exclusively in women (Hong ci al., 2004). There was a marked 
upregulation of Fas/APO1 (CD95) receptor expression in MS tissue (Dowling ci at, 
1996) and soluble CD95 is elevated in MS patients with active disease (Sakai ci at, 
1999). Thus MS sera contains biologically active inhibitors of T cell apoptosis that may 
allow for prolonged abnormal immune responses (Zipp ci al., 1998), and that patients 
with detectable gadolinium-enhancing lesions had lower expression of CD95 (Gomes ci 
at, 2003). 
On the other hand, there is also data which shows that measurement of soluble CD95 is 
not suitable for monitoring MS disease courses (Bansil ci at, 1997; Heesen ci at, 2000), 
and there was no difference in CD95 expression when MS patients and healthy 
individuals were grouped and compared according to liLA-DR status (Zippet al., 1998). 
Matrix metalloproteinases (MMPs) may be another important factor for MS pathogenesis 
(Khrestchatisky ci al., 2003). MMPs are a family of at least 14 zinc-dependent 
extracellular matrix remodeling proteases important in normal development, 
angiogenesis, wound repair, and degradation of protein components of the àtracellular 
matrix (Nagase and Woessner, 1999; Oh ci al., 1999). In addition, MMPs and related 
enzymes can also process a number of cell surface cytokines, receptors, and other soluble 
proteins (Goetzl ei al., 1996; Opdenakker ci at, 2001). In particular it has been shown 
that the the release of the pro-inflammatory cytokine, tumor necrosis factor-alpha (TNF-
a) from its membrane-bound precursor is an MMP-dependent process (Gearing ci al., 
1995). MMPs are expressed by inflammatory cells associated with CNS lesions in animal 
models of MS and in tissues from patients with the disease (Clements ci at, 1997; 
Cuzner ci at, 1996; Dubois et at, 1999; Gijbels ci at, 1992; Hartung ci at, 2000; Maeda 
and Sobel, 1996; Mair ci at, 2002; Yong ci at, 2001). They are synthesized in zymogens 
and, under physiological conditions, are selectively regulated by endogenous inhibitors 
(Brew ci al., 2000; De Clerck, 1989). MMP expression therefore contributes to tissue 
destruction and inflammation in MS (Minagar and Alexander, 2003; Kieseier ci al. 
,1999). Drugs which inhibit MMP activity are effective in animal models of MS and may 
prove useful therapies in the clinic (Bever and Rosenberg, 1999; Borkakoti, 2004; 
Brundula ci at, 2002; Chandler ci at, 1997; Docherty, 1992; Gijbels ci at, 1994; 
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Hewson et al., 1995; Liedtke et aL, 1998; Opdenakker et aL, 2003; Rosenberg, 2001; 
Nelissen et al. .2003). 
More specifically, MMPs attack the basal lamina macromolecules which line the blood 
vessels, opening the blood-brain barrier (BBB), and contribute to the remodeling of the 
blood vessels that causes hyalinosis and gliosis. They also attack myelin (Lukes et aL, 
1999; Gijbels et al., 1993; Leppert et al., 1995). During the acute inflammatory phase of 
MS, they are involved in the damage caused to the blood vessels and may be important in 
the disruption of the myelin sheath and axohs (Kurzepa et al., 2005; Mun-Bryke and 
Rosenberg, 1998; Newman et al., 2001; Ries and Petrides, 1995; Rosenberg, 2002). 
Normally under tight regulation, excessive proteolytic activity is detected in the blood 
and cerebrospinal fluid of patients with acute MS associated with a decrease in tissue 
inhibitors of MMPs (TIMPS) activity (Wjtowicz-Praya et aL, 1997). Because they are 
induced in immunological and non-immunological forms of demyelination, they act as a 
final common pathway to exert a "bystander" effect (Rosenberg, 2002; Kurzepa, 2005). 
Intrathecal synthesis of MMPs and especially of MMP-9 has been suggested (Liuzzi et 
al., 2002). 
Some studies investigating a correlation between MMPs and TIMPs in MS have 
indicated that: serum levels of MMP-9 are higher in MS patients than controls, 
circulatory MMP-3 levels are correlated with disease activity in relapsing-remitting MS 
(higher levels during the relapsing phase), there are significantly lower MMP-9 serum 
levels in primary progressive multiple sclerosis patients compared to relapsing-remitting 
ones, MMP-12 is expressed on phagocytic macrophages in active multiple sclerosis 
lesions, and significantly higher TIMP-1 and TIMP-2 levels occur in MS patients than in 
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healthy controls (Anthony et al., 1997; Correale et al., 2003; Ichiyama et al., 2006; 
Kanesaka et al., 2006; Kieseler et at, 1998; Kouwenhoven et al., 2002.; Leppert etal., 
1998; Lee et at, 1999; Sastre-Carriga et at, 2004; Vos et at, 2003; Waubant et al., 
1999). 
1.2.6 Therapy 
Since MS is confirmed by diagnostic methods, we have to predict, if possible, the process 
of the disease and estimate possibilities of therapeutical intervention. Although there is 
no, as yet, etiological therapy for MS, nor any certain way to inhibit the disease 
processes, or reduce the chronic symptomatology. 
Generally the main therapies for MS use drugs that are effective in the treatment of other 
inflammatory or autoimmune diseases, and comprise of therapies which: (I) prevent the 
ongoing destruction of the nervous system tissue by inflammatory cells, (2) are a 
symptomatic treatment to allow the damaged nervous system to function at a higher level, 
and (3) are a treatment designed to repair damaged CNS myelin (Trebst and Stangel, 
2006). If the destructive inflammatory process in the CNS can be arrested at an early 
stage it may prevent the accumulation of neurological disability. 
During the phase of acute symptoms of the disease corticosteroids (usually prednizone or 
methylprednizolone) or corticotropine (ACTH) are administered at several doses. These 
drugs are given intramuscularly, intravenously, or per os. Corticosteroids act against 
swelling, are immunosuppressive and accelerate the improvement of the clinical 
symptoms of the disease (Leussink et at, 2001; Gelati et at, 2002; Petelin et at, 2004). 
However, their continued and inconsiderate use is absolutely prohibited, because of 
serious undesirable actions. 
To restrict the frequency and seriousness of the relapses in MS, several imunnosupressive 
factors are used in the hope they have a proph'lactic action. None of them have ptoved 
particularly effective as indicated by long time preventive studies and MRI use. For 
instance, azathioprine and cyclosporine failed to prevent relapses of the disease to any 
statistically significant degree, and the use of cyclophospliamide, intended to stabilize the 
progressively worsening disease, did not give the expected results (Rudge, 1998; Brochet, 
1998). The same is true for the combined use of immunosupressive drugs and 
plasmaferesis, although there are contradictory data. 
The use of immunosupressive drugs (azathioprine, cyclosporine, cyclophosphamide, 
methotrexate), was based on the conviction that MS is the result of superimmune 
reaction. Studies (Laplaud and Confavreux, 2006; Becker et al., 1995) have shown that 
there is superimmune stimulation, and by the use of these substances, the frequency of 
relapses is decreased at least in some patients, and the quantity of IgG in CSF is reduced, 
although only temporarily. These results were accepted with reservation, because they 
were not statistically superior to other therapies, and, moreover, the uncontrolled use of 
these drugs is potentially harmful and dangerous. 
The use of immune stimulating factors (Levamisol, Transfer factor), according to the 
theory that the disease is a condition of immune deficiency, failed to offer encouraging 
results. Similar failure was acquired with the use of a number of other therapies, (e.g. 
body radiation, plasmaferesis, and hyperbaric oxygen). 
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Consequently, the use of corticoids or ACTH, still remains for clinicians, the only 
solution for a therapy for the disease, since they do shorten the duration of the symptoms, 
and have relatively less side effects (Wenning cit at, 1994; Glass-Marmor et at, 2006). 
However, these drugs have no action upon the already damaged myelin, and do not 
modify the pathogenetical causes of MS. 
The use of azathioprine is intended to reduce relapses and recommended to retard the 
coming disability, although it also may suppress bone marrow function, so that it 
predisposes to infection (Putzki ci at, 2006). Its use therefore must be done with 
hematological and liver tests, especially for the first time (general blood examination, 
platelets, and serum transaminases). It is believed that it helps at least at some of the 
patients when administrated in time and correctly. 
Current treatments for first-line nontoxic therapy of the relapsing-remitting disease are 
two forms of recombinant IFNJ3, I a and 1 j3 and glatiramer acetate (copaxone) (Amason, 
1996; Biegler ci at, 2006; Chezzi, 2005; Coppola et at, 2006; Edan, 2001; Fellay ci al., 
2001; Galetta ci al., 2002; Greek National Drugs Organization, 2000; Hughes, 1994; 
IFN-13 Multiple Sclerosis Study Group, 1995; Kappos ci al., 2006; KEan ci al., 2001; 
Marckmann cit at, 2004: Rio ci at, 2005; Yong ci al., 1998; Wolinsky, 2004). IFN-a and 
IFN-y were also tested for MS treatment because of their iostatic and immunomodulatory 
properties (Biron, 2001), but IFN-a failed to give the expected results and the use of IFN-
y aggravated the patients (Balkwill, 1989; Panitch et at, 1987). IFNJ3 is the most widely 
used drug and has been shown in clinical trials to decrease the frequency of relapses, 
favorably affect MRI lesions and, in some instances, slow disease progression (Calabresi 
ci at, 1997; Paty and Li, 1993). Its mechanism of action is not clearly understood but it 
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may affect the trafficking of cells into the nervous system (Lou et al., 1999; Hartrich et 
al., 2003; Rudick et at, 1993). Other possible mechanisms of action of IFN13 are: 
lowering IFN-y secretion and inhibiting responses to IFN-y, increasing IL-lO secretion, 
and increasing the apoptosis rates of immune cells (Ahn et al., 2004; Boz et al., 2006; 
Gniadek et al., 2003; Rep et at, 1999; Yushenco et at, 2003; Billiau et al.,2004; FIua et 
at, 2002; Lu et at 1995; Revel et at 1995; Weyenbergh et at, 1998; Weinstock-
Guttrnan et at, 2003). 
IFNj3-la (Avonex) is a glycosylated recombinant mammalian-cell product with an amino 
acid sequence identical to that of natural interferon. IFNJ3-113 (Betaferon) is a 
nonglycosylated recombinant bacterial cell product in which serine is substituted for 
cysteine at position 17. IFNJ3-la is given as a weekly intramuscular injection whereas 
IFN13-1 13 is given as alternate-day subcutaneous injections (Khan et at, 1996). The choice 
between the two preparations depends on the patient and the individual physician. IFN13-
Ia is most commonly prescribed as it requires only weekly injections and appears to be 
better tolerated (Alam et at, 1997; Liu et al., 2001; Rich et at, 2001; Runkel et at, 1998; 
The Multiple Sclerosis Collaborative Research Group (MSCRG), 1996). 
Glatiramer acetate, a mixture of random synthetic peptides (copolymer) synthesized 
initially as a compound to mimic myelin basic protein, has been studied for a 
considerable time as an autoantigen in MS. It appears to act as an MBP analog that 
induces Th2 and Th3 regulatory cells (Aharoni et at, 1997; Dhib-Jabut etal., 2002; Yong 
et at, 2002; Tennakoon et al., 2006). Glatiramer acetate is given as a daily injection and 
has been shown to reduce the relapse rate in MS patients (Heesen etal., 1998; Karandikar 
etal., 2002; Karandikar and Racke, 2005; Neuhaus et at, 2001; Rafts et at, 2006). 
EVA 
The choice of whether to start a relapsing-remitting patient on IFNf3 or glatiramer acetate 
has not been resolved. Patients with depression, those very early in their course or those 
who cannot tolerate JFND are often preferentially treated with glatiramer acetate (Rich et 
at, 2001). 
The general weakness of the patients and their ataxia are symptoms resistant to any 
therapy. The spasticity of hands and feet may also improve with the use of several drugs 
(such as Diazepam, Baclofen, Tizanidine, Dantrolen), but their choice and dose should be 
decided with great care. Painful hand tremor and action tremor of hands correspond, 
sometimes effectively, to treatment with clonazepame, propranolole, or isoniazide 
(together with vitamine BE) (Charles et al., 1999). Otherwise the pains MS patients have 
differ in origin and distribution (nerve pains, musculosceletals), and is the reason why 
they thust be confronted in various ways (salicylics, carvamazepine, amitryptiline, 
physiotherapy) (Solaro, 2006). However, care is needed in the choice of drug, because 
some of these non steroid analgesics, such as indomethacin, actually aggravate 
neurological symptoms. 
Successful treatment for the functional disturbances of the urine cysts of the patients is of 
special importance, because it prevents lithiasis and dangerous infections of the 
uriniparous system. The form of treatment is not always unique (Papageorgiou et aL, 
1993). 
It has been reported that the taking of vitamins, linoleic acid or the restriction of the 
animal fat from the patients' diet may act favorably (van Meeteren et al., 2005). But no 
diet has been judged to be the most effective (Schwarz and Leweling, 2005). 
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Finally, the proper training of the patients to fully use their remaining abilities, with 
assistance, is extremely useful since it contributes to the preservation of any remaining 
mobility, and thus prevents premature bed lying , which can cause serious complications 
(muscle contractures, atrophies, crusts from lying down, infections). The correct 
physiotherapy is always beneficial with probably the best possible exercise being 
swimming in warm water (Peterson, 2001; Papageorgiou et al., 1993). 
MS patients must be encouraged to organize their life in the best possible way, and not to 
give up their interests and special capabilities (Ennis et al., 2006; Sharief, 2004). MS is a 
peculiar and complicated disease, with obvious indications and symptoms during the 
patient's life, and as such, it demands careful and "human" therapy (Paty et al., 1999). 
1.3. The involvement of cytokines in MS pathophysiology 
1.3.1 General aspects 
Cytokines are a heterogeneous group of molecular soluble proteins or glycoproteins 
(Mwt<80 kDa) that participate in both non-specific and immunologically dependent 
inflammatory reactions, in cell growth, differentiation, cell development and in repair 
processes vital to host defence. Cytokines are generally produced in small quantities in 
response to local stimuli, such as the presence of antigens or endotoxins, or the 
transduction of signals provided by other c94okines, during the active phase of adaptive 
and innate immune response, which affect induction and regulation (Germenis, 2000). 
Their secretion is fast, short term and self restricted (Germenis, 2000). In general 
cytokines are not stored intracellulary as preformed molecules (Germenis, 2000). Their 
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composition is a result of new, temporary genetic transcription, which is achieved 
through new and short living RNA's. They are secreted and act on. a variety of cells 
(pleotropism). They include the ones secreted by lymphocytes (called lymphokines), 
macrophages (monokines) and chemotactic inflammatory cells (chemokines). More than 
100 structurally and genetically different cytokines have previously been recognized 
(Germenis, 2000). 
Cytokine action is not specific and does not depend on the antigen. In addition, they can 
exert multiple actions at the same cellular targets. Their action often affects the 
composition and the biological action of other cytokines, resulting in a sequence of 
events in which the next cytokine acts as a mediator to the action of a previous one 
(Germenis, 2000). The result of this cooperative action can be competitive, or 
accumulative, stimulation or inhibitory or possibly to enforce partial actions, or creation 
of a new different action. 
Cytokines are divided, based on their function, into four different groups: a) Mediators of 
innate immunity, secreted mainly by mononuclear phagocytes under the action of 
infectious agents (IFN-a, IFN-13, TNF-a, IL-i, IL-6, chemokines); b) Regulatory factors 
for the activation, multiplication and differentiation of lymphocytes, produced from T-
cells upon antigen stimulation (IL-2, IL-4, TGF-D); c) Regulatory factors for the immune 
response, by activating non-specific active cells (IFN-y, TNF-f3, IL-b, IL-5, IL-12); d) 
Stimulatory factors of leukocyte proliferation, produced by stimulated lymphocytes, and 
other cells, known as growth factors (GM-CSF, M-CSF, G-CSF, IL-3, IL-7) (Roitt et at, 
1998; Germenis, 2000). The main types of cytokines are shown in Table 2. 
Cytokines act on target cells expressing the appropriate cytokine receptor in an autocrine 
or paracrine way. Cytokine receptors are transmembrane proteins with an extracellular 
- - 
	
	 binding domain to the appropriate cytokine and an intracellular part involved in 
transmission of the signal to the cell nucleus (Germenis, 2000; Roitt et aL, 1998). 
C 
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Table 1-2. Individual cytokine classification based on main cytokine types 
(Roitt et at, 1998) 
Cvtokine Types Individual cvtókines 
Lymphokines MAF (macrophage activating factor), MMIF 
(macrophage migration inhibition factor), 
MCF (macrophage chemotactic factor), LMIF 
(leukocyte migration inhibition factor), I-IRFs 
(histamine releasing factors), TF (transfer 
factor) 
Interleukins IL-i, IL-2, ...-1L15 
Tumour necrosis factors TNF-a (cachectin), TNF-13 (lymphotoxin 
Interferons IFN-cz, IFN-13, IFN-y, IFN-w 
Colony stimulating factors G-CSF (granulocyte colony stimulating 
factor), GM-CSF (granulocyte-macrophage 
CSF), M-CSF (macrophage CSF), multi-CSF 
(IL-3) 
Polypetide growth factors aFGF (acidic fibroblast growth factor), bFGF 
(basic fibroblast growth factor), EGF 
(epidermal growth factor), NOF (nerve 
growth factor), PDGF (platelet-derived 
growth factor), VEGF (vascular endothelial 
growth factor) 
Transforming growth factors TGF-a, TGF- 
ci-Chemokines IL-8, NAP-2 (neutrophil-activating protein 
2), PF-4 (platelet factor 4), 3TG (0- 
thromboglobulin) 
-Chemokines MCP-1 9monocyte chemoattractant protein 
1), MCP-3, MIP-3, MIP-la, MIP-lf3 
(macrophage inflammatory protein 10) 
RANTES (Regulated upon Activation 
Normal T Expressed and presumably 
- Secreted chemokine) 
Stress proteins HSPs (heat shochk proteins), GRPs (glucose- 
regulated proteins), ubiquitin, superoxide 
dismutase (Mn) 
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Cytokine receptors are divided into five main groups depending on the motifs or the 
homologous amino acid sequences of their molecules, as shown in Figure 1-1. 
Ig.Superlamily Cytokine Receptor Family Cytokine TNF Seven 
(Type I) Receptor Family Receptor Family Transmembrane 
(Type II) Helix Family 
C- 	 C. 
IL 1R PTK TL6R 	 IL 2R •IL 2R7 	 IL-4R IFN -cz/R TNF RI TNF Ru 
:(rype 1 ) ckit -'-- Y(Ufl).: 	 '- p55 p75- 
IL• 6RA 
Figure 1-1. Cytokine receptor families 
Cytokine receptors share various structural motifs, allowing them to be categorized into 
families (from Abbas et al., 1997). 
The receptors of immunoglobulins' superfamily, like type I and JIlL-IRs, have at their 
extracellular part, a number of domains with homology to those of immunologlobulins. 
The type I cytokine receptor has at its extracellular part, close to the transmembrane one, 
a conserved motif consisting of tryptophane-serine-X-tryptophane-serine (WSXWS), and 
bind cytokines which contain a four a-helix structure such as IL-2, IL-3, IL-4, IL-5,IL-6, 
JL-7, GM-CSF and G-CSF (Hecht et at, 2006). 
The type II class of cytokine receptor consists of the type I and type II receptor for 
interferon. 
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The type III class of cytokine receptor is composed of the two receptors for TNF, which 
have the homologous areas p55 and 75, which arealso homologous to the Fas protein, 
to CD40, and to the receptor for nerve growth factor (Ryffel & Myhatsch, 1993; 
Germenis, 2000). 
The chernokine receptors have a transmembrane structure of seven cz-helices, common to 
all receptors, which bind hetero-trimeric GTP-bound proteins, such as 3-adrenergic 
receptors and rhodopsin (Germenis, 2000). 
Most cytokine receptors consist of two or more transmembrane polypeptidic chains 
which act as a complex. 
IL-12 actions (promotion ofThl responses) are mediated through a high affinity receptor, 
composed of two subunits, designated bi and b2. Of these two subunits, b2 is more 
restricted and its distribution and regulation of its expression serves as a central 
mechanism by which IL-12 responsiveness is controlled (Airoldi etal., 2005). Expression 
of IL-i 2R subunits is upregulated in both microglia and splenic macrophages upon 
stimulation with LPS or IFN-y. In experimental allergic encephalomyelitis, maximum 
levels of IL- 12 p40  and IL- l2p35 mRNA are detected in the CNS at the peak of disease, 
and expression of IL-12 p35 mRNA is more sustained than that of IL-12 p40 (Li et 
aL,2003). In MS, a higher percentage of IL-12R bi and IL-12R b2 positive T cells 
occurred in cerebrospinal fluid (CSF) compared to blood (Ozenci et al., 2001.) The 
functional importance of high IL-12R 02 in MS has been underlined by the finding that 
that IL-12 stimulated IFN-y production and proliferation of PHA-activated T cells 
correlated with levels of IL-12R P2 expression (Durali et at, 2003). According to other 
studies, patients with a relapsing-remitting and secondary progressive form of the disease 
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displayed increased levels of IL-12p40 mRNA in blood white cells compared to controls, 
since patients with the primary progessive form of the disease showed decreased IL-12R 
l mR.NA (Gately et at, 1998; Li et al., 2003; Ozenci et at, 2001; van Boxel-Desaire et 
al., 2001). These findings raise the possibility that the pathogenetic mechanism of 
primary progressive multiple sclerosis may be different from the relapsing-remitting's 
and secondary progressive's, and dosen't use the IL-12R J31 pathway for ml immune 
activation. 
IL- 10 receptor's levels were markedly increased in the spinal cord of a rat model of 
chronic relapsing EAE, and strong immunoreactivity for IL- 1 OR was detected in the 
macrophages of both parenchymal and perivascular areas and in reactive astrocytes in 
active and chronic lesions in postmortem human brain tissue obtained from MS patients 
(Hulshofet al., 2002; Ledebeer et at, 2003). 
Functionally, cytokines have been classified as either pro-inflammatory (Thl type, 
stimulatory) or anti-inflammatory (Th2-type, inhibitory), depending on the final balance 
of their effects on the immune system (Figure 1-2). In order to maintain homcostasis, a 
dynamic balance must be struck between pro- and anti-inflammatory cytokines (Miosec, 
1995). Inadequate concentrations of pro-inflammatory cytokines may result in excess 
inflammation, which can be harmful to the host, as in the case of autoimmune disease. 
However, an excess of anti-inflammatory cytokine concentrations may disrupt the 
clearance of microbial pathogens. The cytokine network reflects a homeostatic balance, 
with mutual cross-inhibitory effects exerted by pro- and anti-inflammatory cytokines on 
cytokine production (Fiorentino et al., 1989; Miosec, 1995; Roitt et at 1998). 
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Figure 1-2. Representation of the Thl/Th2 hypothesis 
Thi cells secrete the cytokine IFN-y and activate inflammatory pathways mainly via 
macrophage activation. Th2 cells secrete cytokines IL-4 and IL-5 that upregulate 
antibody formation via B cells, mast cells, eosinophils, and other pathways. Thi and Th2 
cells can cross-inhibit each other (Adapted from Roitt ci al., 1998). 
In at least two cases, IL-i and TNF-a, the cytokines, except their soluble form, have been 
recognized as membrane proteins, since many of the cytokine receptors have also been 
detected in soluble forms (sRs) (Flecht ci cii. 2006). It is very possible that these 
molecules play a role in the regulation of cytokine production and/or their action in 
several cellular populations (Rose-John ci al., 2006; Germenis, 2000). Although in many 
cases sRs result from proteolytic reactions, which lead to the extractment of the 
extracellular part of the corresponding membrane molecule, in many others it is observed 
that different lengths of mRNA entail the production of soluble or membrane receptors. 
This suggests that cells have some factors that regulate receptor gene transcription, which 
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are mobilized by the action of external messages (probably other cytokines), in order to 
produce soluble and membrane molecules at a certain ratio (Classen-Linke, etal., 2004). 
Many sRs are competitively bound to the membrane molecules of cytokines, resulting in 
the exclusion of the latter's action. However, they may also be bound to cytokines, and in 
- this way protect them from proteolysis in the serum. In this case, they can act as 
transporters and permit the distant (ëndocrinal) action of these cytokines (Germenis, 
2000). It is possible, therefore, that the inhibition of local cytokine action is a biological 
• :- role of sRs, whilst they enforce cytokine action at distant areas, where they arrive in very 
small quantities. Such biological activity as this has been clearly recognized for the 
complex 1L6/IL-6R at the increased sceletal sensitivity at PTH in estrogen-deficient 
women (Masiukiewisz et at, 2002). 
This probably is not the general situation, since the connection of other sRs to the 
corresponding cytokines entails the inhibition of their action (McDermott, 2001). This is 
the case for IL-2R11, where the a-chain is detached from the membrane IL-2R, as well as 
of JL-4R, and of the receptor that binds to TNF proteins I and II (TNF binding proteins I 
and II, TNF BPI, TNF BPII), (Germenis, 2000). Another characteristic example is 
calmodulin, found in the urine of pregnant women and which binds to IL-i in an 
inhibitory way (Germenis, 2000). Furthermore, A2- microglobulin of serum is bound, 
between several other proteins, to IL-1, IL-2, PDGF and FGF, resulting either in the 
enforcement, or in the inhibition of action (Germenis, 2000). 
Finally, inhibition of cytokine action occurs after the connection of their receptor to 
several other substances. Such a substance is a glucopeptide, reported to be a secreted 
competitor of IL-I R (secreted IL-I receptor antagonist, sIL- ira) produced by monocytes, 
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neutrophils, macrophages and fibroblasts, and which appears to act as an inhibitory factor 
of the inflammatory reaction (Learn etal., 2001). 
1:3.2 Cytokines and central nervous system 
Cytokines are involved not only in the immune response, but in a variety of physiological 
and pathological piocesses, including events in the peripheral and the central nervous 
system. They are, therefcre, -. both imthunoregulators and neuromodulators 
(Hadjilambreva et aL, 2005). In fact, cytokine production is under tonic control of the 
peripheral and central nervous system, and cytokine balance may also be modulated by 
the action of neurotransmitters (Kin and Sanders, 2006). Neuroimmune interactions are 
therefore bi-directional. Cytokines and other products of immune cells can modulate the 
action, differentiation and survival of neuronal cells, while neurotransmitters and 
neuropeptides released from neurons play a pivotal role in influencing the immune 
response (Szelenyi, 2001). 
Cytokine might also exert effects in the CNS both directly and indirectly. A direct action 
implies that the cytokines themselves are present in the brain, in and/or around the 
various neuronal cells, while secondary effects are the result of cytokine action on other 
targets in the indirect pathway (Han and Suk, 2005). 
The various cytokines directly affecting the CNS have two possible origins: a) they may 
originate from peripheral immune organs and cross the blood-brain-barrier. Stimulation 
of the peripheral immune system may signal the brain in both a local and systemic 
manner (Planas et al., 2006). Cytokines can reach the CNS directly by crossing at leaky 
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areas the BBB through the circumventricular organs even in healthy, basal conditions; b) 
cytokines may be produced by neuronal cells within the CNS. Most of the cytokines and 
their receptors have been demonstrated and/or postulated in various cell types of the CNS 
in both healthy and disease states (Rasley et al., 2006; Choi et at, 2005; Hofman et at, 
1989). It has been proposed that cytokines, produced by a cascade of neurons and glial 
cells within the brain, may participate in the complex autonomic, neuroendocrine, 
metabolic, and behavioral responses to infection, inflammation, ischemia and other brain 
injuries (Szelenyi, 2001). 
1.3.3 Cytokine receptors and Central Nervous System 
Recent studies support the presence of cytokine and chemokine receptors in the CNS 
(Ambrosini et Aloisi, 2004; Dzenko et al., 2005; Limaota et at, 2003; Shideman et at, 
2006; Valles et at, 2006). More specifically human microglia were found to express 
mRNA transcripts for most cytokine receptors (namely IL-i-I, IL-i-Il, IL-5, IL-6, IL-8, 
IL-9, IL-b, IL-12, IL-13 and IL-15) (Friednunn, 2001; Lee et at, 2002). A large number 
of chemokine receptors have also been found in animal and human studies to be 
expressed in neurons, astrocytes, microglia and oligodendrocytes, either constitutively, or 
induced by inflammatory mediators (Bajetto et at; 2002; Banisadr et at, 2002; Coughlan 
et al., 2000; Gosselin et at, 2005; Liu et at, 2005; Nguyen and Stangel, 2001; Sorensen 
et at, 2002). Astrocytes express IFN-y receptors (Hindiger et at, 2005). Previous studies 
show that IL-is receptor alpha-i isoforms are expressed in selected structures of the 
human fetal brain with greater expression in the hippocampus and cerebellum, than the 
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cortex and thalamus (Kurowska ei at, 2002), and TROY- a member of the tumor 
necrosis factor superfamily- is strongly expressed in the mouse ventricular and 
subventricular zone, which contains neuronal and glial precursors during embryogenesis 
(l-Iisaoka ei al., 2003). 
Cytokine and chemokine receptors are responsible for a number of roles in the 
physiology and pathology of the CNS (Yang ci at 2002). Evidence supports the 
suggestion that chemokines are invOlved in many neuropathological processes in which 
an inflammatOry state persists, as well as in brain tumor progression and metastasis 
(Cartier ci al., 2005; Dogan and Karpus, 2004; Mennicken ci al., 1999; Sorensen ci al., 
- - - 2002; Krumbholtz ci at 2006). Moreover, there is evidence for a crucial role for CNS 
chemokines similar to those which regulate the immune system, such as proliferation and 
developmental patterning (Bonavia ci al., 2003; Peters ci at, 2000; Rezaie ci at, 2002; 
Tissir ci al., 2004), but, in addition, peculiar to the UNS, such as regulation of neural 
transmission, plasticity and survival (Bajetto ci at, 2002; Cho ci al., 2002; Davis ci al., 
2003; Dziembowska ci at, 2005; Ma ci at, 2002; Ragozzino, 2002). 
Indicatively, signaling through the chemokine, CXCR2 inhibited oligodendrocyte 
precursor migration during spinal cord development (Filipovic ci at, 2003; Tsai et at, 
2002), and the CXCR4 affects cell-cycle proteins in neurons (Khan ci al., 2003), a fact 
which raises the possibility that chemokines may contribute to neuronal survival by 
repressing the activity of E2-F apoptotic genes and maintaining neurons in a highly 
differentiated state (Khan ci at, 2003). 
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In pathological and other special conditions (aging, behavioral models) of the CNS, there 
are several data supporting the involvement of cytokines and chemokine receptors. 
Specifically they have been observed to reduce neuropathetic pain responses in mice 
lacking the chemokine receptor CCR2 (Abbadie ci at, 2003; Lindia ci at, 2005). 
In addition, during status epilepticus, IL-i-I has been induced in both hippocampal 
neurons and astrocytes localized in limbic and extralimbic areas (Rizzi ci at, 2003). 
Neuronal IL-i-I expression in the hippocampus outlasted the duration of spontaneous 
:electl.oencephalographic 
 seizures, and was not observed in degenerating neurons. 
Astrocytic expression occurred transiently, between 6 and 18 hours after the induction of 
status epilepticus and was invariably found in regions of neuronal damage (Ravizza and 
Vezzani, 2006). Furthermore, up-regulated IFN-y receptors have been identified in aged 
spinal cord motor neurons (Eldstrem ci at, 2004) and induction of neuronal apoptosis by 
the Amyloid-beta protein has been observed through the TNF 1 receptor in Alzheimer's 
disease (Li ci at, 2004). Deficiency of TNF receptor I causes a decrease in the 
inflammatory response and tissue damage following brain injury, suggesting an active 
role for this receptor in this process (Quintana ci at, 2005). 
In MS, there is some evidence for the implication of cytokine and chemokine receptors in 
the pathogenesis of the disease, (De Groot ci at, 1999; Glabinsk and Ransohoff, 2001; 
Misu ci at, 2003; Muller c/at, 2004; Selleberg c/at, 2000; Sorensen ci at, 1999; Trebst 
and Ransohoff, 2001; Zhang etal., 2000; Omari c/at, 2006), including expression of the 
chemokine receptor CXCR2 in normal and proliferating oligodendrocytes in active MS 
lesions. This further suggests a novel mechanism for the recruitment of oligodendrocytes 
in the area of damage (Omari ci al., 2006), and indicates a pivotal role for CCR2 and 
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CXRC3 in leukocyte recruitment into the CNS in multiple sclerosis (Krumbholtz ci at, 
2006; Mahad and Ransohoff, 2003; Sellebjerg and Sorensen, 2003; Sorensen, 2004). 
Finally, genetic studies have identified IL-4 receptor polymorphisms indicating a role for 
this receptor in MS susceptibility (Suppiah ci al., 2005). 
1.3.4 Cytokines in MS immunology 
There is evidence that cytokines are possibly implicated in three sites during the course of 
the disease: a) peripheral immune activation; b) entry of activated immune cells into the 
CNS, and 3) damage to the oligodendrocyte myelin unit (Cannella and Raine, 1995; 
Hollifleld ci at, 2003; Matusevicious ci al., 1996; Navikas and Link, 1996; Prat ci at, 
2002; Steinman, 1996). 
A proposed model for the involvement of cytokines in the pathogenesis of multiple 
sclerosis is shown in Figure 3. 
The CNS is separated from the general blood circulation by tight-junctioned endothelial 
cells that form the blood brain barrier (BBB). In the normal CNS, immune cells are 
sparse, in contrast to what is observed in MS. Thus it might be assumed that immune 
cells, including T cells, found in the MS brain are of blood origin and that before entering 
the UNS, they have passed the BBB. Only activated T cells are able to cross the BBB. 
This happens because adhesion molecules are overexpresed on activated T lymphocytes 
and therefore their entry into the CNS through blood-brain-barrier is facilitated (Nouza 
and Krejcova 1997; Shibagaki ci at, 1999). Therefore, an initial activation process is 
necessary for the subsequent trafficking of T cells into the CNS. The antigens that trigger 
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the immune response in MS are still unknown but, presumably, CNS-derived myelin 
antigens are presented to T cells in the periphery (Link et aL, 1994; Ruiz-Vazquez and de 
Castro, 2003; Sun J-B et at, 1991). 
Co-stimulatory molecules, together with the signal generated by formation of the 
trimolecular complex, are necessary for the activation of T cells. Recognition of the 
MHC-peptide complex by the T cell receptor (TcR) induces expression of CD40L on T 
cells. Activation of antigen presenting cells (APC) by T cells, through the simultaneous 
engagement of MHC by TcR and of CD40 by CD40L, leads to upregulation of the B7 
family of molecules on APCs. Subsequently, other molecules present on APCs bind to 
molecules on T cells and this interaction is responsible for their activation. 
APCs and T cells secrete several cytokines that may orchestrate immune responses. 
Among these cytokines, IL-12, IFN-y and TNF-a induce Thi-type immune response 
while IL-4 and IL-lU induce Th2-type responses (Martino et at, 1998; Druet et al., 
1995). In MS, it has been suggested that skewing the balance between Thl and Th2 
responses in favor of the latter may be beneficial (Charlton and Lafferty, 1995; Hintzen 
and Polman, 1997). 
The transmigration of leukocytes into the CNS is a multistep process that occurs in an 
ordered sequential fashion. First, there is a co-ordinated expression of vascular (selectins, 
ICAM-1, VCAM-l) and leukocyte (LFA-1, VLA-4) adhesion molecules which facilitate 
adhesive interactions between leukocytes and endothelial cells. The expression of the 
selectins, ICAM-1 and VCAM-1 on endothelial cells is upregulated by the 
proinflammatory cytokines IFN-y and TNF-a (Shrikant et al., 1994). Thus, upregulated 
TNF-cz in MS may play a role in increasing the expression of adhesion molecules, which 
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in turn results in the docking of activated leukocytes to vessel walls. The adhesion of 
molecules to the extTacellular substance and to each other mediates a series of biological 
events. The specificity of the adhesion, which is demanded for each one of these cases, is 
ensured by the contribution of specific adhesion molecules (Elovaara et aL, 2000). These 
molecules are expressed at the cell membrane under the action of specific stimulation. 
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Figurel-3. Proposed model for the involvement of cytokines in the pathogenesis of MS 
Regulation of APC-T cell interaction by cytokines (1); mutual bidirectional cross-inhibitory 
effects of pro- and anti-inflammatory cytokines (2); induction of adhesion molecules by TNF-a 
and IFN-y (3); entry of T cells into the CNS through disruption of the BBB by MIvIP-3 and 
MMP-9 (4); induction of macrophage/ microglia by IFN-y (5); myelin damage by TNF-a, MMP-
3 and MMP-9 (6-7); induction of apoptosis of oligodendrocytes by TNF-a and IFN-y (8); 
macrophage with engulfed myelin peptides (9); induction of B cells by anti-inflammatory 
cytOkines (10); myelin damage by antibodies directed against myelin components (11). (Diagram 
adapted from Ozenci et aL, 2002) 
The biological importance of cellular adhesion is not so much the multiplicity of 
functions that contribute but more its dynamic nature. Adhesion molecules not only 
ensure a very strong intracellular connection but also transmit intracellular messages 
which promote multiplication, differentiation and activation of the cells (Davey et al., 
2005). At present; adhesion molecules are classified into four classes: selectins, 
intergrins, molecules that belong to the immunoglobulins' superfamily, and CD44. Some 
representative adhesion molecules are ICAM-1, ICAM-2, ICAM-3 and VCAM-1 which 
are connected to the intergrins, and mainly serve the adhesion of cells to the endothelium. 
As mentioned earlier, these molecules appear to have an important role in the 
pathogenesis of MS. Several studies concerning the connection of the adhesion molecules 
to multiple sclerosis have shown that the VCAM-1/VLA-4 adhesion pathway is 
expressed at higher levels in chronic MS lesions while ICAM-1/LFA-1 is found in 
lesions, of all ages (Cannella and Raine, 1995), serum ICAM-1 levels are elevated in MS 
patients compared to patients with other neurological diseases and healthy controls, CSF 
VCAM- 1 is elevated over control and disease control samples, levels of serum VCAM- 1 
are significantly elevated in Primary Progressive Multiple Sclerosis (PPMS) compared 
with Relapsing Remitting Multiple sclerosis (RRMS) in remission, while ICAM-1 was 
significantly elevated in PPMS compared to all others MS groups. (Bilinska et al., 1999; 
Dore-Duffy et aL, 1995; Droogan et aL, 1996; Elovaara et aL, 2000; Mc Donell et al., 
1998; Mc Donnel et aL, 1999; Rieckman et aL,1994; Rieckmann et aL, 1998; Sellebjerg 
and Sorensen, 2003). 
Following adhesion, the next step involves chemoattraction of immune cells into the CNS 
mediated through a chemokine gradient, with chemokine concentrations augmented in 
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the CNS relative to blood (Stuve ci at, 1997). Activated cells, capable of expressing 
chemokine receptors, migrate along this chemokine gradient. Immune cells, including 
activated T cells cross the BBB by passing either through or between endothelial cells 
(Tsukada et al., 1993). They then traverse the basement membrane composed of proteins 
of the extracellular matrix. Metaloproteinases (MMP) secreted by immune cells such as 
MMP-3 and MMP-9 may disrupt the basement membrane allowing cells to enter the 
CNS (Leppert ci at, 2001; Lindberg et at, 2001). 
Damage to the oligodendrocyte myelin unit is thought to be a critical event in MS 
pathogenesis, involving the synergistic actiQns of various cells and molecules (Boccaccio 
and Steinman, 1996). Astrocytes and microglia present in the CNS are capable of 
secreting a number of cytokines and MHC Class II molecules and therefore may interact 
with blood-derived immune T cells leading to oligodendrocyte damage directly or 
indirectly (Aloisi ci at, 1999). The secretion of soluble mediators from T cells, such as 
IFN-y and TNF-a has been proposed to exert toxic effects on oligodendrocytes in vitro 
(Ozenci, et at, 2002). Furthermore, the same cytokines, along with IL-lb, are potent 
activators of microglia and macrophages which may further damage myelin (Takeuchi ci 
al., 2006). 
Another mechanism of demyelination in MS is related to apoptosis of oligodendrocytes. 
Activated T cells may play a role in this process through 1FN-y secretion. Addition of 
IFf4-y to cultured oligodendrocytes renders them susceptible to Fas ligand-mediated 
apoptosis by inducing Fas expression on their cell surface (Racke et at, 1994; Sharief et 
at, 2001). 
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The humoral response might also be important in MS pathogenesis. Augmented B cell 
response and autoantibodies to multiple myelin components are present in MS CSF 
(Zabaleta ci at, 2002). B cell proliferation, differentiation and antibody production are 
augmented by cytokines, including IL- 10. The process by which damage occurs to the 
oligodendrocyte myelin unit may be complex and involve all of the above mechanisms 
(Hemmer ci at, 2004). 
1.3.5 Previous studies on main cytokines and MS 
A number of studies have been performed on the secretion of cytokines during various 
stages of MS with conflicting results (Crucian ci at, 1996; Crucian ci at, 1995; Frei ci 
at, 1991; Inoges ci at, 1999; Link, 1998; Link ci at, 1994; Rieclunann ci at, 1994; 
Rieckmann ci at, 1995; Sharief and Hentges, 1991; Hermans ci al., 1997; Navikas ci al., 
1996). Elevated, normal and decreased levels of almost all cytokines have been reported 
(Ozenci ci at, 2002). Experimental animal models of MS have also been proposed in 
order to study different treatment protocols but outcome data is far from clear. Such 
contradictory results with regard to cytokine levels in MS most probably reflect 
methological dilemmas in addition to the complex biology of cytokines (Scrijcver ci at, 
2004). 
Three main cytokines, IFN-y, IL- 10, and TNF-a are believed to play an important role in 
the active phase of the immune response underlying MS (Karni ci al., 2006; Tran ci at, 
2006) and they constitute a major part of this thesis, however, several others such as IL-
12, and IL-4 are also of great interest. 
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1.3.5.1IFN-y 
IFN-y is the only proinflammatory cytokine so far shown to have any clear influence on 
the course of MS (Dai ci al., 2001; Vartarian et at, 1995). It is a homodimeric 
glycoprotein of 21-24 KDa molecular weight and is the central regulator of non-specific 
inflammation (Germenis, 2000). IFN-y is produced from Thl CD4 cells, from the 
majority of CD8 T-lymphocytes and a small number of NK cells (Germenis, 2.000). 
Therefore, IFN-y production from NK cells represerits a T-cell independent pathway for 
macrophage activation, involved in stimulation of the cytokine network afier bacterial 
exposure of the organism. IFN-y has potent proinflammatory properties, including the 
capacity to induce the production of other proinflammatory cytokines, such as IL-12, and 
the expression of MHC Class II molecules on monocyte/macrophages (Aloisi a al., 1999; 
Segal ci at, 2002; Hugh ci at, 1995; Kudinov ci at, 2003). IFN-y-mediated signaling 
leads to increased intracellular Ca 2 levels, therefore lowering the excitability threshold 
of T cells (Billiau, 1996; Young and Hardy, 1995). 
There are conflicting data on IFN-y levels in MS. Elevated numbers of IFN-y mRNA-
expressing blood mononuclear cells and increased serum IFN-y levels compared to 
controls have been reported (Karni, ci al., 2002). Alternatively, other studies have found 
no difference between MS patients and controls with regard to either the percentage of 
IFN-y expressing cells in the blood detected by flow cytometry or blood levels of IFN-y 
mRNA (Link a at, 1994; Noronha et at, 1993; Olsson ci at, 1990). 
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1.3.5.2 IL-JO 
IL-b (also known as cytokine synthesis inhibitory factor) is the most important anti-
inflammatory cytokine described to date (Asadullah ci at, 1998; Germenis, 2000; Kim et 
at, 1992; Moore et al., 1993). It is produced from Th2 T-helper cells and by some 
activated macrophages and has inhibitory effects on potentially dangerous 
proinflammatory cytokines, including TNF-a, IL-2, IFN-y, IL-12, and some chemokines 
(de Waal-Malefyt ci at, 1991; Fiorentino ci at, 1989; Fiorentino ci at, 1991; Germenis, 
2000; Mossman and Moore, 1991; Pahan ci at, 2000; van der Veen ci at, 1993; Vieira ci 
at, 1991;). The inhibitory effects of IL-10 on cytokine production are mainly mediated 
via suppression of expression of MHC Class II molecules and of adhesion and 
costimulatory molecules in monocytes/macrophages and dendritic cells (de Waal-Malefyt 
ci at, 1991). A potential therapeutic role for IL-10 in autoimmune diseases, such as RA, 
type 1 diabetes mellitus and psoriasis has been proposed (Asadullah ci at, 1998; 
D'Andrea ci at, 1993; Howard and O'Garra, 1992; Kennedy ci al., 1992; Mekala ci al., 
2005; Mossman, 1994; Pennline ci al., 1994; Rott ci al., 1994; Oswald ci at, 1992; 
Porrini,ei at, 1998). 
A number of studies have evaluated IL-lO in MS, with partly contradictory results (Brod 
ci al., 1997). Elevated numbers of IL-10 mRNA-expressing blood mononuclear cells, 
compared to controls, have been reported in patients with MS (Rep et at, 1999; Navikas 
etal. 1995). However, decreased IL-lU has also been observed in MS: serum IL-I 0 levels 
and numbers of IL- 10 secreting blood mononuclear cells were reported to be lower in MS 
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patients than in controls (Ozenci et al., 1999; Rep et al., 1996; Xiao et at, 1998; Zdanov 
et at, 2004). 
1.3.5.3 Tumor necrosis factor-a (TNF-a) 
TNF-a is a potent proinflammatory cytokine of l7kDa molecular weight (Gennenis, 
2000. The main cellular source of TNF-a are the LPS-activated macrophages, T cells and 
NK cells (Flohe et al., 2000; Germenis, 2000): TNF-a can be found in soluble and 
membrane forms and its function depends upon the quantity of its production (Germenis, 
2000). Its effects on cells range from the promotion of proliferation to apoptosis. At small 
concentrations TNF-a acts as an autocrine or paracrine regulator of leukocyte and 
endothelial cells functions (Robinson et al., 2002; Shrikant et al., 1994). TNF-a up-
regulates the expression of adhesion molecules on the endothelium, may activate 
polymorphonuclear cells to destroy microbes and induces CD80 and MHC Class II 
expression important in T cell activation (Germenis, 2000; Roitt et al., 1998). TNF-a 
stimulates production of IL-12, which in turn induces IFN-y production (Ozenci et at, 
2000). Because of its potent pro-inflammatory properties, it has been hypothesized that 
TNF-cz is detrimental in autoimmune disease (Shankar and Handa, 2004; Hofinan et al. 
1989). This has been demonstrated in RA and anti- TNF-u treatment has become part of 
the standard therapeutic arsenal for this disease (Strokus et at, 1998; Trinchieri, 1995). 
A number of studies have reported elevation of TNF-a in patients with MS compared to 
controls (Navikas et at, 1996). Numbers of TNF-cz mRNA-expressing blood cells, 
concentrations and levels of TNF-a-secreiing blood mononuclear cells were higher in MS 
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patients than in controls. Elevated levels of TNF-a-secreting cells may be important for 
the induction of pro-inflammatory immune responses in MS (Dowling etal., 1997). 
1.15.4 IL-12 
IL-U (IL-12p70) is a heterodimeric cytokine consisting of two covalently bound 
subunits, named p35 and p40 on the basis of their approximate molecular weights. IL-12 
promotes the development of ThI-type immune responses and is a powerful inducer of 
IFN-y production by T cells and natural killer cells (Adorini, 1999; Aste-Amezaga et at, 
1994; Gately et at, 1998; Seder et aL, 1993; Sieling et aL, 1994; Trinchieri, 2003). IL-l2 
also induces cell-mediated cytotoxicity and exerts co-mitogenic effects in T cells (Rogge 
et at, 1997). 
IL- 12 is thought to play a central role in the pathogenesis of a group of organ-specific 
autoimmune diseases that may include MS, uveitis, type I diabetes mellitus and 
rheumatoid arthritis (RA) (Kang and Kim, 2006). IL-12 acts through its receptor, which 
is composed of two subunits, IL- 1 2Rf3 I and IL-i 2RD2. The interaction of IL- 12 with IL-
12R represents a pivotal crossroad in the development of Th1-type immune responses 
(Rogge et aL, 1999). IL-i 2RJ32 is thought to be a central molecule in these responses 
(Gillespie et at, 2000). 
It has been shown in vitro that IL-12RD2 is a marker for Thl cells and that it determines 
IL-12 responsiveness (Matusevicious et al., 1998; van Boxel-Dezaire, 1999). II has also 
recently been demonstrated that pulmonary T cells from patients with sarcoidosis, but not 
from patients with asthma, exhibit enhanced IL-12RD2 expression, suggesting the 
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importance of IL-12R2 as a marker for Thi-type autoimmune diseases (Fassbender et 
at, 1998; Ozenci et at, 2001) 
In MS, conflicting results regarding IL-12 p40 levels have been reported (Balashov et at, 
1997; Leonard et at, 1995; Rohowsky-Kochan et at, 1999; Fassbender et at, 1998). 
Increases, compared to controls, both in the number of IL-12 p40 mRNA-expressing 
blood MNC and of IL- 12 p40  mR}TA levels in blood have been described (Reesen et at 
1999). In contrast, levels of IL-12 p40 were found to be similar in CSF of both MS 
patients and controls (Drulovic etal., 1997). 
1.3.5.5 IL-4 
Interleukin 4 (IL-4) is a. •pleiotropic Th2-derived immune cytokine, which is 
predominantly produced by activated T lymphocytes, mast cells and basophils 
(Germenis, 2000). IL-4 has been shown to have various activities in many different cell 
types, such as T cells, B cells, monocytes, endothelial cells, and fibroblasts. These 
activities include inhibition of cell proliferation, regulation of adhesion molecules, and 
induction of signal transduction through the JAK/STAT pathway (Duvey et al.,. 2006; 
Luscinskas et al., 1994; Roitt et at, 1998; Rahaman et at, 2002). 
To induce biological activities, IL-4 must bind to its specific receptor, which is generally 
present on the plasma membrane of target cells. IL-4 initiates transmembrane signaling 
by activating two types of transmembrane receptors. The type I receptor comprises the 
IL-4Ra subunit, which binds to IL-4, and the yc chain that is shared by IL-2, IL-7, IL-9, 
and IL- 15. The type II receptor comprises the IL-4Ra chain and the IL- 1 3Ra I subunit, a 
low affinity receptor for IL-13 that constitutively associates with Jak2 or Tyk2. 
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In MS, conflicting results exist regarding IL-4 secretion, several studies indicate a 
downregulation of this anti-inflammatory cytokine during relapses (Bartosik-Psujek and 
Stelmasiak, 2005; Franciotta et at, 2000) whereas others indicate that IL-4 levels in CSF 
was significantly higher during the stable stage as well as during relapse when compared 
to controls (Bienvenu et at, 2000). 
1.3.6 Cytokine methodology 
Different methods focus on different stages of cytokine production and secretion 
(Bienvenu et at, 1998; Nguyen et al, 1999). Cytokine protein levels in extracellular 
fluids may be measured by enzyme-linked immunoassay (ELISA). However, cytokines 
are very rarely found in an unbound state but are nearly always bound to soluble cytokine 
receptors, anti-cytokine antibodies or binding proteins. Since cytokines typically have 
short half-lives, i.e. are rapidly taken up and degrade, results obtained by ELISA are 
frequently negative and/or difficult to interpret. Furthermore, unlike hormones, cytokines 
mostly exert their effects at short distances from the site of production. Therefore, the 
overall serum concentration of cytokine may not reflect its rate of production and/or 
secretion. Detection of cytokines at the levels of the individual cell, i.e. the cytokine-
producing/secreting cell may be more relevant for an understanding of the involvement of 
an individual cytokine in the immune process (Stott, 2000; Sedwick etal., 1983). 
Cytokine mRNA levels can be examined by Northern blot, semi-quantitative reverse 
transcription polymerase chain reaction (RT-PCR) or in situ hybridization. These 
methods are sensitive enough to detect cytokine mRNA in the absence of stimulant. A 
drawback with these methods is that results based on determinations of mRNA levels do 
not necessarily reflect levels of secreted cytokines (Froncillo et al., 1996; Rein et al., 
2001). 
Immunostaining allows phenotyping and, to some extent, detects the amount of cytokine 
expressed in the cell. However, the sensitivity of this method in cytokine detection is low, 
and the method generally requires in vitro stimulation, which may yield results which are 
unrepresentative of the levels of cytokines in vivo (Ozenci et aL, 2002). 
ELISPOT assays, originally described for the enumeration of antibody-secreting cells and 
then modified for the detection of cells secreting cytokines, offer the possibility of 
determining .the number of cells feleasing a specific translated protein. The assays allow 
real-time cytokine detection by identifying the cells actively secreting cytokines at a 
given time point and are sensitive enough to detect cytokine-secreting cells in the absence 
of stimulant. Instead of measuring mRNA or the accumulation of cytokine in the 
cytoplasm of pharmacologically treated cells, ELISPOT assays detect immunologically 
relevant secretion of the cytokine, downstream of any post-transcriptional or post-
translational regulation. Recent developments in ELISPOT assays, including double-
colored ELISPOT assays which allow detection of two different cytokine-secreting cells 
in the same well, and automatic readers which minimize the risk of subjectivity in 
reading plates, have brought new advantages to the use of ELISPOT assays in cytokine 
research (Czerkinsky et at, 1988; Duddy et al., 1999; Jansson et al., 2003; McCutcheon 
et al., 1997; Masse and Gray, 2002). 
However, even ELISPOT assays have some drawbacks including difficulties in 
establishing the assay for new cytokines due to the scarce availability of suitable antibody 
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pairs, and an ability to determine the amount of cytokine secreted by the individual cell, 
i.e., current ELISPOT assays are semi-quantitative. 
Therefore, it is clear that production of cytokines is regulated at several different levels, 
and it is difficult to design a single method ideal for cytokine measUrements in general. 
Furthermore, the method of choice in cytolcine research is totally dependent on the 
question that is being asked. 
1.4. Working Hypothesis 
Taking the previous literature into account, a working hypothesis for the development of 
MS may be suggested. The pathogenesis of multiple sclerosis is highlighted by an 
inflammatory response and myelin destruction. The inflammatory infiltrate in MS lesion 
is composed of T lymphocytes, a small number of B lymphocytes, activated microglia 
and macrophages which interact with myelin sheaths and are actively engaged in the 
demyelinating process. There is a local production or expression of immune-related 
molecules such as MI-IC, adhesion molecules, pro- and anti-inflammatory cytokines and 
chemokines which contribute to an imbalance between Th 1 and Th2 T cell-mediated 
immune response. - 
There are two predominant hypotheses to explain the immune-mediated mechanisms of 
myelin destruction in MS lesions: either direct T-cytotoxic lymphocyte-mediated lysis of 
oligodendrocytes (through their products such as lymphotoxin and perforin or through 
activation of the CD95-signalling pathway) or an indirect mechanism in which activated 
T cells induce toxic cytokine production (e.g. nitric oxide or TNF-a) by accessory T cells. 
T-cell produced cytokines may be involved in the direct damage to oligodendrocytes. If 
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the destructive inflammatory process in the UNS could be arrested at an early stage it 
would prevent the accumulation of neurological disability. 
Therefore, by investigating cytokine secretion patterns as well as the other immune-
regulatory molecules in MS patients and by controlling their effects through 
administration of IFNf3 products to these patients, it would be possible to diminish 
disease progression, reduce relapses and improve quality of life. Investigation of the 
mechanism of action of the two IFNI3 products will be able to suggest a more efficient 
therapeutic modality than current treatments. 
1.5 Aims of the Study 
The aims of the present study were: a) to characterize the cytokinetic profile of MS 
patients by investigating the secretion of the main pro- and anti-inflammatory cytokines 
of peripheral blood mononuclear cells using ELISPOT methodology, b) to investigate: 
the expression levels of cytokine receptors in the three major T cell populations (CD4, 
CD8, NK cells), and to study the induction of apoptosis by measurement of CD95 levels 
in the serum of MS patients, and the involvement of adhesion molecules, VCAM-1 and 
ICAM-1 in lymphocyte trafficking. Also c) to measure the involvement of 
metalloproteinases in oligodendrocyte destruction, d) to study the effect of IFNJ3 
treatment and to elucidate the mechanism of action of the different forms of IFNJ3 
treatment (IFN-la/fl3) on cytokine secretion, percentages of peripheral blood 
mononuclear cells expressing cytokine receptors, expression of adhesion molecules, 
metalloproteinases and apoptotic markers (CD95). e) Finally it was important to evaluate 
the effectiveness of the ELISPOT assay in MS disease monitoring. 
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CHAPTER 2. MATERIALS AND METHODS 
2.1 Clinical methods 
2.1.1 Description of the study population 
The study involved 60 patients diagnosed with multiple sclerosis and 25 age-matched 
healthy controls without any neurological or autoimmune disease randomly admitted to 
the Henry Dynant Hospital in Athens. Informed consent was obtained from all patients 
and the study was approved by the University of Athens Medical School Ethics 
Committee. 
All MS patients were diagnosed with the relapsing-remitting form (RRIvIS) of the disease 
based on laboratory, electrodynamic and imaging control (MRI) examinations. At the 
time of blood sampling the mean age of the patient group was 34*3.2 years (ranging from 
29-3 9 years). All enrolled patients had at least two relapses in the last 2 years, and they 
were not treated with any immunomodulating drug before participating in this study. 
Based on whether or not receiving IFNI3 therapy, the patients group was separated into 
two main subgroups, twenty patients who were not receiving IFNJ3 therapy and forty 
patients who were receiving IFNP treatment for six months. The group that was receiving 
IFN( treatment was further divided into two subgroups: twenty patients were injected 
intramuscularly once a week with 30 pg of Avonex (IFNI3-la) and twenty patients were 
injected subcutaneously every other day with 250 pg of Betaferon (IFND- I 3) for 6 
months. For the patients who were receiving IFN, the mean time from the onset of the 
disease was 3.2±1.2 years, whereas for patients who were not receiving therapy the mean 
time from the onset of the disease was 3 years. 
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The control group consisted of age- and sex-matched individuals: twenty five patients 
(mean age 38.8±6.9 years, range 34-43) with headache who underwent lumbar puncture 
for exclusion of subarachnoidal hemorrhage or patients who underwent spinal anesthesia 
(for hernia repairs or leg, gynecological or urological operations). 
Peripheral blood was sampled from each MS patient without and after 6 months therapy, 
during a clinically inactive and at least 1-month steroid-free period. Samples in month 6 
were obtained 66-72 h after the most recent treatment of JFN. Serum samples of the 
controls were collected in a similar time frame. Aliquots were centrifuged and the serum 
immediately frozen at 
-80°C. 
2.1.2 Evaluation ofpersonal history (Description of the questionnaire) 
All participants, after clinical diagnosis, laboratory diagnostic examination and MRI 
results confirmed their inclusion in one of the two main groups, were asked to complete a 
questionnaire which was filed on a statistical package for further analysis. For accurate 
completion of the questionnaire the help of relatives and caregivers was used when 
necessary. It contained (1) demographic data: sex, age, marital status, occupation and 
educational level, (2) personal history: history of physical illness, history of viral 
infections, vaccinations, autoimmune and inflammatory disorders (e.g. allergies), and 
medication, (3) family history of autoimmune disorders, and (4) life-style information 
(see Appendix I). 
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2.1.3 Blood Sampling 
Blood samples were collected in Fieparin-containing tubes and were immediately 
transferred to the Department of Biological Chemistry in The University of Athens 
Medical School for separation of lymphocytes using the Ficoll procedure (see below). 
Serum/plasma samples were also collected from each patient. 
2.1.4 Peripheral blood mononuclear cells (PBMC) isolation using the Ficoll-Hypaque 
density gradient centrifugation 
Peripheral blood (15ml) collected in heparin-containing tubes was layered on top of 
Ficoll-Hypaque solution (lOml) (Amerhsam). The mixture was centrifligated at 1500 rpm 
for 20 mm, at room temperature, and the distinct cell layers obtained. Erythrocytes and 
granulocytes sedimented at the bottom of the tube and PBMCs were isolated in the 
interface. By using aseptic techniques, PBMCs were collected in separate tubes, washed, 
counted and resuspended in solution containing fetal calf serum (FCS) (80%) and DMSO 
(1 .Sml) (20%). Cell viability was determined by trypan blue exclusion. 
Cryovials containing the lymphocytes (2x I 0 6cells/ml) were stored in liquid nitrogen until 
analysis. 
2.1.5 Freezing and thawing procedures for human PBMCs 
For freezing, PBMCs were suspended at a concentration of 2x10 7/ml in 2ml of freezing 
medium A (60% FCS, 40% RPMI) at room temperature. An equal volume of freezing 
medium B (20% DMSO, 80% FCS), also at room temperature, was added dropwise, 
while gently mixing by shaking the tube. The resulting cell suspension (4m1) was pipetted 
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in aliquots (1.5ml) into cryovials (1.8m1) (Greiner Labortechnik, Frickenhausen, 
Germany). The tubes were placed into a pre-chilled (4 °C) Nalgene Cryogenic Controlled-
Rate Freezing Container (Fisher Scientific, Hanover Park, IL) that was placed into a -80 
C freezer. After 24 h, the samples were transferred to a liquid nitrogen tank for storage 
until required for assay (Kreher et al., 2003). 
For thawing, cryotubes were placed in a water bath (37 °C) and, as soon as the samples 
were completely thawed, they were pipetted into a 1 Sml tube containing a 2-fold amount 
of complete RPMI medium (93% RPMI- 1640, 5% heat-inactivated AB serum, 1% L-
glutamine, 1% Penicillin—Streptomycin) at room temperature. The cells were washed 
twice at room temperature. Cell recovery and viability were determined by acridine 
orange and ethidium bromide (Becton Dickenson, San Jose, CA) staining (Kreher et aL, 
2003). 
2.2 Characterisation of the biochemical profile of MS patients 
2.2.1 Estimation of triglycerides levels in plasma samples 
The method was based on the enzymatic hydrolysis of serum or plasma triglycerides to 
glycerol and free fatty acids (FFA) by lipoprotein lipase (LPL) (Figure 4). Glycerol was 
phosphorylated by adenosine triphosphate (ATP) in the presence of glycerokinase (GK) 
to form glycerol-3-phosphate (G-3-P) and adenosine diphosphate (ADP). G-3-P was 
oxidized by glycerophosphate oxidase (GPO) to form dihydrooxyacetone phosphate 
(DHAP) and hydrogen peroxide. 
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A red chromogen was produced by the peroxidase (POD) catalyzed coupling of 4-
aminoantipyrine (4-AA) and phenol with hydrogen peroxide (11202), proportional to the 
concentration of triglyceride in the sample. 
Triglycerides + 31120 LFL, Glycerol + 3 FFA 
Glycerol + ATP GK  Glycerol-3-P + ADP 
Glycerol-3-P +02 °p° DRAP + H202 
4-AA + 4 Phenol 	 PODH202  Quinoneimine + 1120 
Figure 2-1. Enzymatic hydrolysis of serum or plasma triglyceride to glycerol and free 
fatty acids (FFA) by lipoprotein lipase (LPL) 
Procedure 
An aliquot of 1 ml of monoreagent was mixed with either sample or standard (lOjil) (see 
Appendix II). The tube was allowed to stand for 15 min at room temperature (16-25 °C). 
The absorbance (A) of the samples and the standard was read at 500 nm against the 
reagent blank (1 ml of monoreagent only). 
The triglyceride concentration was estimated using the following formula: 
(Asamp ie/ Astandard) X Csianciar = mgldl triglycerides. 
Samples with concentrations higher than 600 mgldl were diluted 1:2 with saline and 
assayed again and the results multiplied by 2. 
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The reference values according to the manufacturer's instructions (Linear chemicals, 
Spain) were: normal C 150 mg/dL, borderline (150-199 mgldL), high (200-499 mgldL) 
and very high a 500 mg/dL. 
The precision of the method for 10 replicates of each level are shown in the table below: 
Table 2-I. Precision of triglycerides method 
mgldl Within-run Between-mn 
Mean 220 368 512 220 372 490 
SD 1.8 2.6 2.4 1.9 2.8 3.7 
CV% 0.81 0.7 0.7 0.47 0.27 0.76 
N 10 10 10 10 10 10 
In order for the results to be expressed as SI units, a converting factor (mgldL x 0.0113 = 
mmol l) was used. 
2.2.2 Estimation ofglucose concentration in plasma samples 
The method was based on the oxidation of glucose, present in the sample to gluconic acid 
in the presence of glucose oxidase (Figure 2-2). Liberated hydrogen peroxide was 
detected by a chromogenic oxygen acceptor, phenol-ampyrone and the red quinine 
formed was proportional to the amount of glucose present in the sample. 
0 
Glucose + V2 02 + H20 (sOD 	 Gluconic acid + H202 
2 H202 + phenol + 4-ÀY POD 
 *'Red Quinone + 4 H20 
Figure 2-2. Glucose oxidation reactions 
Procedure 
An aliquot of 1 ml of glucose monoreagent was mixed with 'either sample or standard 
(l0sl) and incubated for 10 min at 37 °C (or 20 min at 15-25 °C) (see Appendix II). The 
absorbance of the unknown and the standard was measured against a blank reagent at 510 
nm (500-530 nm). 
Estimation of glucose concentration in the sample was performed using the following 
formula: 
(Asampie! As tandard) X C s tanciartj = mgldl glucose 
The linear range was up to 500 mg/dL and normal values, according to the manufacturers 
instructions (Linear chemicals, Spain) were 76-110 mg/dL. In order for the results to be 
expressed as SI units, the converting factor was: mg/dL x 0.0555 = mmol/L. 
2.2.3 Estimation of HDL-Cholesterol in plasma samples 
The direct method for quantif'ing cholesterol in high density lipoproteins (HDL) was a 
homogeneous enzymatic test without the need for any off-line pre-treatment or 
centrifugation steps. 
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The procedure comprised of two steps. In the first step, cholesterol in lipoproteins other 
than HDL in the test sample were decomposed by the simultaneous action of cholesterol 
esterase and cholesterol oxidase at pH 7.0, giving, as end-products, cholestenone and 
hydrogen peroxide, the latter being decomposed to water and oxygen by catalase. 
In the second step, a surfactant, which specifically acts on HDL, was added to the 
reaction product ofthe first step being the remaining cholesterol quantified by a Trinder's 
type reaction in which the aniline derivative, HDAOS [N-(2-hydroxy-3-sulfopropyl)-3,5-
dimethoxyaniline], and 4-aminoantipyrine (4-AA) as a coupling reagent were condensed 
by H202 in the presence of peroxidase (POD) to form a red quinoneimine dye 
proportional to the concentration of HDL-cholesterol in the sample. 
Procedure 
A volume of 300 R1  of HDL-C enzyme reagent was mixed of sample (4i.tl) (see Appendix 
Ii). The mixture was incubated for 5 min at 37 °C. Then, POD/4-AA (lOOgI) reagent was 
added and mixed. After 30 seconds, the absorbance of the sample (Ai) and the calibrator 
(Ai) was read at 37 0C at 600 nm against the reagent blank and after 3 minutes a second 
absorbance reading was taken at 37 °C of the sample (A21) and the calibrator (A2). 
The reagent blank was a mixture of enzyme reagent (300p1) and H2O (4i.tl)  and the 
calibrator was a mixture of enzyme reagent (300j.tl) and LDL/HDL calibrator reagent 
(41.xL) (under the same procedure as the sample). 
Estimation of the concentration of HDL-C was performed using the following formula: 
(A2 - Ai) / (A2 - A1) x Ccalibrator = mgldl HDL-cholesterol 
The clinical values of HDL-cholesterol used to classify risk groups (based on Warnick & 
Wood, 1995) are shown below: 
Table 2-2. Clinical values of HDL-cholesterol used to classify risk groups 
Cholesterol from lipoproteins of high density RISK 
Men 
>55mgIdL Low 
35-55 mg/dL Moderate 
<40 mg/dL High 
Women 
>65 mg/dL Low 
45-65 mg/dL Moderate 
<45 mg/dL High 
The characteristics of the analytical performance according to manufacturers instructions 
(Linear Chemicals, Spain) were (a) precision, the coefficient of variation of the within-
run test (N=10) was commonly found under 3%; (b) sensitivity, using a 1:75:25 sample 
reagents at 600 nm, cholesterol (50 mgr) produced a net absorbance between 0.050/0.090 
and (c) correlation, this test (y) was compared with a commercially available method (x) 
and the results were the following: r= 0.997, r0.987x + 1.4 
2.2.4 Estimation of total cholesterol in plasma samples 
The method for total cholesterol measurement in plasma involved the use of three 
enzymes: cholesterol esterase (CE), cholesterol oxidase (CO) and peroxidase (POD). In 
the presence of the former, a mixture of ADPS (N-ethyl-N-propyl-m-anisidine) and 4- 
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aminoantipyrine (4-AA) was condensed by hydrogen peroxide to form a quinoneimine 
dye proportional to the concentration of cholesterol in the sample (Figure 2-3). 
Cholesteryl esters CE 	 Cholesterol + Fattyacids 
Cholesterol +02 
	
CO 	 Cholestenone + 1-1202 
4-AA + ADPS 	 H202 p,jg 
	
Quinoneimine + 41-120 
Figure 2-3. Reactions for cholesterol measurement in plasma 	 - 
Procedure 
Sample (lojsl) was mixed with monoreagent (1.0 ml) and the mixture (see Appendix II) 
incubated for either 10 min at room temperature or 5 min at 37 °C. The absorbance (A) of 
either the sample of the standard was read at 550 nm against the reagent blank. 
The reagent blank contained monoreagent (1.0 ml) and the standard solution contained 
monoreagent (I ml) and cholesterol standard (10 gI). 
Estimation of total cholesterol was performed using the following formula: 
(Asanipie/ Astandard) x Cstan janj = mgldl total cholesterol 
Samples with concentrations higher than 600 mg/dl were diluted 1:2 with saline and 
assayed again and the results were multiplied by 2. 
Updated clinical values of total cholesterol were used to classify risk groups as shown 
below: 
Table 2-3. Clinical values of total cholesterol used to classify risk groups 
Total Cholesterol concentration Risk Classification 
C 200 mg/dl Desirable 
200-239 mg/dL 
	
: Borderline high 
>240mg/dL High 
The linearity of the method was up to 600 mg/dL. 
According to the manufacturer's instructiohs (Linear Chemicals, Spain), the precision of 
the method for 20 replicates of each level is shown in the table below: 
Table 2-4. Precision of the cholesterol method 
mgldl Within-run Between-run 
Mean 143 162 267 143 162 267 
SD 2.4 2.1 1.7 2.9 3.1 4.3 
CV% 1.7 1.29 0.64 2.02 1.91 1.61 
N 20 20 20 10 10 10 
Sensitivity: Using a 1:100 sample/reagent dilution at 550 nm, 10 mg cholesterol produced 
a net absorbance of approximately 0.030. 
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2.3 Study I: Evaluation of cytokine secretion levels in MS patients and 
controls 
? I flntnntin n,,d nn,,nqnrntinn ncn,tnl4no c'o,-roflnr, h,nnnn ppLfr I.., RI ic'Pr)T 
methodology 
Human cytokine ELISPOT assays were performed as described by Helms et al., 2000. 
Briefly, cell suspensions were prepared at different densities, ranging from 5 x 10 5 to 2 x 
106 cells/mI. Each cell suspension (100 p1/well) was added into ELISPOT plate 
microwells which contained nitrocellulose membranes in the bottom pre-coated with the 
desired anti-cytokine capture antibody. Cell suspensions were incubated at 37 °C in a 5% 
CO2 humidified incubator for 24hrs. The next day, cell suspensions were aspirated, the 
welts were washed 2x with deionized (DI) water and allowed to soak for 3 - 5 min during 
each wash step. They were further washed three times with well prepared washing buffer 
(200jil/ml PBS with 0.1% Tween-20). The Detection Antibody Solution (towards the 
cytokine in question) was added (100 p1 /well), and the plate incubated for 2 hr at room 
temperature. The wells were again washed three times with washing buffer (200 sl/well), 
allowed to soak I - 2 min during each wash step and Streptavidin-HRP solution (100 
pu) added to each well. The plate was then incubated for 1 hr at room temperature and 
after washing wells four times with washing buffer (200p.1/ml); they were further washed 
twice with PBS (200 id/mI ). AEC Substrate Solution (100 p1) was added to each well 
and spot development monitored between 5 - 60 min. Substrate reaction was stopped by 
washing wells with DI water and the plate air-dried at room temperature for 2 hr to 
overnight, until it was completely dry. 
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2.3.2 Image analysis oJELISPOT data 
An ImmunoSpot Image Analyzer (Aid, Gennany), specifically designed for the 
ELISPOT assay was used. Digitized images were analyzed for the presence of areas in 
which color density exceeds background by an amount set on the basis of the comparison 
of experimental wells (containing T cells, APC and antigen) and control wells 
(containing T cells and APC only). After background and noise subtraction, custom 
software was used to analyze spot morphology for circularity and density distribution to 
identify and separate touching and overlapping spots (Karulin etal., 2000). Objects that 
met these criteria were recognized as spots and counted. The measurement of spot-size 
distribution was also a built-in function of the software; it was based on the array of spot 
sizes in a given well sorted according to distinct size categories. 
2.3.3 Optimization of ELISPOT methodology 
Optimization of the ELISPOT assay for sensitivity (among different ELISPOT company 
kits) and minimization of backgrOund signal was performed before evaluation of the 
experimental samples. The Becton Dickinson ELISPOT plates were selected for their 
higher sensitivity and the camera settings were adjusted based on the company's specific 
requirements by an experienced technician of the manufacturing company (Aid, 
Germany). 
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2.3.4 ELISPOT data statistical analysis 
ELISPOT frequencies were compared between groups using a t-test calculated by 
SigmaStat (version 7.0, SPSS, Chicago, IL). Statistical significance was set at p<0.05. 
The coefficient of variation (CV) to assess the relative variability of intra-assay variations 
was calculated according to the formula CV= (Standard deviation of spot counts from 
triplicate wells/Mean spot counts in the same triplicate wells) xlOO. 
2.4 Study II: Percentage of peripheral lymphocytes expressing cytokine 
receptors in MS patients and controls 
2.4.1 Cell cultures for studying ofpercentages ofperipheral lymphocytes expressing 
IFN7R, IL -1 OR, INF-aR and IL-12R. 
PBMCs (2xl06/ml) were resuspended in Dulbecco's modified Eagle medium 
supplemented with penicillin (50 U/mI), streptomycin (50.tg/ml), L-glutamine (2 Mm), 
MEM non-essential amino acid solution (1%) and fetal calf serum (10%) (all from 
Gibco), and plated in plates (12-well) (Nunc, Roskilde, Denmark) at 5X10 6/well. Cells 
were cultured for 72 h (3 7°C, 5% CO2) with or without PHA (2sg/ml), collected and 
used for flow cytometric determination of IFN-7R, IL-bR, TNF-czR and IL-12R131 
subunits. 
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2.4.2 Flow-cytometric detection of PBMC expressing IFN-yR, IL-bR, ThTF-aR and IL-
12R in MS patients 
For flow cytometric analysis, untreated or phytohemagglutinin (PFLA)-activated blood 
PBMC were washed with PBS, counted and resuspended at 5X10 6/ml in PBS containing 
BSA (1%). Cell suspensions (100 i.tl per test) were used. Cells were incubated with 
unlabelled anti- IFN-yR, anti-IL-bR, anti-TNF-czR and anti-IL-12Rl mAbs (Becton-
Dickinson Mountain View, CA), or irrelevant IgG2a (final concentration I jig/mI for all) 
for 15 min at RT, washed and incubated with biotinylated mouse anti-rat F(ab')2 
fragments (1:500, 15 mm, RT). After another wash, cells were incubated with PB-
streptavidin (1:100, 15 mm, RT). During the same step, cells were co-stained with 
PerCP-anti-CD3/FITC-anti-CD4, PerCP-anti-CD3/FJTC-anti-CD8, or FITC-anti-CD56, 
to detect CD4 T cells, CDS I cells or NK cells, respectively (Becton-Dickinson 
Mountain View, CA). After a final wash, cells were resuspended in PBS (200 RI)  and 
analysed by FACScan flow cytometer using CellQuest software (both from Becton-
Dickinson). A total of events (20.000 per test) were routinely acquired. CD4 T cells, CD8 
I cells and NK cells were gated electronically, and expression of IFN-7R, IL-I OR, TNF-
oR and IL-12R subunits were analysed separately for these cell populations. 
2.5 Study III: Estimation of the apoptotic marker CD95 (Fas) 
expression 
2.5.1 Quantitative determination of soluble CD95 in human plasma samples 
The sCD95 kit (Diaclone Research, France) is a solid phase sandwich enzyme-linked-
immunosorbent assay, using a monoclonal antibody specific for sCD95 coated onto the 
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wells of a microtiter plate. Samples, including standards of known sCD95 concentrations 
and unknowns, were pipetted into these wells. During the first incubation, the sCD95 
antigen and a biotinylated monoclonal antibody specific for sCD95 were simultaneously 
incubated. After washing, the enzyme (streptavidin-peroxydase) was added. After 
incubation and washing to remove the entire unbound enzyme, a substrate solution, 
acting on the bound enzyme, was added to induce a coloured reaction product. The 
intensity of this coloured product was directly proportional to the concentration of sCD95 
present in the samples. 
Procedure 
An aliquot of sCD95 standard (100 pL) (ranging from 93.75 to 3000 pg/mI), plasma 
sample or control sample was added to the sCD95 microwell plate followed by diluted 
biotinylated anti-sCD95 antibody (50 jil). The plate was covered and incubated for 1 hour 
at room temperature (18 °C - 25°C). At the end of the incubation time, the plate was 
washed three times with washing buffer and of streptavidin-FIRP solution (100 p1) 
distributed to all wells, including blank wells. The plate was again covered and incubated 
for 30 min at room temperature. 
After a further three washes, ready to use tetramethylbenzidine (TMB) substrate solution 
(100 gL) was added to all wells, including the blanks. The plate was incubated in the dark 
for 12-15 min at room temperature. Direct exposure to light was avoided by wrapping the 
plate in aluminum foil. 
The enzyme-substrate reaction was stopped by quickly pipetting H2SO4  lM (100 p.L) 
stop reagent into each well, including the blank wells, to completely and uniformly 
inactivate the enzyme. Results were read immediately after the addition of the H2SO4 
stop reagent. 
The absorbance of each well was read on a Chemwell spectrophotometer (Awareness, 
USA) using 450 nm as the primary wavelength and optionally at the 620 nm as the 
reference wavelength. 
Data analysis was performed by the generation of a linear standard curve by plotting the 
average absorbance on the vertical axis versus the corresponding sCD95 standard 
concentration on the horizontal axis. the amount of sCD95 in each sample was 
determined by extrapolating OD values to sCD95 concentrations using the standard 
curve. In terms of assay sensitivity, the minimum detectable dose of sCD95 was less than 
47 pg/mI (based on manufacturer's instructions). 
Concerning the precision of the assay according to manufacturer's instructions, for intra-
assay the upper values were 1719 ± 106, CV 6.1% and the lower values were 703 ± 39, 
CV 5.5%. For inter-assay variation, the upper values were 1752 ± 145, CV 8.2% and the 
lower values were 856 ± 68, CV 7.9%. 
2.6 Study IV: Estimation of expression of the adhesion molecules 
VCAM-1 and ICAM-1 
2.61 Quantitative determination of soluble Vascular Cellular Adhesion Molecule-i 
(s VCAM-1) in human plasma samples 
The VCAM-1 kit (Diaclone Research, France) is a solid phase sandwich enzyme-linked-
immunosorbent assay, using a monoclonal antibody specific for VCAM- 1 pre-coated 
onto wells of microtiter strips. Samples, including standards of known sVCAM-1 
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concentrations, controls and unknowns were pipetted into these wells. During the first 
incubation, the sVCAM-1 antigen and a biotinylated monoclonal antibody specific for 
VCAM-1 were simultaneously incubated. After washing, the enzyme (streptavidin-
peroxidase) was added. After incubation and washing to remove the unbound enzyme, a 
substrate solution, which acted on the bound enzyme, was added to induce a colored 
reaction product. The intensity of this colored product was directly proportional to the 
concentration of sVCAM-1 present in the samples. 
Procedure 
An aliquot of sVCAM-1 standard (ranging from 50 to 1.56 ng/ml), plasma sample or 
control sample (100 gil) was added into the VCAM- 1 microwell plate followed by the. 
diluted biotinylated anti-sVCAM-1 antibody (SOgsl). The plate was covered and incubated 
for 1 hour at room temperature (18 °C - 25 °C). At the end of the incubation time, the 
plate was washed three times with washing buffer and streptavidin-HRY solution (100g11) 
distributed to all wells, including blank wells. The plate was again covered and incubated 
for a further 30 min at room temperature. 
After a further three washes, ready to use tetramethylbenzidine (TMB) substrate solution 
(100 gil) was added to all wells, including the blanks. The plate was incubated in the dark 
for 12-15 min at room temperature. Direct exposure to light was avoided by wrapping the 
plate in aluminum foil. 
The enzyme-substrate reaction was stopped by quickly pipetting H2SO4 1M (lOOpI) stop 
reagent into each well, including the blank wells, to completely and uniformly inactivate 
the enzyme. Results were read immediately after the addition of the H2SO4 stop reagent. 
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The absorbance of each well was read on a Chemwell spectrophotometer (Awareness, 
USA) using 450 nm as the primary wavelength and optionally at the 620 nm as the 
reference wavelength. 
Data analysis was performed by the generation of a linear standard curve by plotting the 
average absorbance on the vertical axis verthis the corresponding sVCAM-1 standard 
concentration on the horizontal axis. The amount of sVCAM- 1 in each sample was 
determined by extrapolating OD values to sVCAM- I concentrations using the standard 
curve. - 
The average concentration of sVCAM-1 in normal serum samples (according to 
manufacturer; Diaclone Research, France) was 626 ± 340 nglmL as detected in 80 normal 
human serum samples. The minimum detectable dose of sVCAM-1 was less than 0.6 
ng/mL (based on manufacturer's instructions). For intra-assay variation, the upper values 
were 48.79 ± 0.221, CV 0.45% and the lower values were 5.81 ± 0.132, CV 2.27%. 
2.6.2 Quantitative determination of soluble Inter Cellular Adhesion Molecule-I (5ICAM-
1) in human plasma samples 
The ICAM-1 kit was a solid phase sandwich enzyme-linked-immunosorbent assay, using 
a monoclonal antibody specific for ICAM-1 pre-coated onto wells of microtiter strips. 
Samples, including standards of known sICAM-1 concentrations, controls and unknowns 
were pipetted into these wells. During the first incubation, the sICAM-1 antigen and a 
biotinylated monoclonal antibody specific for ICAM-1 were simultaneously incubated. 
After washing, the enzyme (streptavidin-peroxidase) was added. After incubation and 
washing to remove the unbound enzyme, a substrate solution, which acted on the bound 
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enzyme, was added to induce a colored reaction product. The intensity of this colored 
product was directly proportional to the concentration of sICAM- 1 present in samples. 
Procedure 
A volume of sICAM-1 standard (ranging from 8 to 0.25 nglml), plasma sample or control 
sample (lOOpi) was added to the ICAM-1 microwell plate followed by the diluted 
biotinylated anti-sICAM-1 antibody (50 tL). The plate was covered and incubated for I 
hour at room temperature (18 °C - 250C). At the end of the incubation time, the plate was 
washed three times with washing buffer and streptavidin-HRP solution (100 jil) 
distributed to all wells, including the blanks. The plate was again covered and incubated 
for 30 min at room teniperature. 
After a further three washes, an aliquot of ready to use TMB substrate solution (100 lil) 
was added to all wells, including the blanks. The plate was incubated in the dark for 12-
15 min at room temperature and direct exposure to light avoided by wrapping the plate in 
aluminum foil. 
The enzyme-substrate reaction was stopped by quickly pipetting H2SO4  stop reagent (100 
p1) into each well, including the blank wells, to completely and uniformly inactivate the 
enzyme. The results were read immediately after the addition of the H2SO4 stop reagent. 
The absorbance of each well was read on a Chemwell spectrophotometer (Awareness, 
USA) using 450 nm as the primary wavelength and optionally at the 620 nm as the 
reference wavelength. 
Data analysis was performed by the generation of a linear standard curve by plotting the 
average absorbance on the vertical axis versus the corresponding sICAM- I standard 
concentration on the horizontal axis. The amount of sICAM-1 in each sample was 
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determined by extrapolating OD values to sICAM-1 concentrations using the standard 
curve. 
The average concentration of sICAM-1 in normal serum samples (according to 
manufacturer, Diaclone Research, France) was 571 ± 168 nglmL as detected in 77 normal 
human serum samples. The minimum detectable dose of sICAM- 1 was less than 0.1 
ng/mL. For intra-assay variation, the upper values were 7.82 ± 0.081, CV 1.03% and the 
- lower values were 1.17 ± 0.033, CV 2.82%. For inter-assay variation, the upper values 
were 8.05 ± 0.317, CV 3.93% and the lower values were 1.03 ±0.084, CV 8.15%. 
2.7 Study V: Estimation of metalloproteinase-9 (MMP-9) and tissue 
inhibitor of metalloproteinase-1 (TIMP-1) levels in serum samples 
2. 7.1 Quantitative determination of metalloproteinase-9 (MMP-9) in human plasma 
samples 
The metalloproteinase assay employed the quantitative sandwich enzyme immunoassay 
technique where a monoclonal antibody specific for MMP-9 has been pre-coated onto a 
microplate. Standards and samples were pipetted into the wells, and MMP-9 was bound 
by the immobilized antibody. After washing away unbound substances, an enzyme-linked 
polyclonal antibody specific for MMP-9 was added to the wells. Following a wash to 
remove unbound antibody-enzyme reagent, a substrate solution was added to the wells 
and color developed in proportion to the amount of total MIvIP-9 (pro and/or active) 
bound in the initial step. Color development was stopped and the intensity of the color 
measured. 
Me 
Procedure• 
Assay diluent (100 p1) (R&D systems, Minneapolis, MA) was added to each well, 
followed by Standard, Control, or sample (100 p1) per well. The plate was covered with 
adhesive strip and incubated for 2 hours at room temperature on a horizontal orbital 
microplate shaker (0.12" orbit). 
Wells were aspirated and washed, repeating the process three times for a total of four 
washes. Washing was performed by filling each well with Wash Buffer (400 RI)  using a 
sqUirt bottle. Complete removal of liquid at each step was essential to good performance. 
After the last wash, any remaining Wash Buffer was removed by aspirating or decanting. 
The plate was inverted and blotted against clean paper towels. 
MMP-9 conjugate (200 j.tl) was added of to each well, the plate was once again covered 
and incubated for 1 hour at room temperature on the shaker. 
Wells were aspirated and washed, repeating the process three times for a total of four 
washes. Substrate Solution (200 p1) were added to each well and the plate was incubated 
for 30 minutes at room temperature on the benchtop, protected from light. 
Stop Solution (50 RI)  was further added to each well and the color in the wells changed 
from blue to yellow. 
The optical density of each well was determined within 30 minutes, using a microplate 
reader set to 450 nm with reference wavelength at 540 nm. 
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According to the manufacturer's instructions (R&D systems, Minneapolis, MA), the 
precision of the method for three samples of known concentration tested twenty times on 
one plate to assess the intra-assay precision or in forty separate assays to assess the inter-
assay precision are shown in the table below: 
Table 2-5. Precision of the MMP-9 assay 
Intra-assay Inter-assay 
Sample 1 2 3 1 2 3 
n 20 20 20 40 40 40 
Mean 
(nglml) 
0.833 2.04 11.0 0.972 2.95 122 
SD 0.017 0.099 0.316 0.077 0.184 0.845 
CV% 2 1.9 2.9 7.9 7.8 6.9 
Sensitivity: The minimum detectable dose of MMP-9 was typically less than 0.156 
nglmL. 
2. 7.2 Quantitative dete?ñivation of Tissue Inhibitor ofMetalloproteinase 1 (TIMP-1) 
concentrations in human plasma samples 
The TIMP- 1 assay employed the quantitative sandwich enzyme immunoassay technique 
where a monoclonal antibody specific for TIMP-I has been pre-coated onto a microplate. 
Standards and samples were pipetted into the wells, and TIMP-1 was bound by the 
immobilized antibody. After washing away unbound substances, an enzyme-linked 
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polyclonal antibody specific for TIMP-1 was added to the wells. Following a wash to 
remove unbound antibody-enzyme reagent, a substrate solution was added to the wells 
and color developed in proportion to the amount of total TIMP-1 bound in the initial step. 
The color development was stopped and the intensity of the color was measured. 
Procedure 
Assay diluent (100 xl) (R&D systems, Minneapolis, MA) was added to each well, 
followed by of Standard, Control, or sample (100 jsl) per well. The plate was covered 
with adhesive strip and incubated for 2 hours at room temperature on a horizontal orbital 
microplate shaker (0.12" orbit). 
Wells were aspirated and washed, repeating the process three times for a total of four 
washes. Washing was performed by filling each well with Wash Buffer (400 p1) using a 
squirt bottle. Complete removal of liquid at each step was essential to good performance. 
After the last wash, any remaining Wash Buffer was removed by aspirating or decanting. 
The plate was inverted and blotted against clean paper towels. 
TIMP-1 conjugate (200 p1) was added to each well, the plate once again covered and 
incubated for 1 hour at room temperature on the shaker. 
Wells were aspirated and washed, repeating the process three times for a total of four 
washes. Substrate Solution (200 p1) was added to each well and the plate was incubated 
for 30 minutes at room temperature on the benchtop, protected from light. 
Stop Solution (50 p1) was further added to each well and the color in the wells changed 
from blue to yellow. 
The optical density of each well was determined within 30 minutes, using a microplate 
reader set to 450 nm with reference wavelength at 540 nm. 
M. 
According to the manufacturer's instructions (R&D systems, Minneapolis, MA), the 
precision of the method for three samples of known concentration tested twenty times on 
one plate to assess the intra-assai precision or in forty separate assays to assess the inter-
assay precision are shown in the table below: 
Table 2-6. Precision of the TIMP-1 assay 
- Intra-assay Inter-assay 
Sample 1 23 1 2 3 
n 20 20 20 40 40 40 
Mean 
(nWml) 
1.23 3.45 6.09 1.26 3.45 6.38 
SD 0.054 0.116 0.181 0.086 0.197 0.467 
CV% 4.4 3.4 3.0 6.8 5.7 7.3 
Sensitivity: Sixty-eight assays were evaluated and the minimum detectable dose (MDD) 
of TIMP-1 ranged from 0.004 - 0.064 nglmL. The mean MDD was 0.011 nglmL. 
2.8 Statistical analysis 
The results were statistically processed with the use of a SPSS programme for Windows 
and the Pearson chi-square test used to compare categorical variables. The values of the 
laboratory findings were initially checked for possible outliers with the use of boxplots. 
Since many statistical tests assume the data were normally distributed, individual 
variables were tested for normality totally and within groups. In order to determine 
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whether the distributions of the quantitative variables matched, with the normal 
distribution, histograms were used to display the distribution of values for the variables 
and probability plots (Normal Q-Q plots). Additionally the Kolmogorov-Smirnov test 
(pc0.05) confirmed that the individual variables differed significantly from a normal 
distribution. Due to the lack of normality in the distribution of values of most of the 
studied parameters, the selected statistical methods for the process were. non-
parametrical. A Kruskal-Wallis test was used for the comparison of values between the 
patient groups. Data are p,resented as mean ± standard deviation (SD) and all results were 
tested at a statistical level of significance of pc 0.05. 
CHAPTER 3. RESULTS 
3.1 Demographic data 
Table 3-1. Principal socio-demographic characteristics of subjects (n85) 
MS w/o 
treatment 
MS with 
IFND- 
MS with 
IFN3- 
la 
 
Controls 
Number 20 20 20 25 
Age (years) 32±1.3 
(mean±SD)  
36±3.1 34±3.2 38.8±6.9 
BMI(Kgr/m') 24.2±2.1 22±3.4 23.5±3.6 25.3±3.8 
Gender 
Male 5 10 7 10(40%) 
Female 15 10 13 	 - 15 (60%) 
Maritalstatus 
 
Married 42 38 40 13 (52%) 
Single 18 22 20 12 (48%) 
Education  
0-6 years 6 2 4 1(4%) 
6-12 years 25 29 27 6(24%) 
> 12 years 27 31 29 18(72%) 
Employment  
Currently 
employed 
52 48 50 18 (72%) 
Unemployed 1 	 8 12 10 7 (28%) 
The principal demographic characteristics of the two groups are shown in Table 3-1. Of 
the sixty MS patients, seventy one comma six per cent (forty three) were women and 
twenty eight comma three per cent (seventeen) were men. During statistical analysis, the 
MS group was assessed as a whole without taking into consideration the different types 
of IFNf3 treatment or not. The mean age (±SD) of the MS and control group was 34 ± 3.2 
and 38.8±6.9 years respectively. There was no statistically significant difference for the 
age of individuals in the two groups (p>O.OS). The mean BMI varied significantly 
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(P<0.01) between the two groups; the MS patients' mean score was lower than that of the 
controls. 
Female gender was dominant in all groupS with a percentage of 71.6% for MS patients 
and 60% for the controls. The majority of the individuals were married. Forty five per 
cent and twenty four per cent of the MS and control groups respectively had basic 
education (up to high school). However, the majority of the subjects in both groups 
- (48.3% for MS and 72% for controls) were well-educated (beyond high school). 
A total of 83.3% of the MS population had paid employment at the time of study as well 
as 72% of the controls. 
Table 3-2. Main lifestyle features of the subjects (n85) 
MS patients Controls 
Cigarette smoking 
 
Non-smokers 23 (38.3%) 19 (76%) 
Smokers 37 (61.6%) 6(24%) 
Alcohol  
> 1 drink daily 8 (13.3%) 5 (20%) 
2-3 drinks weekly 20 (33.3%) 5 (20%) 
<2 drinks weekly 32 (58.3%) 15 (60%) 
Leisure physical activity 
 
No activity 45 (75%) 3 (12%) 
Less than 1 hour per week 10(16.6%) 2 (8%) 
Between 2-3 hours per 
week 
5(8.3%) 8 (32%) 
3 hours or more per week 0 (0%) 12 (48%) 
Table 10 shows some characteristics of the life-style of the subjects. The study focused 
on alcohol consumption, cigarette smoking and leisure physical activity of the subjects, 
because the participants shared a large number of every-day habits. They followed a 
similar diet (Mediterranean diet, with the use of olive oil and fresh vegetables); lived in 
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the same geographical region and their occupations were mostly in the private sectors 
(e.g. bankers, accountants). However, smokers were outnumbered by non-smokers in the 
MS population (61.6%) but not in controls (24% were smokers). The majority of MS 
(58.3%) and control subjects (60%) consumed low quantities of alcohol (<2 drinks 
weekly). Regarding physical activity in their leisure, an increased percentage of MS 
patients (75%) were inactive at all whereas only 8.3% exercised between 2-3 hours per 
week. Among the control subjects, 32% exercised for between 2-3 hours per week and 
48% more than 3 hours per week. 
3.2 Clinical data 
The clinical characteristics of MS patients are summarized in Table 3-3. 
Table 3-3. Clinical characteristics of MS patients 
MS patients 
No of subjects 60 
Sex(F/M) 43/17 
Mean age (years) 34±3.2 
Age of onset (year) 27.3±8.8 
Age at inclusion (year) 32.2±9.8 
Mean disease duration (years) 3±1.5 
No. of relapses in the last 2 years 2±1.3 
Mean treatment duration (month) 6 
Mean baseline EDSS score 2.5±1.2 
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Degree of disability 	
10(16.6%) Low 	
143(71.6%) Moderate  
High 	 I 7(11.6%) 
EDSSexpanded disability status scale) 
It is important to note the predominance of female gender among the patients indicating a 
possible predictive factor of the disease. Furthermore, the patients were relatively young 
with a mean age of 34±3.2 years. Mean disease duration was 4±1.5 years for MS patients, 
with 2±13 relapses in the last two years. Mean EDSS score of the patients was 2.5±1.2 
and the degree of disability was moderate in most cases (seventy one comma six per 
cent). 
Upon admittance to the Neurologic Clinic and following diagnosis of relapsing-remitting 
form of MS, all patients had to undergo a routine analysis of biochemical parameters as 
summarized in Table 3-4. 
Table 3-4. Baseline laboratory data analysis of MS patients 
Mean ±SD Normal range 
WBC (x10 3/pJ) 7.06±2.6 4.8-10.8 
AST (lU/I) 19.8±10.8 <40 
ALT (lu/I) 23.9±18.3 <35 
ff3 (pg/mI) 2.8±0.5 1.7-4.1 
ff4 (ng/dl) 1.1±0.2 0.7-1.6 
TSH (pJU/ml) 1.5±1.3 0.3-4.7 
TgAb (lU/mI) 47.4±100.8 <40 
TPOAb (lU/mI) 109±344.5 <40 
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WBC, white blood cells; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; ff3, free tri-iodothyronine; ff4, free-thyroxine; TSH, thyrotropine; 
TgAb, anti-thryroglobulin antibody; TPOAb, anti-thyroid peroxidase antibody. 
Although their white cell count, hepatic enzyme levels and thyroid hormones were within 
normal ranges, increased amount of anti-thyroglobulin (47.4±100.8IUIml) and anti-
thyroid peroxidase antibodies (109±344.5JU/ml) were observed. 
Table 3-5 shows some of the most frequent medical conditions usually associated with 
MS. 
Table 3-5. MS patients' personal history of other disorders 
None 13 (21.6%0 
Optic neuritis 50 (83.3%) 
Autoimmune disease 20 (33.3%) 
Inflammatory disease 18 (30%) 
Viral 	 infections 	 (HIV, 	 HTLV, 
Hepatitis B)  
19(31.6%) 
Allergies 15 (25%) 
Vaccinations (Influenza, Hepatitis B) 29 (48.3%) 
Mental disorders, depression 12 (20%) 
In our study population a high percentage of patients (eighty three comma three per cent) 
had symptoms of optic neuritis or other sensory symptoms specifically associated with 
the onset of disease. Confounding autoimmune or inflammatory diseases were also 
present in their personal clinical file (33.3% and 30% respectively). A significant 
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percentage of viral infections (31%), allergies (25%) and vaccinations (48.3%) were also 
reported. 
Finally, mental disorders were also present, with a particular tendency for depressive 
symptomatology which was observed in twenty per cent of patients. 
In order to obtain more information of the biochemical status of our study population, an 
evaluation of their lipid profile as well serum glucose levels was performed. Table 14 
shows the baseline values of main lipids and glucose of MS• patients upon their 
admittance to the study. 
Table 3-6. Lipid profile and glucose levels of MS patients 
Mean ±SD Normal range 
Cholesterol (mg/dl) 199.6±40.9 <190 
MDL Chol (mg/dl) 54.8±13.1 >35 
Triglycerides (mg/dI) 185.2±57.1 <180 
Glucose (mg/dl) 102±21.1 <120 
Specifically, MS patients presented a high total cholesterol concentration in their serum 
(199.6±40.9mgldl) as well as increased triglycerides (185.2±57 mg/dl). HDL-Cholesterol 
and glucose levels were found to be within the normal range. 
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3.3 Study I: Evaluation of cytokine secretion in MS patients and 
controls 
Secretion of Thi (IFN-y, TNF-a, IL-12) and Th2 (IL-b, IL-4) type cytokines was 
evaluated in peripheral blood mononuclear cells of MS patients with or without treatment 
with IFNJ3, using the ELISPOT methodology described in Chapter 2. 
Table 15 summarizes the ELISPOT data on cytokine secretion levels from MS patients 
with or without IFNJ3 treatment as well from control subjects. Significant changes were 
observed for most cytokines between MS patients and controls as well as following 
treatment with the two types of IFNP as described below. 
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3.3.1 Evaluation of IFN-y secretion 
Patients with MS receiving no treatment demonstrated significantly increased levels of 
IFN-y -secreting PBMCs (154.15±2.6) compared to healthy controls (24±2.64, P<0.01). 
Treatment of MS patients with JFN3-1a significantly reduced IFN-y levels (52.1±1.62) 
but without reaching normal levels. However, treatment with IFNJ3-113 decreased the 
number of IFN-y cells even further, below normal levels (23.2±2.62, P0.098), proving 
more efficient in reducing IFN-y secretion levels than IFNf3-la (Figure 3-1). 
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Figure 3-1. ELISPOT analysis of IFN-y -secreting PBMCS of MS patients (n60) with 
and without IFNP treatment compared to controls (n25, **pco.ol). 
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3.3.2 Evaluation of ThTF-a secretion 
The number of TNF-a—secreting lymphocytes was markedly increased (121.9±4.39) in 
MS patients compared to healthy subjects (21.9±3.21, P<O.O 1). Treatment with IFNf3- I a 
significantly reduced TNF-a secretion levels in MS patients (56.4±2.36, P<O.Ol). 
Additionally, IFN-10 administration was more effective than IFNf3-la in decreasing 
TNF-a levels (45.4±3.12, Pc0.01) but failed to reach normal levels (Figure 3-2). 
Figure 3-2. ELISPOT analysis of TNF-a-secreting PBMC of MS patients (n=60) with 
and without IFNI3 treatment compared to controls (n=25, **pco.ol). 
3.3.3 Evaluation of IL-JO secretion 
Patients with MS presented decreased levels of IL-b-secreting PBMCs (36.4±3.65) 
compared to healthy controls (64.5±4.78, PC0.01). Treatment with IFN(3-la significantly 
elevated IL- 10 levels to 54±2.1 in MS patients. IFNf3- 1 3 treatment was also effective in 
increasing the number of IL- 10-secreting cells (55.1±2.1, P<0.0 1) (Figure 3-3). 
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Figure 3-3. ELISPOT analysis of IL-b -secreting PBMC of MS patients (n60) with and 
without IFNf3 treatment compared to controls (n25, **Pc001) 
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3.3.4 Evaluation of IL-12 secretion 
IL-12 secreting PBMCs were detected in all patients with MS; either with or without 
treatment and healthy subjects. Increased levels of IL-12 were observed in patients with 
MS without receiving any treatment (159.6±6.1) compared to healthy subjects (106±8.9, 
P=0.05). These levels decreased after treatment with IFNI3-la (109±5.7) as well as with 
IFNp-lp (122.51.3) but did not attain statistical significance (Figure 3-4). 
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Figure 3-4. ELISPOT analysis of IL-12 -secreting PBMC of MS patients (n60) with and 
without IFNP treatment compared to controls (n25). 
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3.3.5 Evaluation of IL-4 secretion 
Lower levels of JL-4 were observed in MS patients (62.63 ±4.7) compared to controls 
(94.86±2.7, P=0.08), but increased after treatment with IFN. Specifically, IFNI3-la 
treatmeni increased the number of IL-4-secreting cells to 108±3.6, whereas IFNF3-lD 
proved even more effective in significantly elevating the number of IL-4 cells to 
179.5±2.0 (Pc0.01, Figure 3-5) 
- 	
: 
;ç - 
r 
L. 
	
4 	 -. 
C 	
..•• 	 • 
I 	 •rt 
4 
 CL.. 
I • 	 • C 	 = • 
- • 4 •.r _ ___ 
Figure 3-5. ELISPOT analysis of IL-4 -secreting PBMC of MS patients (n60) with and 
without IFNf3 treatment compared to controls (n=25, **p<o.ol). 
ill 
3.4 Study II: Percentages of peripheral lymphocytes of MS patients and 
controls expressing cytokine receptors 
3.4.1 Flow cytometric analysis of percentages of IL-12 receptor-hi (IL-12Rf31) 
expressing T and NK cells from patients with MS and healthy subjects before and afler 
PHA activation 
Blood T cells and NK cells constitutively expressed IL-12Rf31 a vivo as shown in Table 
16. Percentages of CD4 and CD8 T cells expressing IL-12R1 did not differ between MS 
patients and healthycontrols (Table 3-8). Percentages of IL-12Rl expressing NK cells 
were higher in patients with MS, without or with treatment with IFNf3, compared to 
healthy individuals (P<O.Ol, P<0.05, respectively). 
Three-day culture with PFIA (2j.tg/ml) strongly augmented expression of IL-I2R1 on T 
cells (Table 3-8, Figure 3-6). The percentage of PHA-activated CD4 and CD8T cells 
expressing JL-I2Rf31 were higher in patients with MS (Pc0.05) than in healthy subjects. 
NK cells from MS patients and controls expressed IL-I2Rf31 to a similar extent after 
PHA stimulation, without any difference between the groups (Table 3-9). IFNO treatment 
further reduced IL-12Rj31 levels of T and NK cells to that similar to normal levels, with 
IFNI3- 1 a being more effective in reducing IL-I 2R13 1 levels than IFNf3-1 P (Figure 3-7). 
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Table 3-9. Statistical analysis of percentages of T and NK cells expressing IL-12R131 
P (contr P (contr P (conir P P P 	 (contr 
vs 	 MS vs 	 MS vs 	 MS 'contr4-PHA (conlr+PHA ±PHA vs 
kv/o IFNfl- /FN/3- is 	 MS 	 w/o vs MS IFN,B- MS IFN/J- 
real) (a) JIB) treat. +PHA) I a +PHA) 1/J+PHA) 
CD4 NS NS NS NS NS NS 
CD8 NS NS NS NS NS NS 
NK 0.01t 0.05 0.05 NS NS NS 
** Significant differences 1<0.01 level 
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Figure 3-6. Percentage of PHA-activated CD4 (A), CD8 (B) T cells and NK (C) cells 
from a representative MS patient (w/o treatment) expressing IL- 1 2RJ3 I. Solid line, 
staining with anti-IL-12R mAb. Dashed line, control staining with an isotype-matched 
mAb. Numbers in each plot indicate percentages of positive cells after subtraction of 
control signal. 
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Figure 3-7A. Percentage of in vitro and PHA-activated CD4 cells from patients with MS 
(n=60) 	 and 	 healthy 	 subjects 	 (n25) 	 expressing 	 IL-12Rf31. 
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Figure 3-713. Percentage of in vitro and P1-IA-activated CDS cells from patients with MS 
(n60) and healthy subjects (n=25) expressing IL-12R1. 
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Figure 3-7C. Percentage of in vitro and PHA-activated NK cells from patients with MS 
(n=60) and healthy subjects (n=25) expressing IL12R1.(**Pc0.01). 
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3.4.2 Flow cytometric analysis of percentages of T and NK cells from patients with MS 
and healthy subjects expressing IFN-yR , before and afier PHA activation 
Peripheral blood cells from untreated patients with MS had significantly smaller amounts 
of IFN7R than those from control subjects. Percentages of IFN-yR-expressing CD4 and 
CD8 cells differed significantly between MS patients and controls (Pc0.05, P<0.01, 
respectively). The percentage of JFN-yR-expressing NK cells did not differ between MS 
and control subjects (Table 3-10). Percentages of PHA-activated CD4 and CDST cells 
expressing IFNyR were higher in patients with MS (P<0.05) than in healthy subjects. NK 
cells from MS patients and controls expressed IFN-7R to a similar extent after PHA 
stimulation, without any significant difference between the groups (Table 3-1 1). PHA 
stimulation significantly increased expression of IFN-7R on T cells (N0.05, Table 3-1 1). 
After 6 months of IFNJ3 treatment, T-cell IFN-7R expression was increased, being only 
slightly lower than that of the control subjects (Figure 3-8). 
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Table 3-1 1. Statistical analysis of percentage of T and NK cells expressing IFN7R 
(contr P 	 (-COntr P 	 (conE,- 'P (conrr±PHA P P 	 j'contr 
- 's 	 MS vs 	 MS vs 	 MS vs 	 MS 	 w/o (contr+PHA +PHA 	 vs 
v/a IFNfl-la) IFNfl-lfl,) teat. +PHA} vs MS IFNfl- MS IFN/3- 
reat.) ]a+P1j4,) 1/3+PH4I 
CD4 0.05 NS NS NS NS NS 
CD8 0.01 NS NS NS NS NS 
NK NS NS NS NS NS 0.05 
** Significant differences <0.01 level 
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Figure 3-8A. Percentage of in vitro and PHA-activated CD4 cells from patients with MS 
(n60) and healthy subjects (n25) expressing IFN-7R. 
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Figure 3-813. Percentage of in vitro and PHA-activated CDS cells from patients with MS 
(n=60) and healthy subjects (n=25) expressing IFN-7R (**P<0.01). 
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Figure 3-8C. Percentage of in vitro and PFIA-activatd NK cells from patients with MS 
(n60) and healthy subjects (n=25) expressing IFN-7R. 
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3.4.3 Flow cytometric analysis of percentages ofT and NK cells from patients with MS 
and healthy subjects expressing TNF-a receptor (TNF-aR), before and after PHA 
activation - 
Blood T cells and NK cells constitutively expressed TNF-aR in vitro as shown in Table 
3-12. Percentages of CD4 and CD8 T cells expressing TNF-aR did not differ between 
MS patients and healthy controls (Table 3-12). Percentages of TNF-aR expressing NK 
cells were higher in patients with MS, without or with treatment with IFN, compared to 
healthy individuals (P<O.Ol, Pc0.05, respectively). 
Three-day culture with PHA strongly augmented expression of TNF-aR on T cells 
(Tables 3-12, 3-13). Percentages of PHA-activated CD4 and CD8T cells expressing TNF-
aR were significantly higher in patients with MS (P<0.05) than in healthy subjects. NK 
cells from MS patients and controls expressed TNF-aR to a similar extent after PHA 
stimulation, without any difference between the groups (Figure 3-9). 
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Table 3-13. Statistical analysis of percentage of T and NK cells expressing TNFuR 
in 
r 	 contr n 	 - r 	 I  consr n r 	 contr - 	 cun:r'-rnis -r n 	 / r 	 cunir 
's 	 MS vs 	 MS - vs 	 MS 's 	 MS 	 wlo 'contr+PHA +PH,4 	 vs 
v/o IFNfl-1a) IFN/3-1fl) treat. +PHA) vs MS IFNfl- MS IFN/3- 
teal.) 1a+PHA) J/3+PfJ4) 
CD4 NS NS NS NS NS NS 
CD8 NS NS NS NS NS NS 
NK 0.01 0.05 0.05 NS NS NS 
** Significant differences <0.01 level 
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Figure 3-9A. Percentage of in vitro and PHA-activated CD4 cells from patients with MS 
(n=60) and healthy subjects (n=25) expressing TNF-aR. 
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Figure 3-9B. Percentage of in vitro and PHA-activated CD8 cells from patients with MS 
(n60) and healthy subjects (n25) expressing TNF-ciR. 
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Figure 3-9C. Percentage of in vitro and PHA-activated NK cells from patients with MS 
(n=60) and healthy subjects (n=25) expressing TNF-czR (**p<001) 
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3.4.4 Flow cytotnetric analysis of percentage ofT and NK cells from patients with MS 
and healthy subjects expressing IL-i OR, before and after PHA activation 
Peripheral blood cells from untreated patients with MS had significantly smaller amounts 
of IL-I OR than those from control subjects. Percentages of IL-i OR -expressing CD4 and 
CDS cells differed significantly between MS patients and controls (Pc0.05, P<0.01, 
respectively). The percentage of IL- 1 OR -expressing NK cells did not differ between MS 
and control subjects (Table 3-14). PHA stimulation increased expression of IL-bR on T 
cells (Table 3-14). Percentages of PHA-activated CD4 and CDST cells expressing IL-
IOR were higher in patients with MS (Pc0.05) than in healthy subjects. NK cells from 
MS patients and controls expressed IL-bR to a similar extent after P1-IA stimulation, 
without any difference between the groups (Table 3-15). 
After 6 months of IFNJ3 treatment, T-cell IL-b OR expression was increased with IFN- 1 a 
treatment showing a better effect on elevation of IL-bR levels than IFNI3-lb (Figure 3-
10). 
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Table 3-15. Stalistical analysis of percentage of T and NK cells experessing Th-1QR 
. (contr P (contr P (contr P  (contr+PHA P P 	 (contr 
's 	 MS vs 	 MS vs 	 MS vs 	 MS 	 w/o (con tr+PHA +PHA 	 vs 
v/o IFN/3-la) IFN/3-1/3,) treat. +PHA,) vs MS IFN/3- MS IFN,8- 
real.) la+PHA) ]/3+PHA) 
CD4 0.05 NS NS NS NS NS 
CD8 O.Ol** NS NS NS NS NS 
NK NS NS NS NS NS 0.05 
** Significant differences c 0.01 level 
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Figure 3-IOA. Percentage of in vitro and PHA-activated CD4 cells from patients with MS 
(n=60) and healthy subjects (n=25) expressing IL- bR. 
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Figure 3-1 OB. Percentage of in vitro and PHA-activated CD8 cells from patients with MS 
(n=60) and healthy subjects (n=25) expressing IL-bR (**PcO.Ob). 
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Figure 3-1C. Percentage of by in vitro and PHA-activated NK cells from patients with 
MS (n=60) and healthy subjects (n25) expressing IL-10 R. 
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3.5 Study III: Estimation of the apoptotic marker sCD95 (Fas) 
expression 
sCD95 levels were detectable in sera of MS patients, with or without treatment and 
healthy controls with significant differences (Table 3-16). 
MS patients without treatment demonstrated increased levels of sCD95 in their sera 
(1447±125) compared to healthy individuals (517.79±256.19, Pc0.01). Treatment with 
IFNI3- I a further induced CD95-mediated apoptosis, as shown by significantly elevated 
CD95 levels (2695±134, P<0.01). The same pattern of increased sCD95 levels was also 
observed in MS patients receiving IFNP-10 treatment (2711±104, Pc0.01, Figure 3-1 1). 
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Figure 3-11. Serum sCD95 levels of MS patients (n=60) with and without IFNf3 treatment 
compared to controls (n=25, **p<O.Ql). 
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3.6 Study IV: Estimation of the adhesion molecules VCAM-1 and 
ICAM-1 expression 
The expression of the soluble forms of adhesion molecules (VCAM-1 and ICAM-1) in 
MS patients compared to controls is summarized in Table 3-17. 
MS patients presented increased levels of sVCAM-1 (564.14±127.20) compared• to 
controls (453.04±241.27, P0.05). IFNI3-la/113 treatments significantly elevated VCAM-
1 levels to 661.64±169.76 and 685±104.2 respectively (Figure 3-12). 
No differences were observed in sICAM-1 levels between MS patients (442.15±125) and 
healthy subjects (427.05±247.2). Furthermore, treatment with IFNP-la/lp failed to 
induce any significant change in ICAM-1 levels of MS individuals (values were 489±216 
after IFNf3-la and 472.1±202 after IFND-fl3 respectively, Figure 3-13). 
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Figure 3-12. Serum sVCAM-1 levels of MS patients (n=60) with and without IFNI3 
treatment compared to controls (n25, **pcool) 
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Figure 3-13. Serum sICAM-1 levels of MS patients (n60) with and without IFNI3 
treatment compared to controls (n25). 
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3.7 Study V: Estimation of levels of metalloproteinase-9 (MMP-9) and 
tissue inhibitor of metalloproteinase-1 (TIMP-1) in serum samples 
MS patients without treatment showed significantly increased sMMP-9 levels 
(226.06±5.1), decreased sTIMP-1 levels (796.3±1.1) and a higher 5MMP-9/sTIMP-1 
ratio (0.35±0.07) compared to controls (161.90±8.1, 964.4±2.4, 0.17±0.11 respectively, 
Table 3-18). 
However, treatment with IFNP decreased significantly sMMP-9 levels (P<0.01 for IFNf3-
hi and P=0.05 for IFNJ3-fl3), increased sTIMP-1 levels and reduced the sMMP-9/sTIMP-
1 ratio at MS patients. 
Notably, IFNJ3-la decreased sMMP-9 levels of MS patients to 187.73±6.3 (Figure 3-14) 
and increased sTIMP concentration to normal levels (967±3.2, Figure 3-15). The sMMP-
9/sTIMP- 1 ratio was also reduced to 0.21±0.17 following IFN- 1 a treatment. 
Furthermore, treatment of MS patients with IFN(-1 j3 reduced sMMP-9 levels 
(195.33±8.3), increased sTIMP-1 levels (883±3.2) and decreased the sMMP-9/sTIMP-1 
ratio (0.25±0.23). 
IFNI3-la treatment was shown to be more effective (Figure 3-14) in reducing sMMP-9 
levels and increasing sTJMP-1 compared to IFN3-10 (Figure 3-15). 
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Figure 3-14. Serum MMP-9 levels of MS patients (n=60) with and without IFNII 
treatment compared to controls (n25, **pco.ol). 
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Figure 3-15. Serum TIMP-1 levels of MS patients (n60) with and without IFN 
treatment compared to controls (n=25). 
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CHAPTER 4: DISCUSSION 
The present study was designed to characterize the regulation of the inflammatory 
background underlying MS pathophysiology mediated by cytokines as well as 
investigating the mode of action and biological role of IFND treatment for MS patients 
Elucidation of the mechanisms of action of the different forms of IFNf3 treatment (IFN-
1a110) on cytokine secretion as well as on other immunoregulatory molecules (adhesion 
molecules, metalloproteinases and apoptotic markers) may prove of clinical importance 
for the choice of treatmeit and disease monitoring as well as in the follow up of patients. 
MS represents the most common inflammatory demyelinating disorder of the human 
central nervous system, and is the leading cause of non-traumatic neurological disability 
in young adults in Europe and North America. The estimated European mean annual MS 
incidence rate is 4.3 cases per 100,000, whilst almost 1 million people are affected 
worldwide every year (Kumar & Clark 2002; Rich ci aL, 2001). 
The burden for young adults caused by the disease is multiple: personal, social, and 
financial and is particularly heavy for their caregivers. Early and accurate diagnosis 
together with a better selection of appropriate therapy for each disease type is, thus, a 
desirable combination for an improved outcome. 
Today, there are several possible treatments for MS including copaxone (glatiramer 
acetate), mitoxandrone and interferon-beta (JFNf3- I all 13) (Rizvi and Aqius 2004; 
Flackenecker 2004; Fox 2004). The exact mode of action and the biological role for none 
of these drugs are known, therefore making selection and appropriate dose very difficult, 
whilst creating debate and disagreement among clinicians (Durelli 2004). However, the 
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evidence to date suggests that high-dose, high-frequency regimens of IFNf3 might offer 
superior efficacy over a low-dose, low-frequency regimen in terms of relapse rates and 
MRI measures of disease. 
IFNf3 has been used for more than 10 years in the treatment of MS and has proved to 
exhibit better clinical efficacy compared to other therapies (Pozzilli et aL, 2006). 
Although initially designed as an antiviral drug, the therapeutic benefit of IFNJ3 appears 
to be based on immunomodulatory mechanisms, several of which still need to be 
elucidated (Takaoka & Yanai, 2006). 
Two different recombinant IFN's, IFNJ3-1 a (Avonex and Rebief) and IFND-1 
(Betaferon) are approved for the treatment of relapsing and remitting form of MS (Ann 
Marie and Rudick, 2006; Montalban and Rio, 2006). They differ in recommended 
dosage, and in route and frequency of administration, and consequently most probably 
also in clinical effectiveness. 
The present study attempts a comprehensive approach for the characterization of the 
inflammatory profile contributing to the autoimmune defects of MS patients. The main 
regulators of inflammation, cytokines, as well as their receptors, were extensively studied 
in the peripheral blood of MS patients, together with other soluble mediators and 
apoptotic markers. The immunomodulatory activity of both forms of IFNP upon these 
parameters was also investigated so as to elucidate their mechanism of action and suggest 
a preferable selection between the two forms for therapy. 
The study group was composed of 85 individuals, 60 MS patients diagnosed with the 
remitting relapsing form of the disease and 25 controls, carefully selected based on their 
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clinical diagnosis, laboratory examination and MRI results so as to form two well-
matched groups. All individuals had Greek nationality, shared similar genetic and 
environmental elements and occupational habits. 
The study population had a narrow age-span: 30-45 at the time of the study. The mean 
age in the MS group was 34±3.2 years and is in accordance with epidemiological studies 
in MS where the highest prevalence rates have been estimated for the 3 5-54 years age 
group in both sexes and all European countries (Pugliatti et al., 2006). 
Based on the age of MS patients, the control group was carefully selected (mean age: 
38.8±6.9 years) so that there was no statistically significant age difference between the 
two groups (p>0.05). However, this fact does reduce the ability to extrapolate these 
results to either younger or older age groups. 
4.1.1 Female gender is a risk factor for MS 
Previous studies have suggested that female gender may be an established risk factor for 
MS and this was also consistent with the present study data (Pugliatti et al., 2006). 
Available MS epidemiological estimates indicate that total estimated prevalence rate of 
MS in Europe for the past three decades is 83 per 100,000 with higher rates in northern 
countries and a female: male ratio of approximately 2.0. Prevalence rates are higher for 
women in all countries considered in the study. 
In this present study, from the MS group, 43 participants were female and 17 male. 
Marital status, level of education and form of employment did not show any significant 
differences between the two groups (p>0.05). 
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4.1.2 Cigarette smoking may worsen disease activity 
Cigarette smoking and low alcohol consumption was related to MS presence. Smokers 
were outnumbered by the non-smokers (61.6%) in the MS population but not in controls 
(24% were smokers). The majority of MS (58.3%) and control subjects (60%) consumed 
low quantities of alcohol (<2 drinks weekly). Recent studies have shown that patients 
with MS, angina and asthma had slightly higher rates of current smoking than the general 
population (Nortvedt et al., 2005) and that smoking may, present a risk factor for MS 
(Reman et aL, 2001; Ruse et aL, 2003). In the same study, although many MS patients 
had quit smoking, as many as 40% were still smoking. An earlier study of a similar 
general population showed that smoking was related to a markedly reduced health-related 
quality of life and that previous smokers had almost the same score as people who had 
never smoked (Ruse et al., 2003). This might suggest that ceasing smoking may help MS 
patients. 
4.1.3 Leisure physical activity is vital for MS patients 
Another lifestyle factor known to strongly influence the health-related quality of life is 
physical leisure activity (Ruse et al., 2003). MS patients reported spending markedly less 
time on both strenuous and light physical leisure activity. An increased percentage of MS 
patients (75%) were virtually inactive whereas only 8.3% exercised between 2-3 hours 
per week. This is probably related, in part, to the physical disability many of these 
patients had. However, the possible effects of vigorous training on the disease process in 
MS as yet remain unknown. 
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A concern for patients' thermosensibility might influence advice given regarding physical 
activity. Nevertheless, two studies have shown that aerobic training positively influences 
the quality of life of MS patients, and further, that the more disabled group appeared to 
profit most from the training programme (Petajan et al., 1996; Mostert & Kesselring 
2002). 
In addition to a positive effect on quality of life, the result of increased physical activity 
gives, a general benefit in the reduction of weakness, fatigue and other health risk factors 
associated with detraining and deconditioning (Mostert& Kesselring 2002). 
Despite low physical leisure activity, MS patients had a lower mean BMI than the general 
population. Previous studies have reported that almost three times as many MS patients 
as the general population were below the recommended range (Nortvedt et al., 2005). 
This may be related to a change in metabolism after the onset of disease or muscle 
atrophy as a result of reduced muscle activity resulting from neural impairment, although 
this is less likely in our study, as most of the patients were still ambulatory and working. 
Regarding their clinical characteristics, all MS patients in this study had the relapsing-
remitting form of the disease with a relative early age of onset (27.3±8.8 years) and a 
mean disease duration of 4 years. Their degree of disability was ieported as moderate in 
the majority of cases (71.6%) and their treatment with IFNf3 lasted for six months for the 
under freatment subgroup. 
Various factors such as genetic, autoimmune and environmental have previously been 
considered in the etiopathogenesis of MS (Dijkstra et aL, 1993) and many studies 
emphasize the role of hepatic and hormonal disturbances in patients with MS (Ajuebor et 
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at, 2006; de Seze et al., 2005; Petek-Balsi et al., 2005; Kotilainen et al., 2005; Edwards 
and Constantinescu, 2004). Therefore, a variety of laboratory parameters were evaluated 
in MS patients including white blood cell level, hepatic enzyme levels and thyroid 
hormone concentrations. 
4.1.4 Thyroid dysfucntion may be related with MS 
Baseline laboratory data for hepatic function were within normal range values as well as 
thyroid hormonal values, however, anti-thyroglobulin antibody and anti-thyroid 
peroxidase antibody titers were markedly elevated in these patients compared to normal. 
These observations are in accordance with previous studies where thyroid dysfunction is 
much more common in patients with MS as compared to the general population. There 
are reports for both hyper-and hypothyroidism in MS patients (Iwasaki et al., 1988; 
Kiessling et at, 1980; Klappas et at, 1992). Furthermore, antithyroid antibodies, mainly 
those for the thyroglobulin and microsomal fraction of thyroid cells are frequently found 
in many patients with MS (De Keyser et at, 1988; loppoli et at, 1990; Kiessling et at, 
1980) and their elevated presence suggests the involvement of autoimmune mechanisms 
in the development of thyroid dysfunction in these patients. 
4.1.5 Optic neuritis is a common disorder among MS patients 
Co-existence of other medical conditions which either lead to or are associated to MS 
status was also evaluated in the MS population of the present study. The personal history 
data for other disorders revealed that there was a prevalence of optic neuritis in MS 
patients (83.3%). This is in agreement with earlier studies where MS was commonly 
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associated with visual system problems and MS patients may have initially presented 
with ophthalmologic symptoms (Cerovski ci aL, 2005). 
Manifestations of multiple sclerosis in the eye include both afferent and efferent visual 
pathways. OpticS neuritis, the most common ocular indication of multiple sclerosis, may 
be the initial symptom of clinical disease. Recent long-term follow-up data show that 
most patients with demyelinating optic neuritis have an excellent prognosis for recovery 
of central visual acuity. Evidence is emerging, however, for a significant and broad 
reduction in both contrast sensitivity and color perception in multiple sclerosis patients 
despite near-normal visual acuities (Sisto ci aL, 2005). Ocular motor deficits in multiple 
sclerosis include internuclear ophthalmoplegia and nystagmus, resulting in diplopia, 
oscillopsia, blurred visual, loss of stereopsis, and reading fatigue. Multiple sclerosis may 
also be associated with ocular inflammatory diseases, in particular pars planitis and 
retinal periphlebitis (Cerovski ci aL, 2005). 
In summary, it is possible that observations of ocular problems may be an initial 
manifestation of multiple sclerosis and may predict additional demyelinating events. 
Therefore, recognizing these syndromes and signs will help clinicians to properly 
evaluate the patients, and help develop an effective therapeutic plan. 
4.1.6 History of vaccination, autoimmunity and inflammatory disorders underlies MS 
manfestation 
The history of childhood and early life vaccination has previously been associated with 
an increased risk of MS exacerbation (Zingg, 2005). Although there is strong evidence 
against an increased risk of MS exacerbation after influenza immunization, contradictory 
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data exist relative to hepatitis B, varicella, tetanus, or Bacille Calmette-Guerin 
vaccinations and MS exacerbation (Rutschmann et al., 2002). 
In the present study, the history of vaccination, autoimmunity and inflammatory disorders 
ranged from 30-40% of MS patients which is consistent with previous studies which have 
shown that the risk of MS increases with a positive history of all the above (Demichelli et 
al., 2003; Hernan et al., 2006; Tischler and Shoenfeld, 2004; Vial and Descotes, 2004). A 
potential association between vaccination and autoimmune diseases has been questioned 
in the past few years (Vial and Descotes, 2004), and is largely based on case reports. The 
available evidence, derived from several negative epidemiological studies, is reassuring 
and indicates that vaccines are not a major cause of autoimmune diseases (Salleras et al., 
2006). However, there are still uncertainties as to whether a susceptible subpopulation 
may be at a higher risk of developing an autoimmune disease without causing an overall 
increase in disease incidence. 
4.1.7 Viral infections are implicated in MS aetiopathogenesis 
It has been proposed that multiple sclerosis is caused by an interaction of genetic and 
environmental factors. Previous viral infections, particularly Epstein-Ban virus were 
reported by 31.6% of MS patients in this present study. Previous epidemiological and 
basic research studies have demonstrated a possible association between Epstein-Ban 
virus infection and the risk of MS (Haahr and Hollsberg, 2006) and several 
physiopathologic mechanisms, including molecular mimicry and bystander activation, 
have been proposed for this association (Alonso et at, 2006; Thacker et at, 2006). 
The human neurotropic polyomavirus--JC virus (JCV) has also been implicated in MS 
pathology, as a possible etiologic agent of demyelination of the central nervous system 
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(Pietropaolo et aL, 2005). JCV is also responsible for progressive multifocal 
leukoencephalopathy, a fatal demyelinating disease of the central nervous system that 
occurs mainly in immunosuppressed patients, especially those with HIV/AIDS (Khalili 
and White, 2006). 
4.1.8 Mental disorders co-exist with MS pathology 
Regarding the co-existence of mental disorders with MS, the patients in this study 
reported numerous symptoms, including spasticity, fatigue, cognitive dysfunction, pain 
and predominantly, in 20% of the patients, depression (Crayton and Rossman 2006). 
Other studies have also presented depression as the most frequent psychiatric disorder in 
MS patients (Buchanan, 2006; Gottberg et al., 2006; Wallin ci at, 2006). Its etiology is 
multifactorial and is likely associated with psychosocial stress, focal demyelinating 
lesions, and immune dysfunction (Gold and Irwin, 2006). Proper diagnosis and severity 
assessment are critical prior to initiation of therapy and patients with suicidal tendencies 
should be referred for immediate psychiatric consultation and be closely monitored. 
Depression may exacerbate cognitive dysfunction in MS patients and early intervention 
has been reported to prevent decline in the quality of life of these patients (Wallin ci al 
2006). 
4.1.9 Dyslipidemia isa common feature of MS patients 
The evaluation of the lipid profile of MS patients indicates that the mean value for both 
total cholesterol and triglycerides concentration were increased in MS patients compared 
to normal. Recently, it has been suggested that total cholesterol and low density 
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lipoproteins (LDL) levels can behave as biological markers of activity in demyelinating 
diseases (Giubilei et al., 2002). It has been proposed that a lipid peroxidation disturbance, 
caused by free radicals is involved in the breakdown of the myelin sheath. Several 
subsequent studies have also demonstrated the role of increased free radical production 
andlor a decreased antioxidant defense in the central nervous system as causal factors for 
MS (Bo et aL, 1994; Hunter el aL, 1985; Langeman et aL, 1992). While the principal site 
of pathology is the CNS, lipid status and membrane properties of platelets and 
erythrocytes in the peripheral blood are also altered (Leoni et al., 2002; Wheeler and 
Ford, 1998). Increased lipid peroxide levels have also been previously observed both in 
cerebrospinal fluid and in the blood of MS patients (Hunter et al., 1985). However, 
although there is accumulating evidence for the importance of lipids in MS pathology, 
further studies need to be designed so as to determine whether measurement of plasma 
cholesterol and triglycerides levels are of practical use in monitoring the disease course. 
4.1.10 Cytokines regulate immune response in MS 
Cytokine production is considered an important factor in determining disease activity in 
chronic autoimmune and inflammatory diseases (Chen et al., 2006). The prevailing 
paradigm in the pathogenesis of MS and its animal model, experimental allergic 
encephalomyelitis (EAE), suggests that these diseases have their origin in the disruption 
of self-tolerance for CNS antigens. This disruption results in manifestation of cell-
mediated autoreactivity that is mainly governed by activated T cells with a Th 1 
phenotype, i.e., those associated with a relatively high level production of so-called Thi 
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cytokines (e.g., IFN-y) and a relatively low-level production of Th2 cytokines (e.g., IL-
10) (Navikas and Link, 1996; Ozenci et at, 1999). 
Based on the present data it is clearly evident that aberrant immune responses occur in 
MS, and it is likely that the spectrum of cytokines produced decisively influences disease 
outcome. The detrimental consequences of IFN-'y and the beneficial effects of IFNJ3-
treatment in MS support this hypothesis (Goodin, 2006; Ozenci et at, 2000). However, 
there are still major gaps in our knowledge of the involvement of cytokines in MS. 
Numerous studies have addressed the question of cytokine levels in MS, often with 
conflicting results; elevated, normal and decreased levels of almost all cytokines have 
been reported (Crucian et at, 1996; Drulovic et at, 1997; Link, 1998; Link et at, 1994; 
Matusevicious et at, 1996; Matusevicious et at, 1998; Ozenci et at, 2000; Rieckman et 
at, 1994; Rohowsky-Kohan et at, 1999; Musette et al. 1996). 
4.1.11 ELISPOT assay presents a valuable tool for estimation of cytokine secretion in MS 
The present study was designed to better characterize the cytokine profile of a well-
defined population of MS patients with the relapsing remitting form of the disease both 
with and without treatment with JFNf3 through the use of a more sophisticated assay, the 
enzyme-linked immunospot (ELISPOT), than has previously been used. This assay 
allows real-time cytokine detection by identifying the cells actively secreting cytokines at 
a given time point and is sensitive enough to detect cytokine-secreting cells in the 
absence of stimulant. Instead of measuring mRNA or the accumulation of cytokine in the 
cytoplasm of pharmacologically treated cells, ELISPOT assays detect immunologically 
relevant secretion of the cytokine (Karulin et al., 2000). 
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Until recently, data from ELISPOT assays performed to investigate cytokines in MS had 
been limited to studies of IFN-y. The recent availability of suitable pairs of antibodies has 
now made possible the application of ELISPOT assays to the study of other cytokines as 
well, revealing new insights in the involvement of cytokines in MS. However, in the 
present study, the ELISPOT assay was succesfully applied, permitting accurate 
estimation of the understudy cytokines, and giving valuable and clear informations about 
thecytokine levels in MS. 
4.1.12 Th1/Th2 cytokine imbalance in MS: role of IFN-y and TNF-a 
In the present study, the secretion levels of a selection of both proinflammatory (IFN-y, 
TNF-cz and IL-12) as well as anti-inflammatory (IL-4, IL-b) cytokines were evaluated in 
MS patients compared to healthy controls, in order to reveal any possible imbalance 
between Thi and Th2 immune response. The data clearly show an increased secretion of 
Thb cytokines and reduced secretion of the Th2 cytokines compared to controls, thus 
indicating an important role for these cytokines in the activation of the immune system in 
MS. 
More specifically, increased levels of IFN--y-secreting cells were observed in MS patients 
compared to controls. IFN-y has potent proinflammatory properties, including the 
capacity to induce the production of other proinflammatory cytokines, such as IL- 12 
(Ozenci et al., 2000) and the expression of MHC class II on monocytes/macrophages 
(Kudinov et aL, 2003). Furthennore, IFN-y-mediated signaling leads to increased 
intracellular Ca 2 
 levels, thereby lowering the excitability threshold of T cells (Martino et 
aL, 1998). 
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Elevated numbers of IFN-y mRNA-expressing blood mononuclear cells (Link et at, 
1994) and increased serum IFN-y levels, compared to findings in controls, (Hohnoki et 
at, 1998) have been reported in MS patients. However, other studies have found no 
difference between MS patients and controls with regard to either the percentage of IFN-
7-expressing cells in blood detected by flow cytometry (Nguyen et at, 1999) or the blood 
levels of JFN-y mRNA (Gayo et al., 1999; Huang et al., 1999). These studies did, 
however, clearly show a dramatic accumulation of spontaneously IFN-y-secreting MNC 
in MS patients' .CSF. Therefore, it can be concluded that there is a possible local 
overproduction of IFN-'y in UNS and a stronger ThI autoimmune reaction in UNS than in 
peripheral tissues. This reaction is responsible for myelin destruction in the pathology of 
MS, since the peripheral tissues are not affected although blood cells seem to contribute 
to autoimmune activation. 
TNF-a is another potent pro-inflammatory cytokine found elevated in our study with 
effects ranging from the promotion of proliferation to cell apoptosis. TNF-a induces 
CD40 (Salgado et at, 1999) and MHC class II expression, which are important in T cell 
activation. It has been shown to stimulate production of IL-12, (Ozenci et at, 2000) 
which in turn induces IFN-y production. Also it has the ability to induce expression of 
adhesion molecules at the blood-brain-barrier facilitating entry of immune cells into the 
CNS. 
Our data are in agreement with a few studies which report elevation of TNF-a in patients 
with MS compared to control levels. Numbers of TNF-a mRNA-expressing blood cells, 
(Navikas et at, 1996) serum TNF-cz concentrations (Hohnoki et at, 1998) and levels of 
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TNF-a -secreting blood MNCs (Ozenci et at, 2000b) were found higher in MS patients 
than in controls. 
Elevated levels of TNF-a -secreting cells might be important for the induction of 
proinflammatory immune responses in MS. However, a randomized double-blind placebo 
controlled study showed that inhibition of TNF-a by recombinant soluble TNF-a receptor 
p55 immunoglobulin fusion protein (Lenercept) treatment was not beneficial in MS 
(LMSSG 1999). 
As a consequence of its potent proinflammatory properties, it has been hypothesized that 
TNF-a may be detrimental in autoimmune diseases and this has already been 
demonstrated in rheumatoid arthritis, (Feldman et al., 1991) where anti-TNF-a treatment 
is now part of the standard therapeutic arsenal for this disease (Moreland etal., 1997). 
4.1.13 IL-12 is an important inducer of Al immune response 
An important cytokine favoring the deviation of (auto)immune response in the Thi 
direction is IL- 12. IL- 12 is a powerful inducer of IFN-y production by T cells and natural 
killer cells (Trinchieri, 1995). IL-12 also induces cell-mediated cytotoxicity and exerts co 
mitogenic effects on T cells (Storkus et at, 1998). IL-12 acts through its receptor, which 
is composed of two subunits, IL-i 2Rfi I and IL-i 2Rf32. The interaction of IL- 12 with IL-
12R represents a pivotal crossroad in the development of Thi-type immune responses 
(Gately et at, 1998). 
The number of IL-12-secreting cells was elevated in our MS patients compared to 
controls. Conflicting results regarding IL-12 levels have been reported in MS. Increases, 
compared to findings in controls, both in the number of IL- 12 p40 mRNA-expressing 
blood MNC (Matusevicius et al., 1998) and of IL-12 p40 mRNA levels in blood, (van 
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Boxel-Dezaire ci aL, 1999) have been described. In contrast, serum levels of IL-12 p40 
were similar in MS patients and controls (Fassbender ci aL, 1998; Heesen ci aL, 1999). A 
recent study, evaluating the IL-12-IL-12R system in MS and employing ELISPOT assays 
showed no difference in the numbers of IL-12-secreting blood MNCs between patients 
and controls, although the percentages of PHA-activated CD4 T cells expressing IL-
12R2 were elevated in MS compared to healthy subjects; indicating that CD4 T cells 
from MS patients are more prone to Thl-type activation (Ozenci ci at, 2001). 
IL-12 is thought to play a central role in the pathogenesis of a group of other organ-
specific autoimmune diseases including uveitis, type I diabetes mellitus and rheumatoid 
arthritis (Kang and Kim, 2006; Petrovic-Rackov, 2005). IL-12Rf32 is central molecule to 
these responses as it has been shown in vitro that IL-12R132 is a marker for Thi cells and 
that it determines IL-12 responsiveness (Rogge ci al., 1997; 1999). It has also recently 
been shown that pulmonary T cells from patients with sarcoidosis, but not from patients 
with asthma, exhibit enhanced IL-12Rj32 expression, again suggesting the importance of 
IL- 1 2Rf32 as a marker for Th I-type autoimmune disease (Rogge ci al., 1999). 
High IL- 12 production at the time of initiation of the immune response can be due to 
exposure to microbial agents possessing molecules called pathogen-associated molecular 
patterns (PAMPs) recognized by TOLL-like receptors on antigen-presenting cells 
(Obonyo et al., 2006; Wang ci al., 2006). 
4.1.14 IL-JO, as a potent inhibitor ofproinflammatory cytokines 
IL-10 is the most important anti-inflammatory cytokine described to date and, in this 
present study, the level of IL- 10 secreting cells in the peripheral blood of MS patients 
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was markedly reduced compared to controls. Since IL-10 is known to exert inhibitory 
effects over proinflammatory cytokthes (IL-2, IL-12, TNF-a and IFN-y), low IL-101evels 
in blood may further enhanc ml immune responses, which are harmful for disease 
progression (Ozenci ci al., 1999; Rep ci al., 1999). Long considered as a Th2 cytokine, 
IL- 10 is now seen as an overall counter-regulator for the production of other cytokines 
(de WaaI-Malefyt ci al., 1991; Fiorentino ci at, 1991). The inhibitory effects of IL- 10 on 
cytokine production are mainly mediated via suppression of the expression of MFIC class 
II and of adhesion and co stimulatory molecules on monocytes/ macrophages and 
dendritic cells (de Waal Malefyt and Moore, 1998). A potential therapeutic role for IL-b 
in autoimmune diseases, such as rheumatoid arthritis, (Isomaki ci al., 1996) type 1 
diabetes mellitus (Pennhine ci at, 1994) and psoriasis, (Asadullah ci at, 1998) has been 
proposed. 
A number of studies have evaluated IL-10 in MS, with partly contradictory results. 
Elevated numbers of IL- 10 mRNA-expressing blood MNCs, compared to numbers in 
controls, (Navikas ci at, 1995) were reported in patiënth with MS. However, decreaed 
IL-10 levels and IL-lO blood MNCs mRNA have been observed in MS (Huang ci at, 
1999; Salmaggi ci at, 1996). In this present study, the numbers of IL- lO-secreting blood 
MNCs were also lower in MS patients than in controls. Such a decrease of IL-lO in blood 
might further enhance Thi-type immune responses which are harmful for disease 
activity. More specifically, the presence of low IL- 10 peripheral blood levels in MS 
patients may theoretically be either the cause or the result of Thi immune response 
activation observed in these patients. This can be possibly due to the inhibitory effects of 
IL- 10 over the production of ml cytokines since Thi and Th2-type cytokines have been 
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reported to exert mutual inhibitory effects over each other (Ozenci et aL, 1999; Rep et 
aL, 1999). 
>4.1.15 Low IL-4-producing Tceiis are associated with the stable stage of MS 
Another Th2 cytokine that contributes to the stable stage of the disease is JL-4 which, 
similarly to IL-b, was found to be secreted in reduced levels compared to normal 
controls in the present study. This finding is in agreement with a previous study 
employing an intracellular cytokine staining technique. This enabled the analysis of 
CD3 CD8, and CD8 T cells, which differentiated into IL-4-producing (12) subsets 
after short-term stimulation, in peripheral blood samples from MS patients and healthy 
subjects. Significantly lower percentages of IL-4-producing T cells were found in stable 
MS patients than in controls, and in active than in stable patients. It was furthet shown 
that IL-4 can respectively drive CD4 T cells to Thi and Th2, and CD8 T cells to Tcl 
and Tc2 polarization (Franciotta, 2000). 
Previous studies have also shown a downregulation of IL-4 in MS patients during 
relapses (Urcelay et al., 2005). However, contradictory studies exist showing that IL-4 
levels in CSF during the stable stage as well as during the relapse were significantly 
higher than that in the control group (Bartosik-Psujek and Stelmasiak, 2005). Also in situ 
hybridization studies with complementary DNA oligonucleotide probes for human IL-4 
and expression of IL-4 mRNA found elevated levels of expressing MNC in peripheral 
blood from untreated patients with MS compared to patients with other neurological 
diseases and healthy subjects (Link et al., 1994). In another study, expression of IL-4 was 
reduced in patients still in the relapsing-remitting phase compared to patients with 
secondary chronic progressive MS (Soderstrom, 1995). The present data indicate that 
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decreased levels of IL-4 secreting blood mononuclear cells are present in the relapsing-
remitting form of the disease further leading to a polarisation of CD4 I cells to ml 
response through this cytokine. 
Overall the cytokine data of our study indicate that IFN-y, TNF-a, IL- i 2 and IL- 10 may 
be used as candidate complementary diagnostic markers for MS and, moreover, as 
possible therapeutic agents or targets (IFN-y, and TNF-a) or therapeutic modulators (IL-
10, IL-4). The present study has the advantage over the previous ones in that 
measurements have been p&formed in parallel on the same lymphocyte pools of MS 
patients presenting their cytokinetic profile at the given period. Previous studies have 
investigated the same cytokines in different patients or treatment times with a variety of 
techniques thus resulting in contradictory data, making very difficult to predict the state 
(or pathway) of the immunological response. 
4.1.I6IFN/3 treatment affects the ThJ/7h2 cytokine imbalance 
Since clinical studies have shown that treatment of MS patients with IFNf3 reduces the 
frequency and severity of clinical relapses in relapsing-remitting MS (Meier et at,2006), 
the basis of these beneficial effects merited extensive investigation. The present study 
indicates that treatment with IFN[3-lczJl j3 significantly reduces pro-inflammatory cytokine 
secretion and elevates the anti-inflammatory one. Furthermore, IFN- 1 J3 was found more 
beneficial than IFND-la in reducing proinflammatory cytokine levels (IFN-y, TNF-a), 
and in elevating anti-inflammatory cytokines (IL-4, IL-b) whereas IFNf3-la was more 
efficient in reducing IL- 12 levels( Gayo et al., 1999; Weber et at, 1999). Therefore, the 
immunological effects of IFNP treatment in multiple sclerosis include reduction of Th 1 
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cells secretion while maintaining the potentially beneficial effects of the Th2 response 
(Duddy ci al., 1999; Ochi ci al., 2004). This observation is in accordance with a previous 
study where IFNI3-la inhibited IFN-y secretion and enhanced IL-4 in MS patients 
(Jansson ci al., 2003). Other studies have also been performed rejarding the benefits of 
IFNF3 treatment particularly in the clinical aspects of the disease and especially in 
reduction of relapses and disease progression. Specifically, a reduction was shown in the 
Expanded Disability Status Scale, in the rate of relapses and in the T2 burden of the 
disease in patients recieving IFNI3-lci therapy during an 8 years-period compared to a 
group of MS patients witha 2 years later onset of therapy. Also, a reduced annual relapse 
rate was observed in MS patients after i years of treatment compared to baseline 
(Coppola ci at, 2006; Kappos ci at, 2006). 
Consistent with the results of the present study, previous studies have reported 
modulation of high serum levels of IL-12 and TNF-a after IFNP treatment (Fillion ci at, 
2003; Brod ci at, 1996; Wang, 2000; Losy ci at, 2002), potentiation of IL-10 production 
by blood mononuclear cells of MS patients after IFNJ3 treatment (Chabot et Yong, 2000; 
Porrini ci al., 1995; Rudick ci at,1998), and increase of IL-4 serum levels after IFN 
treatment using ELISA assay methodology (Rudick ci at, 1998; Cebria-Perez ci at, 
2000). However, decreased numbers of blood ononuclear cells secreting TNF-a and 
increased numbers of IL- 10 secreting blood mononuclear cells were also detected in MS 
patients after IFNP treatment using the ELISPOT assay (Ozenci ci al., 1999; 2000). 
Finally, enhancement of IL- 10 expression and reduction of IFN-y producing T cells in 
MS patients was also observed after IFNJ3 treatment using a flow cytometric approach 
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(Rep cit at, 1999; Rudick et at, 1996). Therefore, the present data show clearly that IFND 
treatment acts by inhibiting the Thi immune overexpression underlying MS and at the 
same time it enhances the reduced Th2 immune response. However, it is still uncertain 
whether IFNI3 treatment acts simultaneously at both Thl and l'h2 immune response or 
whether it acts only in one of them and this indirectly modulates the other. 
Previous studies have reported contradictory results regarding the effect of IFN 
treatthent in cytokine levels of MS patients (Furlan cit al, 2000; Khademi ci al. 2000; 
Bahner ci al., 2002; Rothuizen cit at, 1999; Andersson ci at, 1993). Specifically, a 
transient increase of IFN-y blood levels after a short-term treatment with IFN-1f3 was 
observed by solid-phase ELISA without significant modification of IL-4 or TNF-a levels 
(Nicoletti ci at, 2000). In another study no sustained alteration in the plasma levels of IL-
12, TNF-a and IL-lO cytokines was found in MS patients after a 3 month treatment 
period with IFN-1 a (Duddy et at, 1999). 
The differences obtained between our data and other studies may be mainly attributed to 
the different assay methods used in a variable number of patients with different forms and 
at different stages of the disease. The ELISPOT assay provides a more precise and 
valuable assay for the estimation of the secretion of cytokines compared to the other 
methods since it permits a real time and high sensitivity estimation of the cells that 
secrete a certain cytokine (Stott, 2000; Sedwick ci at, 1983). Since other studies (Jansson 
ci at, 2003; Ozenci et at, 2000) using the same assay for cytokine levels estimation, 
present similar findings and the fact that our data agree with the established course of the 
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disease (enhancement of ml response and weakening of the Th2 immune response 
during relapses and exacerbations, and reversibility of this status after IFND treatment) 
suggest the credibility of our data. Moreover the present study has the advantage over 
others (Bienvenu et at, 2000; Drulovic et at, 1997) that cytokine measurements have 
been performed in parallel from same lymphocyte pools of a satisfactory number of MS 
patients presenting their cytokinetic profile at a given period. 
It is not certain whether overexpression of the ml immune response is the cause or the 
result of the inflammatory lesions in the CNS of MS patients, but it is obvious that this 
mechanism plays a key role in the pathogenesis of the disease. Evidence in favor to this 
statement is the clinical improvement observed in these patients after IF'N13 treatment 
which is accompanied by a shift of Th1/Th2 balance towards Th2. This ThI-cytokine 
overexpression may possibly lead to activation of other immunological molecules (such 
as matrix metalloproteinases, apoptotic markers, cytokine receptors, adhesion molecules) 
which are discussed later in this chapter (Contasta et at, 1999; Kami et al., 2006; Rep et 
at, 1999). 
In summary, evaluation of the specificity and sensitivity of the ELISPOT assay in 
identifying even a small number of cytokine-secreting cells based on our study, provides 
a promising tool for monitoring IFNI3 treatment response in patients with multiple 
sclerosis. However, before conclusions about exact pathogenesis or suggestion of 
therapeutic targets can be made, the differences between the two components of IFNJ3-
(Ia and 10) relating to the regulation of cytokine profile and of other immunological 
markers need further investigation. 
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4.1.17 Percentages of cells expressing cytokine receptors in MS 
An imbalance in cytokine homeostasis is considered to play a major part in the 
pathogenesis of immuno-inflammatory diseases (Louis, 2001;Campell and Harrison, 
1990; Dayer et al., 2005) and determination of cytokine levels in body fluids is important 
in defining their role in health and disease. However, the level of a certain cytokine 
reflects only one aspect of its net effect. Cytokines act mainly through their receptors in 
order to regulate immune responses and they are not functional in the absence of their 
receptor on the target cell membrane. Therapeutic approaches are usually developed with 
the purpose of impeding the interaction between the ligand (cytokine) and its specific 
receptor, or interactions that involve the use of anti-inflammatory cytokines to switch off 
inflammation (Moller and Villiger, 2006; Pennline et at, 1994). 
While a number of studies have described changes in cytokine levels in MS, expression 
of cytokine receptors has received little attention (Gimenez et at, 2006; Karni et at, 
2006). 
In the present study, we estimated percentage of T and NK cells expressing cytokine 
receptors on their surface in MS patients, with and without IFNI3 treatment, using flow 
cytometry. 
4.1.18 Percentage of T and NK cells expressing IL-12R may regulate the cytokine 
network in MS 
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MS is associated with elevated levels of IL-l2RJ3l compared to controls (Li ci at, 2003; 
van Boxel-Dezaire ci at, 2001). In this study, although the percentages of CD4 and CD8 
I cells expressing IL-12Rl did not differ significantly between MS patients and healthy 
controls, the percentage of IL-12RJ31 expressing NK cells were significantly higher in 
patients with MS without or with treatment with IFNJ3 compared to healthy individuals. 
Furthermore, PEA-stimulation strongly augmented IL-12R131 in all cell types. Therefore, 
it is reasonable to suggest that, even in absence of increased levels of IL-12, the net effect 
of IL-12 on T cells might be augmented by elevated percentage of cells expressing its 
receptor in MS. - 
The IL-12/!L-12R system is a turning point for the type of immune response that will 
develop during activation (Gately ci at, 1998; Ozenci S al., 2001). IL-12R seems to be a 
central molecule in the regulation of the cytokine network that shifts the immune 
response to Th 1 type (Adorini, 1999; Seder ci at, 1993).. In vitro, it has been repetitively 
shown that IL-12R is a marker for Thi cells (Rogge ci at, 1997, 1999). It has also been 
recently also reported that pulmonary T cells from patients with sarcoidosis, but not 
asthma, show enhanced IL-12R expression, suggesting the importance of IL-12RJ31 as a 
marker for Th I-type autoimmune disease (Chang ci aL,2000;Rogge ci al., 1999; Skarsvik 
ci at, 2005). The present data on percentage of cells expressing IL-12R indicate a clear 
elevation in percentage of NK cells expressing IL-I2RD1 and an increased suspectibility 
of ThI (CD4 1 and CD8 1 ) cells of MS patients compared to controls at expressing higher 
percentage of IL-12Rf32 after PEA stimulation. These two types of cells are critical 
coefficients of the Thl immune response and since they are shown to be activated by IL- 
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12 binding to IL-12 receptors, it is indicated that T cells from MS patients are more prone 
toThi type of activation. 
Treatment with both forms of IFNJ3 was proved efficient in decreasing percentage of all 
cell types expressing JL-12R. Therefore, this implies that IFNP inhibits the characteristic 
ml immune response by acting through modulation of percentage of cells expressing IL-
12R. It is not however, clear if this is a direct action of IFNI3 in percentage of cells 
expressing IL- 1 2R, or indirect through the reduction of IL- 12 secretion which furthers 
leads to downregulation of percentage of cells expressing IL-12R. 
4.1.19 Percentage of T and NK cells expressing IFN-y R has a dual regulatory role on 
IFN-y effects 
Percentage of peripheral blood cells expressing IFN'yR on their surfaces was diminished 
in untreated patients with MS compared to control subjects. Although the percentage of 
IFNyR-expressing CD4 and CDS cells differed significantly between MS patients and 
controls, IFNyR-expressing NK cells did not show any difference between the two 
groups. These findings are in accordance with previous studies where expression of the 
IFNyR-beta chain was low during active untreated disease (Ahn et al., 2004). After IFNf3 
therapy, the IFNyR-beta/alpha ratio increased after 3 months but had fell at 12 months 
(Ahn et al., 2004). Increased susceptibility to apoptosis with high IFN7R-beta chain 
expression at 3 months is likely to remove activated T cells during IFNI3 therapy (Ahn et 
al., 2004; Bongioanni et at, 1999). This can be explained by the fact that IFN-y R at low 
concentrations favors the pro-inflammatory actions of IFN-y, whereas at high 
concentrations it induces its' apoptotic actions. There is evidence that the elevation of 
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IFN-7R-beta chain expression after IFNj3 therapy enforces the apoptotic action of IFN-y 
to activated ThI lymphocytes (despite the inhibition of its secretion by IFN3) and by this 
way affects positively the course of the disease (Bongioanni et at, 1999). 
IF'Nf3 therapy ameliorates MS, possibly by lowering IFN-7 secretion and inhibiting 
responses to IFN-'y (Rep et at, 1999; Yasuda et at, 1999). IFN-y effects are regulated by 
IFN-7R expression and it has been shown that IFN-y is pro-inflammatory at low IFN-yR 
levels, but induces apoptosis in cells with high IFN-7R levels (Ahn et at, 2004). Given 
that reduced IFN-y binding after IFNI3 treatment may be related to lymphocyte activation, 
it is possible that the major effect of IFNfI treatment is a decrease in T-cell activation. T 
cells are activated at the Thi immune response mainly by IL-12, IFN-'y, and TNF-a and 
they are regulated through binding of these cytokines to their receptors. Since IFNI3 
affects all of these components it raises the possibility of exerting its actions mainly 
through this mechanism. 
4.1.20 Role ofpercentage of T and NK cells expressing TNFJ.R in MS 
Percentage of NK cells expressing TNFIR was significantly elevated in MS patients 
compared to normal controls. TNF-a in MS is responsible for peripheral blood leukocyte 
priming (Dowling et al., 1997). The present findings are consistent with the study of 
Ziaber et al., 2000 who showed higher serum levels of TNF soluble receptors sp55 and 
sp75 in MS patients during MS acute exacerbation and in chronic progressive forms as 
compared to MS remission and other neurological diseases (Ziaber et al., 2000). IFN 
therapy reduced the percentage of cells expressing TNF-aR, further reducing TNF-a 
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activity during the disease process. This finding suggests that IFNI3 exerts of its action by 
reducing the percentage of cells expressing TNF-aR, thus inhibiting the action of TNF-a 
at T lymphocytes. Therefore, TNF-a-TNF-a R binding at T lymphocytes is an important 
mechanism for the development of Thi immune response in MS as well as a piornising 
selective therapeutic target. 
Furthermore, a study in the EAE model showed that immunosuppression by TNF and 
protection against EAE does not require the p55 TNFR, whereas the same receptor is 
necessary for the detrimental effects of TNF during the acute phase of the disease 
(Kassiotis and Kollias, 2001). Thus, blocking the function of the p55 TNFR in 
autoimmune dethyelination may inhibit the noxious proinflammatory activities of TNF 
without compromising its immunosuppressive properties (Kassiotis and Kollias, 2001). 
4.1.211'ercentage of T and NK cells expressing IL-i OR are involved in suppression of 
Th2.irnmune rcsponse in MS 
Percentage of peripheral blood cells expressing IL- 1 OR was significantly reduced in MS 
patients compared to controls. Low percentage of all cell types, CD4, CD8 and NK cells, 
presented IL- 1 OR expression. This was partly expected based on the reduced secretion 
levels of this cytokine by MS patients. However, PHA stimulation leads to increased 
expression of IL-I OR in these cells up to normal levels. Our data are in agreement with 
the study of Vandenbark et aL, (2001) where reduced frequencies of IL-lO-secreting 
PBMCs were established by ELISPOT in untreated MS patients and healthy controls. 
Furthermore, these data show clearly the suppression of Th2 immune response in MS 
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which is partly expected since Th2 activation is inhibited by ml cytokines which are 
overexpressed in MS. 
IL-10 is a potent inhibitor of IL-12 and IFN-y and its effects are mediated by the high 
affinity IL-lO receptor which is structurally related to IFN receptors (Ho ci at, 1993, Liu 
et at, 1994). The inhibitory role of IL- 10 in the pathogenesis of MS and EAE is based on 
the finding that IL- 10 can suppress the expression of inflammatory mediators by 
activated immune cells and glial cells (Ledeboer ci aL, 2000; Moore ci at, 2001). 
Furthermore, IL-I OR has been shown• to recruit the signaling pathways of IL6-type 
cytokine receptors, and many IL- 10 responses are also induced by IL-6 (Hirano ci al., 
1998). 
Not many studies exist regarding IL-bR expression in peripheral blood of MS patients. 
Most studies involve the immunohistochemical localization of IL-i OR in postmortem 
brain tissue of MS patients, showing strongest IL- 10 immunoreactivity in reactive 
astrocytes within active demyelinating lesions and the hyperceliular rim of chronic active 
MS lesions (Cannella and Raine, 2004; Huishof ci at, 2002). Moieover, strong 
immunoreactivity for IL-bR was detected on macrophages in both parenchymal and 
perivascular areas and on reactive astrocytes in active and chronic MS lesions. These 
results indicate that IL- 10 has an active role in CNS immune responses whilst the specific 
patterns offi protein localization and protein expression of IL-bR in MS lesions at 
different stages of development suggest that IL- 10 and its receptor participate in 
processes leading to the formation of chronic MS lesions (Huishof ci at, 2002). 
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The present data of IL- 10 decreased secretion and suppressed percentage of peripheral T-
lymphocytes expressing IL1OR in MS patients, verifies the theory of peripheral Thi 
activation and supression of Th2 response in MS and indicates a different role of IL-b 
and its receptor at the peripheral immune response compared to its inflammatory actions 
in the cells of the central netvous system. 
IFNj3 treatment increased the percentage of cells expressing IL-i OR in MS patients after a 
six month period. Although the exact mechanism of action of IFNj3 on IL-10 secretion is 
not known, there is evidence that it may enhance the capacity of dendritic cells to 
stimulate autologous 1-cells to secrete IL-lO and further upregulate their receptors 
(Wiesemann et at, 2002). Regarding the differential effects of the two forms of IFNI 3 
treatment, it is clear from our study that IFNI3-la was more effective in normalizing the 
percentage of cells expressing the cytokine receptors under study compared to IFNJ3-1f3, 
suggesting a different mechanism of action between the two forms of IFNf), and 
providing a rhore promising new therapeutic approach. 
4.1.22 Impaired T-cell apoptotic mechanisms in MS: role of CD95 
Failure of CD95-mediated apoptosis of autoreactive I cells has been postulated as a 
major disease mechanism in MS (Pender, 1998). CD95 (Fas) is originally described as a 
cell surface molecule that belongs to the family of TNF receptors mediating cytolytic cell 
death. It can be detected in a membrane-bound and a soluble form (Zipp et at, 1998a). 
CD95 transmits an apoptotic signal in susceptible target cells when induced to trimerize 
by ligation of agonistic antibody or the natural CD95 ligands (CD95L), another member 
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of the TNF superfamily (Zurak, 1997; Dhein et at, 1995). The soluble form of CD95 has 
apoptosis blocking properties, and the function of soluble CD95 as apoptosis inhibitor or 
promoter is still controversially discussed (Zipp et al., 1999). Activation induced 
apoptosis may occur in the central nervous system in normal individuals to delete 
naturally occurring autoreactive T cells (Gold et at, 1997; Zipp et aL, 1999). In MS a 
genetically determined failure of this methanism may lead to survival of autoreactive T 
cells and may induce CNS damage (Bilinska et aL, 2002; Pender, 1998; Okuda et al. 
2006). Furthermore, recovery from EAE is associated with apoptosis of T cells, leading 
to the conclusion that the impaired apoptotic mechanism is a major pathogenic pathway 
in MS (Macci  et aL, 1999). 
Also, CD95 positive microglial and T cells are infrequently found in brain tissue of 
patients with MS (Dowling etal., 1996; Kobji and Matsumoto, 2000). Therefore, it is still 
an open question whether T cells or microglial destructive effects dominate the effects of 
apoptosis in MS. This section of the present study aimed to clarify whether soluble CD95 
may be detected in the sera of MS patients and to investigate the effect of IFNI3 treatment 
upon CD95 expression. 
The present data showed that sCD95 levels were detectable and increased significantly in 
the sera of MS patients compared to healthy controls. This is in contrast to Giusani et al., 
(1998) who failed to find any differences in sCD95 serum levels of MS patients in 
different disease stages not classified by disease activity. 
However, the present findings are in accordance with the results of Zipp et at, (1998b), 
who reported elevated serum levels in the relapsing remitting type of MS. However, in 
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this study they found no correlation with activity as defined by lesion formation using 
MRI. This observation indicates that the elevation of sCD95 and the consequent 
activation or inhibition of apoptosis- through binding to CD95L (thus preventing its 
binding to membrane CD95 and apoptosis), does not affect the CNS cells, but rather 
additional apoptotic mechanisms may contribute to the impaired apoptotic process in MS. 
Additionally, Inoue et al., (1997) have demonstrated significantly elevated sCD95 levels 
in CSF of 40 active RR MS patients compared to 10 patients with other inflammatory 
neurological diseases but not in comparison with controls. Giusani et at, (1998) showed 
that the sCD95 CSF/serum ratio was increased in MS patients and concluded that they 
may reflect an increased sCD95 mediated apoptosis of encephalitogenic autoreactive T 
cells in the active stage of MS. As it is difficult to draw functional conclusions from the 
detection of soluble receptors, further studies have dealt with cell-surface molecules and 
functional in vitro assays. Zipp et al., (1 998a) has showed that sera of MS patients 
protected a glioma cell line from CD95 mediated apoptosis leading to the hypothesis of 
an anti-apoptotic activity in MS. 
On the other hand, Alcazar et al., (1998) demonstrated a neuronal apoptosis-inducing 
potential of CSF specimens of active primary-progressive MS patients. Increased CD95 
cell surface expression in T cells in MS was postulated by Ichikawa et al., (1996). 
However, Zipp et al., (1998a) could not confirm their findings by analysing T-cell 
surface expression of CD95 and CD95 mediated functional apoptosis in MS versus 
healthy controls. Macchi et at, (1999) demonstrated in vitro that PHA-stimulated 
peripheral blood mononuclear cells from MS patients were less sensitive to apoptotic 
signals than cells from controls and are in general accordance with the present data. 
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Contradictions between the various reports may be due to methodological differences in 
sCD95 quantitation, as the different commercial kits used probably had different 
sensitivities and specificities (Mahovic ci at, 2004). Since several different functional 
forms of sCD95 have been described (Cascino ci at, 1995), the same primary antibody 
should be used for all comparative studies. In addition, patient and controls groups in the 
different studies may not be exactly the same in terms of activity, stage, and duration of 
disease. 
Hwever, due to these contradictory data, sCD95 cannot at present be justified as a MS 
activity marker. 
The mechanism whereby IFNf3 elicits its beneficial clinical effects in MS patients is not 
clear although induction of CD95-mediated T cell apoptosis may play a role (Zipp, 2000; 
Sharief ci at, 2002). In this study, treatment with IFNP induced an elevation in 
circulating sCD95 after a six-month period. Information on neutralising antibody status 
of the patients in the study was not available to allow a similar evaluative analysis to be 
performed. Therefore, it can be concluded that IFNJ3 acts by elevating sCD95 at the onset 
of therapy, thus supporting a beneficial role of this molecule at the course of MS. The 
subsequent reduction in sCD95 levels can be explained by the immunoregulatory results 
of long-term IFND treatMent. The present data are in agreement with this observation (i.e. 
elevation of sCD95 in short term after the onset of IFNI3 treatment) and indicate this 
effect is a very important mechanism of action of IFNj3 in MS. 
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The results demonstrated in this thesis show that IFNf3-113 was slightly more efficient 
than la at increasing sCD95 levels, reflecting different action mechanisms between the 
two forms. Although no previous comparative data exist between the two forms of IFN, 
this finding needs further investigation. 
In conclusion, the elevated serum sCD95 levels may be a reflection of the immune 
dysregulation underlying the MS disease process and may explain, to some extent, the 
paradox of the presence of unequal frequencies of MBP-specific T cells in the peripheral 
blood of MS patients and healthy individuals (Zhang et al., 1994). Since differences in 
serum and CSF sCD95 levels were hoted.in MS clinical studies, sCD95 does not appear 
to be a definite disease marker in MS (Boylan et aL, 2001). 
4.1.23 Altered T lymphocyte trafficking in MS due to increased levels of adhesion 
molecules 
Multiple sclerosis is thought to be caused by a T cell-mediated attack on CNS myelin and 
axons (Brosnan and Raine, 1996; Traugott and Lebon, 1988). The transmigration of 
leukocytes from the peripheral nervous system into the UNS is a multistep process that 
occurs in an ordered sequential fashion. A co-ordinated expression of vascular (selectins, 
ICAM-1, VCAM-l) and leukocyte (LFA-1, VLA-4) adhesion molecules facilitates the 
adhesive interactions between leukocytes and endothelial cells (Shimizu et al., 1991; Jia 
et al., 1999). The expression of the selectins, ICAM-1 and VCAM-1 in endothelial cells 
is upregulated by proinflammatory cytokiries IFN-y and TNF-a (Dhib-Jalbut et al., 1996). 
Therefore, upregulated TNF-a in MS may play a role in increasing the expression of 
adhesion molecules, which in turn results in the docking of activated leukocytes to vessel 
walls. 
179 
The expression of the soluble fonns of adhesion molecules (VCAM-1 and !CAM-l) in 
this study was increased in MS patients compared to controls. Contradictory data exist 
regarding evaluation of serum sICAM-1 and sVCAM-1 in MS. Some studies show an 
increase in sVCAM-1 and sICAM-1 levels in MS patients compared to controls 
(Baraczka et at, 2001; Dore-Duffy etal., 1995; Mc Donell et at, 1999), and others show 
no significant difference between serum s ICAM-1 and s VCAM-1 levels of MS patients 
and controls (Correale et at, 2003; Droogan et at, 1996). The observation of increased 
levels of adhesion molecules is in accordance with the current theory of Thi immune 
activation in MS, which induces an altered expression of adhesion molecules, further 
affecting the trafficking of activated Thi cells into the CNS. 
However, the presence of contradictory data which show no difference in the levels of 
adhesion molecules between MS patients and controls indicate that these molecules may 
not be of vital importance for the demonstration of Thi immune response or that Thi 
immune response is mainly intrathecal (Kraus et al., 2004; Robinson Agramonde et at, 
2001). The differences between the studies may also be attributed to the number of 
samples that were examined, and to the form and the stage of the disease of the patients 
under investigation. 
Treatment of MS patients with IFND resulted in an increase in the plasma concentration 
of sVCAM- 1, and in elevation of the plasma concentrations of ICAM- 1. sVCAM- 1 has 
been reported to block the function of the VLA-4 molecule at physiological 
concentrations, and its production may be induced in brain endothelial cells by IFN-y and 
TNF (Kallmann et at, 2000).The effects on plasma concentrations of sVCAM-1 are in 
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agreement with previous studies (Calabresi et at, 1997; Muraro et al., 2000; Calabresi et 
al., 2001; Matusevicious et al., 1998). 
Rowever, contradictory data exist regarding sICAM-1 concentration where no change 
was found in plasma levels during treatment with IFNI3 (Gelati et at, 1999;-Jiang et at, 
1997), which agrees with other studies finding either no effect or a transient increase in 
sICAM-1 concentrations in MS patients treated with IFNJ3 (Corsini et at, 1997; Kilinc et 
al., 2003). 
There is evidence that IFNP facilitates the conversion of cell-associated adhesion 
molecules (such as VCAIVI-l) into its soluble form, which interacts with its receptor in T - 
cells and, as such, prevents the interaction of the latter with endothelial cells (Calabresi et 
at, 1997). Several studies indicate that IFNJ3 also decreases the expression of chemokines 
and their receptors, reducing the chemotactic signal guiding the way into the CNS for 
inflammatory cells (Zang et at, 2001; Comabella et at, 2002). These inhibitory actions 
of IFNP are crucial for the deVelopment of the disease, since they block the 
transmigration of inflammatory T-cells into the CNS and therefore their destructive 
effects on myelin sheaths. 
It has been previously reported that sVCAM-1 can down-regulate leukocyte expression 
of CD49dIVLA-4 in vitro (Calabresi et at, 1997). However, other studies did not observe 
any correlation between plasma concentrations of CD49dI VLA-4 and sVCAM-1, and 
plasma concentrations of sVCAM- 1 were maximally increased already after I month of 
treatment, whereas T cell expression of CD49d/VLA-4 decreased further from 1 month to 
3 months of treatment, suggesting that there is no simple relationship between increased 
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plasma concentrations of sVCAM- 1 and decreased T cell expression of CD49dIVLA-4 
(Jensen et al., 2005; Muraro etal., 2000). 
IFN-1j3 proved slightly more efficient at increasing sVCAM-1 levels, and IFNJ3-la at 
increasing sICAM-1 levels, supporting the presence of different mechanisms of action 
between the two components of IFND. 
4.1.24 Role of MMPs in regulating T lymphocyte migration through BBB and tissue 
destruction in MS 
Matrix metalloproteinases (MMP5) comprise a family of at least 23 zinc-containing 
endopeptidases that can degrade extracellular proteins (Leppert et aL, 2001). MMPs 
control cell migration acrOss the blood—brain bather (BBB), by disrupting the sub-
endothelial basement membrane and other components of the extracellular matrix 
(ECM), and eventually affect tissue desction in MS (Chandler et al., 1997; Lee et at, 
1999). MMP activities are tightly regulated in on least three different levels (Hartung and 
Kieseier, 2000; Ries and Petrides, 1995; Yong et al., 2001): gene transcription, 
proenzyme activation and activity of tissue inhibitors of metalloproteinases (TIMPs). 
TIMPs, which are widely expressed in the extracellular milieu, form complexes with 
either activated MMPs or with their proforms after their secretion and so reduce their 
activity (Ogata et at, 1995; Shapiro et al., 1995; Yong et al., 2001). The role of MMPs in 
controlling transmigration of activated T lymphocytes through the blood-brain-barrier, 
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makes interesting the study of their expression-and of their inhibitors—in MS patients in 
order to detect their possible role in the developement of the disease. 
MS patients without treatment showed significantly increased MMP-9 levels, compared 
to healthy controls. Increased expression of various MMPs (MMP-2, -3, -7 and -9) have 
previously been demonstrated in postmortem MS brains (Anthony ci al., 1997; Cuzner ci 
al., 1996), and MMP-9 has been detected in acute MS lesions and localized in 
macrophages and astrocytes and also in white matter perivascular mononuclear cells 
(Cuzner ci al., 1996; Maeda and Sobel, 1996). In EAE, the animal model for MS, both 
MMP-9 and MMP-7 hadtheir expression peak at the same time S the appearance of 
clinical signs (Kieseier ci al., 1998). Also, in MS, high gelatinase B (MMP-9) activity has 
been shown in cerebrospinal fluid (CSF) (Gijbels ci at, 1992). Increased MMP-9 CSF 
levels in MS patients were associated with BBB damage using gadolinium (Gd)-magnetic 
resonance imaging (MRI), and methyiprednisolone treatment, by downregulating MMP 
transcription, reduced both Gd enhancement and CSF MMP-9 (Rosenberg ci at, 1996). 
Elevated MMP-9 mRNA levels in peripheral blood mononuclear cells (PBMNC5) 
(Kouwenhoven ci at, 2001; Lichtinghagen ci al., 1999; Ozenci et at, 1999) and raised 
MMP-9 levels in serum and CSF from MS patients have also been detected (Lee ci at, 
1999; Leppert ci al., 1998; Lichtinghagen ci at, 1999; Avolio ci al.,2003), and they were 
associated with clinical or MRI disease activity (Lee ci at, 1999; Waubant cial., 1999). 
The present study shows increased MMP-9 levels in the serum of MS patients without 
treatment compared to controls, potentiating further the involvement of MMPs in the 
regulation of cell migration across the BBB, by disrupting the extracellular matrix, and 
affecting tissue destruction in these patients. 
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Tissue MMP activity reflects a balance between MMPs and TIMPs. In the present study 
MS patients showed decreased lIMP-I levels compared to controls. It has been 
hypothesized (Bever and Rosenberg, 1999) that early in MS lesions, increased MMP-9 is 
followed by BBB damage, but later, during repair processes, TIMPs and MMP-2 may 
prevail by remodeling of the extracellular matrix, which may correspond with the chronic 
progressive stage of MS (Wjtowicz-Praya et cii., 1997). These changes in the MMPs 
action may be partly attributed to the immunomodulatory therapy, but on the other hand 
they may reflect a physical remodeling attempt including TIMPs actions, related to the 
physiologital roles of metalloproteinases. 
The MMP-9/TIMP-1 ratio in serum is higher in MS than normal controls in this study. 
The increase is due to MMP-9 activity which results in higher values in MS patients. 
More interestingly, a higher serum MMP-9/ TIMP-1 ratio is linked to the phase of 
activity of the disease evaluated either clinically or from the Gd-MRI, compared to 
inactive disease. This increase in the ratio would be compatible with a prevalence of 
protease over its inhibitor contributing, on pathological grounds, to disease activity. 
These findings are in agreement with previous reports (Lee et at, 1999; Waubant et al., 
1999; Fainardi et at, 2006) showing that high levels of MMP-9 were associated to 
clinical or MRI disease activity. Lichtinghagen et ai. (1999) reported a higher MMP-
9ITIMP-1 ratio in active MS patients even compared to healthy controls. This indicates 
that there is a shift of the balance between MMP-9 and TIMP-1 towards MMP-9 in MS 
patients, thus facilitating the entry of T lymphocytes in to the CNS through the BBB 
according to our hypotesis. 
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Treatment with IFNI3 decreased MMP-9 levels, increased TIMP-1 levels and reduced the 
MMP-9/TIMP-1 ratio in MS patients. Strong evidence is emerging that MMPs initiate 
early proteolytic activity on the integrity of blood brain barrier (BBB) (Lukes ci at, 1999; 
Rosenberg ci al., 1992; 1996; Opdenakker cial., 2003) and that IFND, through its effects 
on MMPs, might contribute to restoration of the damaged BBB (Leppert ci at, 1996; 
Stuve ci at, 1996; Ma ci at, 2001; Bartholome ci at, 2001; Galboiz et at,2002; Nelissen 
ci aL,2002; Uhm ci at 1999; Waubant ci at,2003). 
Trojano et al. reported that IFNf31J3 treatment decreased MMP-9 expression in RRMS 
patients (Trojano ci at, 1999). A follow-up study of 6 patients for 12 months has shown 
that IFNJ3 treatment was associated with suppression of MMP-9 and MMP-7 mRNA in 
RRMS patients (Galboiz ci at, 2001). However, no significant changes were observed in 
secondary progressive MS group in this study. Therefore it can be concluded that IFN 
treatment reduces MMP-9 expression in MS pariens with the relapsing-remitting form of 
the disease, without having such an effect in the secondary progressive form of the 
disease. This observation indicates that either MMP's have no significant role in the 
pathogenic mechanisms of secondary progressive MS, or that IFNI3 has not for some 
reason (due to anti-IFNP antibodies, different pathogenic mechanisms) 
immunomodulatory effects on MMPs in the secondary progressive form of the disease. 
Two studies have also evaluated the effects of IFNj3 on TIMP-1 levels longitudinally. The 
numbers of TIMP-1 mRNA expressing blood mononuclear cells were higher after 6-12 
months of IFNj3 treatment compared with pre-treatment values where MMP-9 and 3 
expressing cells were decreased (Ozenci ci at, 2000). In 38 patients with MS, MMP-2 
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and TIMP-1 levels were found similar during 9 months of IFN 0 therapy, whereas MMP-
9 levels significantly decreased and TIMP-2 levels significantly increased in comparison 
with values obtained before treatment (Giannelli ci at, 2002). 
Finally it has been suggested that the more pronounced effects of IFNP might be via 
increasing TIMP- 1 levels rather than changing MMP-9 levels (Karabudak et al., 2004; 
Waubant ci at, 2003). Taken into account that TIMP-1 decreases activated T cell 
migration; and MMP1TIMP balance restores BBB integrity; the data of this study are in 
accordance with the clinical stability of MS patients and the present study data showing 
an increase in TIMP-1 and decrease in MMP-9 after IFNf3 treatment of MS patients, are 
in agreement with these results 
4.2 Conclusions 
According to the experimental data presented in this thesis (increased TNF-a, IL- 12 and 
IFN-'y secretion, and decreased IL-b, IL-4 secretion from PBMCs of multiple sclerosis 
patients), the basic conclusion is the presence of a strong stimulation of Thi immune 
response and a suppression of Th2 immune response in multiple sclerosis patients (i.e. a 
shift of the immune response towards the Thi pathway and activation of the cell-
mediated immunity). 
The changes observed in cytokine levels are accompanied by an altered cytokine receptor 
expression profile in key immune cells. In particular, it was observed an increased 
expression of IL-12fIlR and TNF-czR by NK cells, and a reduced expression of IFN-1R 
and IL-bR by T cells. These alterations lead to an overexpression of the ThI immune 
response which results to increased production of the sCD95 apoptotic marker, followed 
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by an increased production of sVCAM-1 and sICAM-1 adhesion molecules, increased 
expression of MMP-9 and reduced levels of TIMP- I. Consequently, all these molecules 
participate towards an infiltration process of activated T-lymphocytes in the CNS, 
possibly contributing to the initiation or the preservation of the inflammatory process that 
causes damage to the oligodendrocytes and their myelin sheaths, resulting in the clinical 
phenotype of MS. 
Therefore, especially the increased pro-inflammatory cytokines seem to act mainly by: a) 
regulating the levels of their receptors in T and NK cells, b) increasing the sCD95 levels 
and thus reducing the apoptotic rates of 1-lymphocytes, c) increasing the membrane and 
soluble forms of adhesion molecules VCAM- I and ICAM- I, facilitating by this way the 
interactions between the surface adhesion molecules of the activated T lymphocytes and 
VCAM-1 and ICAM-1, and therefore, the passage of these cells through the BBB and 
their entry into the CNS, d) increasing MMP-9 levels, reducing lIMP-i levels, and 
increasing the MMPITIMP- 1 ratio, thus inducing the disruption of the BBB and the 
adhesion of activated T lymphocytes at the vascular endothelium, facilitating the entry of 
these cells in the CNS. 
This activation of ThI immune response appears to be reversed by IFNP treatment 
resulting in clinical improvement (prevention of the relapses) of these patients. Thi 
stimulation may be either directly the cause of the myelin damage by direct cytokine 
action at myelin or cytokine induced apoptosis of oligodendrocytes or the immune 
reaction against the already damaged myelin by another cause (a virus for example). In 
both cases an antigenic stimulation, endogenous or exogenous or both is necessary for the 
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start and the demonstration of ml lymphocyte response at central nervous system and 
peripheral blood. Stimulated Tbl lymphocytes of the peripheral blood probably avoid 
regulatory apoptotic mechanisms and enter in the - CNS under the influence of 
chemotactic agents enforcing the inflammatory process. Inductioif of adhesion molecules - 
at the endothelium of the blood brain bather by cytokines, and disruption of the blood 
brain barrier by matrix metalloproteinase's which are secreted by T cells and 
monocytes/macrophages facilitates the entry of Thl cells in the CNS. In parallel to the 
activation of cellular immunity. by the ml immune response, it seems that activation of 
humoral immunity occurs, since IFN-y may induce the differentiation of B-cells to 
plasma cells secreting IgG immunoglobulins (antibodies) against myelin components in 
the CNS. 
IFNf3 has a strong immunomodulatory action in the MS patient. Based on the present data 
and the experimental material of other authors, IFNP possibly enhances the Th2 immune 
response and at the same time inhibits the ThI immune response. The present hypothesis 
regarding this phenomenon is that IFNf3 exerts it's action mainly by stimulating the 
secretion of IL-b, thus inhibiting the secretion of IL-12 which is the first step for the 
demonstration of Thl immune response (our data show that IFNf3-la is more effective at 
decreasing IL-12 and that IFNI3-113 is more effective at decreasing TNF-a and IFN-y and 
elevating IL-4 and IL- 10) (Soilu-Hanninen ci al., 1995). Other interesting actions of IFNf3 
which may contribute to their immunomodulatory action at MS patients are: inhibition of 
expression of MHC II molecules and induction of expression of MHC I molecules, 
inhibition of cellular multiplication, and especially the inhibition of Thl cells migration 
into the CNS. According to this hypothesis IFND may act at other components of Thi 
immune response too. Indeed, IFN-P was shown to affect all the main players of the MS 
immune response. In particular, it reduces the levels of the serum pro-inflammatory 
cytokines (IFN-y, TNF- a and IL-12), increases the levels of serum anti-inflammatory 
cytokines (IL-4 and IL-b), decreaes the expression of IL-1201 R and TNF-aR, 
increases IFN-yR and IL-bR expression levels, raises serum CD95, ICAM-1 and 
VCAM-1 levels, as well as TIMP-1, and lowers serum MMP-9 levels and the MMP-
9/TIMP-1 ratio. IFNI3-lcz was proved more effective at decreasing IL-12 levels and its 
receptor IL-l21R expression in T and NK cells, increasing sICAM-1 levels, decreasing 
MMP-9 levels, increasing TIMP-1 levels, and decreasing MMP-9/s TIMP-1 ratio; 
whereas IFNJ3-1J3 was more effective in decreasing IFN-y and TNF-a levels, increasing 
IL-4 and IL- 10 levels, decreasing TNF-aR levels in T cells, increasing s CD95 levels, and 
sVCAM-1 levels. 
Although there are some contradictory data, mainly due to differences in the number of 
samples, the type of methods, as well as the phase and type of the disease, our present 
data of MS immunopathology and its potential modulation by IFNP therapy provide 
valuable evidence since they are in accordance with the disease process and are 
accompanied by clinical improvement of MS patients. Moreover this 
immunopathological model based on our data and the potential different actions of IFNf3-
1 a and - lP forms over the disease process, are very promising areas for further 
investigation. The formulation of a therapeutic approach targeting the cytokine network 
in parallel with the immunomodulatory influence of IFNJ3 (la and 10) in MS may 
provide a novel diagnostic and prognostic prospective for effective disease management 
based on its autoimmune background. 
Furthermore, the ELISPOT method proves to be a usefUl, and a very sensitive assay for 
cytokine detection by comparison of its results with other currently available methods. 
4.3 Scope for future studies 
Future studies that would allow further elucidation of the immunopathological 
mechanisms underlying MS should involve estimation of the frequency of IL-i, IL-6 and 
IL- 10 group of pro-inflammatory cytokine-secreting cells, namely IL- 19, and IL-22, as 
well as of the Th3 cytokine, TGF-D at MS patients with and without treatment with IFN3 
(-Ui and -1k) and controls using the ELISPOT assay. This would provide a full picture of 
the cytokine status of MS patients as well as of the effect of IFNJ3. 
Furthermore, estimation of IL-i, IL-4, IL-6, IL-b, 1L-12, 1L-19, lL-22, IFN-y, TNF-a, 
and TGF-J3 levels in the CSF of MS patients of untreated patients compared to treated 
with IFNJ3 would be very important in order to investigate the generalization of the Thi 
immune response into the CNS or just in the periphery of these patients. 
The study may also be expanded by the evaluation of further cytokine receptor 
expression in peripheral blood cells as well by the estimation of additional 
metalloproteinases, MMP-2, and MMP-3 in the serum and CSF of MS patients before 
and after treatment. 
Additional molecular studies for the presence of HHV-1, HHV-6, HLTV-I and measles 
viral components in the DNA of MS patients would provide important information on the 
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involvement of possible viral exogenous agents, participating in the triggering of the 
immune reactivity observed in multiple sclerosis. 
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Appendix I 
Questionnaire 
I. Demographic data 
Marital status. The participants were divided into two sub-groups: married and single 
Educational level. Three groups were formed: up to 6 years of education, between 6 and 
12 years, over 12 years of education. 
Employment. Two groups were formed: currently employed and unemployed. 
II. Life-style features 
Cigarette-srnoking.Two sub-groups were formed: non smokers and smokers 
Alcohol. Three subgroups were formed: Heavy drinkers (more than 1 drink per day), 
moderate drinkers (3 times weekly up to I drink daily), light or non drinlcers (less than 2 
times weekly, less than two drinks). 
Leisure physical activity. Four groups were formed: no activity, less than 1 hour per 
week, between 2-3 hours per week and 3hours or more per week. 
III. Personal history 
Incidence of optic neuritis. 
History of autoimmune disease. 
History of inflammatory disease. 
History of viral infections. The participants were asked specifically for previous HIV, 
HTLV and Hepatistis V infections 
Vaccinations. The participants were asked specifically for Influenza and hepatitis B 
vaccinations 
Family history of mental disorders. The participants were asked specifically specifically 
for incidences of depression, anxiety disorders and psychotic disorders. 
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Appendix II 
Suppliers 
Glycerol Sigma-Aldrich, Hellas 
Triglyceride monoreagent mixture 
- 	 Linear Chemicals, Spain 
Glucose I OOmg/dI Linear Chemicals, Spain 
Glucose monoreagent mixture Linear Chemicals, Spain 
HDL-C enzyme reagent Linear Chemicals, Spain 
POD/4-AA reagent Linear Chemicals, Spain 
Cholesterol monoreagent Linear Chemicals, Spain 
Cholesterol 200 mg/dL Linear Chemicals, Spain 
sCD95 (Fas) ELISA kit Diaclone Research,France 
sVCAM- 1 ELISA kit Diaclorie Research,France 
sICAM-1 ELISA kit Diaclone Research,France 
MMP-9 ELISA kit R&D systems, Minneapolis, 
MA 
TIMP-1 ELISA kit R&D 	 system 	 Minneapolis, 
MA 
ELISPOT plates Diaclone Research,France 
Antibodies (primary and secondary) Becton-Dickinson 	 Mountain 
View, CA 
Materials 
Solutions and Buffers 
Triglyceride nonoreagent mixture PIPES buffer 50 mmol/L pH 6.8, LPL? 12 
KU/L, GK? 1 KU/L, GPO a 10 KU/L, ATP 
2.0 mmol/L, Mg2 40 mmol/L, POD ? 2.5 
- KU/L, 4-AA 0.5 mmol/L, phenol 3 mmol/L, 
non-icon tensionactives 2 gIL (w/v) 
Glucose monoreagent mixture Phosphate 70mmolfL, Phenol 5 mmol/L, 
Glucose Oxidase 10 U/mL, Peroxidase 1 
U/mL, 4-aminoantipyrine 0.4 mmolIL 
HDL-C enzyme reagent GOOD'S buffer lOOmmol/L pH 7.0, MgCl2 
18 mmolfL, CE 800 U/L, CO 500 UIL, 
catalase 100 KUIL, HDAOS 0.7 mmol/L 
POD/4-AA reagent POD 4 KU/L, 4-AA 4 mmolIL, N3Na C 0.1 
%, specific surfactants < 1.5 % (v/v) 
Cholesterol monoreagent mixture PIPES 200 mmol/L pH 7.0, sodium cholate 
1 mmol/L, cholesterol esterase > 250 UIL, 
cholesterol oxidase > 250 UIL, peroxidase> 
I 	 KUIL, 4-aminiantipyrine 0.33 mmol!L, 
ADPS 0.4 mmolIL, non-ionic tensioactives 
2 g/L (w/v) 
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Glycerol 2.26 mmol/L, equivalent to 200 
mg/dL of glycerol trioleate 
Glucose 100 mg/dL 
Cholesterol standard. Cholesterol 200 
mg/dL 
Triglycerides standard 
Glucose standard solution: 
194 
References 
Abbadie, C., Lindia, J.A., Cumskey, A.M.,Peterson, L.B.,Mudjett, J.C., Buyne, E.K.,de 
Martino, J.A., McIntyre, D.E. & Forest, M.J. (2003). "Impaired neuropathetic pain 
responses in mice lacking the chemokine receptor CCR2." Proc NatI Acad Scie USA 13: 
7947-52. 
Abbas, A., Lightman, A. & Pober, J. (1997). "Cellular and Molecular 
Immunology."(Edited by: Saunders, 3d edition).USA, Saunders text and review series. 
Acar, J., Idiman, F., Idiman, E., Kirkali, 0., Cakmakei, H. & Ozakbas, S. (2003). 
"Nitric oxide as an activity marker in multiple sclerosis."J Neurol 250:588-592. 
Adorini, L. (1999). '.'Interleukin-12, a key cytokine in Thi-mediated diseases."CelI Mol 
Life ScieSS:1610-25. 	 -- 	 - 
Aharoni,R., Teitelbaum, T., Sela, M. & Arnon, R. (1997)."Coplymer 1 induces T cells 
of the T helper type 2 that cross react with myelin basic protein and supress experimental 
autoimmune encephalomyelitis."Proc Nati Acad Sci USA 94:10821-6. 
Ahn, J. ,Feng, X., Patel, N.,Dhawan, N. & Reder, A.T. (2004)." Abnormal levels of 
interferon-gamma receptors in active multiple sclerosis are normalized by IFN-beta 
therapy: implications for control of apoptosis."Front Biosci 9:1547-55. 
Airoldi, I.,Di Carlo, E.,Cocco, C.,Sorrentino, C.,Fais, F.,Cilli, M.,D'Antuono, 
T.,Colombo, M.P.& Pistoia, V. (2005). "Lack of Ill2rb2 signaling predisposes to 
spontaneous autoimmunity and malignancy."Blood 106:3846-53. 
Ajuebor, M.N.,Carey, J.A. & Swain, M.G. (2006). "CCR-5 in T cell-mediated liever 
disease:what's going on?" J Immunol 177: 2039-45. 
Alam, J.,Goelz, S.,Rioux, P.,Scaramucci, J.,Jones, W.,Mc Allister, A.,Campion, M. & 
Rogge, M. (1997). "Comparative pharmacokinetics and pharmacodynamics of two 
recombinant human interferon beta-la(IFNf3-la) products administrated intramusculary 
in healthy male and female volunteers."Pharm Res 14:14546-549. 
Alcazar, A., Rigidor, I., Masjuan, J., Salinas, M., Alvarez, A. & Cermeno, J.C. (1998) 
"Induction of apoptosis by cerebrospinal fluid from patients with primary-progressive 
multiple sclerosis-in cultured neurons."Neurosci Len 255:75-8. 
Aloisi, F., Penna, G., Polazzi, E., Minghetti, L. & Adorini L. (1999). "CD40-CD154 
interaction and IFN-gamma are required for IL-12 but not prostaglandin E2 secretion by 
microglia during antigen presentation to ml cells."J Immunol 162:1384-91. 
Aloisi, F., Ria, F., Penna, 0., Minghetti, L.& Adorini, L. (1999). "Functional maturation 
of adult mouse resting microglia into an APC is promoted by granulocyte-macrophage 
195 
colony-stimulating 	 factor 	 and 	 interaction 	 with 	 Thl 	 cells." 
J Immunol 164:1705-12. 
Alonso, A.,Egues, Olazabal, N. & Ayo Martin, 0. (2006). "Infection by Epstein-Ban 
virus and multiple sclerosis."Neurologia. Jun;21(5):249-55. 
Amason, B.G. (1996). "Interferon beta in multiple sclerosis."Clin Immunol 
Immunopathol 81:1-11. 
Ambrosini, F. & Aloisi, F. (2004). "Chemokines and glial cells :a complex network in 
the central nervous system"Neurochem. Res. 29:10117-38. 
Ann Marrie, R.& Rudick, R.A. (2006) "Drug Insight: interferon treatment in multiple 
sclerosis."Nat Clin Pract Neurol 2:34-44. 
Andersen, 0., Lygner, P.E., Bergstrom, T. & Andersson Vahlne, A. (1993): "Viral 
infections trigger multiple sclerosis relapses: a prospective seroepidemiological study." I 
Neurol 240:417-423. 
Andersson, M., Khademi, M., Wallstrom, E.& 011son, T. (1997). "Cytokine profile in 
interferon-n treated multiple sclerosis patients:reduction of interleukin- 10 m RNA 
expressing ceilsin peripheral blood."Eur J Neurol 4:567-57 1. 
Anthony, D.C., Ferguson, B., Metyzak, M.K., Miller, K.M., Esiri, M.M. & Perry, V.H. 
(1997). "Differential matrix metalloproteinase expression in cases of multiple sclerosis 
and stroke."Neuropathol AppI Neurobiol 23:406-15. 
Asadullah, 1-I.,Sterry, W.,Stephanek, K.,Jasulaitis, D.,Leupold, M.,Audring, 1-I.,Volk, 
H.D.& Docke, W.D. (1998). "IL- 10 is a key cytokine in psoriasis. Proof of principle by 
IL- 10 therapy:a new therapeutic approach."J.Clin Invest 101:783-94. 
Aste-Amezaga, M.,D' Andrea, A.,Kubin, M.& Trinchieri, G. (1994). "Cooperation of 
natural killer stimulatory factor/interleukin-12 with other stimuli in the induction of 
cytokines and cytotoxic cell-associated molecules in human T and NK cells."Cell 
 
Immunol 156:480-92. 
Avolio, C.,Fuggieri, M.,Giuliani, F.,Liuzzi, M.,Leante, R.,Riccio, P.,Livrea, P.& Trojano, 
M. (2003). "Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis 
subtypes."J Neuroimmunol 136:46-53. 
Ayers, M.M., Hazelwood, L.J.,Catmull, D.V.,Wang, D.,Mc Kormack, 0.,Bemard, C.C.& 
Orian, J.M. (2004). "Early glial responses in murine models of multiple sclerosis." 
Neurochem mt 45:409-19. 
196 
Bahner,D.,Klucke, C.,Kitze, B .,Elitok, E.,Bogumil, T.,Dressel, A.,Tumani, H.,Weber, 
F.,Poser, S.& Bitsch, A. (2002). "Interferon-beta-lb increases serum interleukin-12 p40 
levels in primary progressive multiple sclerosis patients." Neurosci Left 326:125-8. 
Bajetto, A., Bonavia, R., Barbero, S. & Schettini, G. (2002). "Characterization of 
ehemokines and their receptors in the central nervous, system: physiopathological 
implications." J Neurochem 82:1311-29. - 
Balashov, K.E.,Smith, D.K.,Khoury, S.J.,Hafler, D.A.& Weiner, H.L. (1997). "Increased 
interleukin 12 production in progrSsive multiple sclerosis:induction by activated çD4+ 
cells via CD40 ligand interaction."Eur J Immunol 25:1125-8. 
Balkwilll, F.R. (1989). "Inerferons."Lancet 1:1060-1063. 
Banisadr, G.,Queraud-Lesaux, F.,Boutterin, M.C.,Perlapart, D.,Zalc, B.,Rostene, 
W.,Haour, F.& Parsadaniatz, S.M. (2002). "Distribution,cellular localization and 
functional role of CCR2 chemokine receptors in adult rat•brain."J Neurochem 81:257-69. 
Bansil, S.,Holtz, C.R. & Rodowsky-Kochan, C. (1997). "Serum s APO-1/Fas levels in 
multiple sclerosis." Acta Neurol Scand 95:208-10. 
Bar Or, A.,Oliveira, E.M.,Anderson, D.E.,& Hafler, D.A. (1999). "Molecular 
pathogenesis of multiple sclerosis."Clin Neurol Neurosurg 106:246-8. 
Baraczka, K.,Nekam, K.,Pozsonyi, T.,Jakab, L., Szonyoth, M.,& Seztak, M. (2001). 
"Concentration of soluble molecules (s VCAM-1, s ICAM-1 and s L-selectin) in the 
cerebrospinal fluid and serum of patients with multiple sclerosis and systemic lupus 
erythematosus with central nervous involvement." Neuroimmunomodulation 9:49-54. 
Bamett, M.H., & Sutton, I. (2006). The pathology of multiple sclerosis: a paradigm shift. 
Cun Oiin Neurol 19:242-247. 
Bartholome, E.I.,van Aelst, I.,Koyen, E.,Kiss, R.,Willems, F.,Goldman, M.,& 
Oppendakker, G. (2001). "Human monocyte-derived dendritic cells produce bioactive 
gelatinase B:inhibition by IFN-f3."J Interferon Cytokine Res 21:495-501. 
Bartosik-Psujek, H.,& Stelmasiak, Z. (2005). "Correlations between IL-4, IL-12 levels 
and CCL2, CCL5 levels in serum and cerebrospinal fluid of multiple sclerosis patients." J 
Neural Transm 112:797-803. 
Becker, C.C.,Gidal, B.E.& Fleming, J.O. (1995). "Immunotherapy in multiple sclerosis, 
Part 1."Am J Health Syst Pharm 52:1985-2000. 
Beneviste, E.N. (1997). "Role of macrophages/microglia in multiple sclerosis and 
experimental allergic encephalomyelitis." J Mol Med 7:165-173. 
197 
Bever, C.H.,& Rosenberg, G.A. (1999). "Matrix metalloproteinases in multiple 
sclerosis.Targets of therapy or markers of injury."Neurologv 53:1380-1381. 
ni, fl..1.. all, P. tr.. 1) UT T.._. C V fl..4... C fl P DlCgi...1, 13. VV. Ian, 0.fl.,'.J1 	 o.u. 1enakoon, o.n.,nai&c, ivi.n.,.x. 	 randikar, NT T I, .J. 
(2006). "Gelatimer abetate (GA) therapy induces a focused oligoclonal CD8+ T cell 
repertoire in multiple sclerosis."J Neuroimmunol 25. 
Bienvenu, J.A., Moneret, G., Gutowski, M.C., & Fabien, N. (1998). "Cytokine assays 
in human sera and tissues." Toxicology 129: 55-61. 
Bienvenu, J.A., Moneret, G, Fabien, N., & Revillard, J.P. (2000). "The clinical 
usefulness of the measurement of cytokines." Clin Chem Lab Med 38: 267-85. 
Bilinska, M.,Frudecka, I.,& Podemski, R. (1999). 'The level of soluble forms of 
interleukin-2 receptor and adhesive molecules ICAM-1 and VCAM-1 in platelets of 
multiple sclerosis patients."Pol Mercuriusz Lek 6 :23-6. 
Bilinska, M.,Frydecka, I.,Podemski, R.,Teodorowska, R.,& Grazka, E. (2001). 
"Expression of Fas antigen on T cell subpopulations in peripheral blood of patients with 
relapsing-remitting multiple sclerosis." Med Sci Monit 7:251-255. 
Bilinska, M.,Frydecka, I.,Podenski, R.,& Cruszka, E. (2002). "Serum levels of s1NFR-1 
and sFas in patients with relapsing-remitting multiple sclerosis."Med Sci Monit 8: 720-3. 
Bilinska, M., Frydecka, I., Podemski, R.,& Gruszka, E. (2003). "Fas expression on T 
cells and sFas in relapsing-remitting multiple sclerosis." Acta Neurol Scand 107: 387-
393. 
Billiau, A. (1996)."Interferon-y biology and role in pathogenesis."Adv Immunol 62:61-
130. 
Billiau, A.,Kieseier, B.C., & Hartung, H.P. (2004). "Biologic role of interferon beta in 
multiple sclerosis."J Neurol 251: II/10-1114. 
Biron, C.A. (2001). "Interferons alpha and beta as immune regulators-a new 
look."Immunity 14:661-664. 
Bo, L., Dawson, T.M., Wesselingh, S., Mork, S., Choi, S., Kong, P.A., Hanley, D., & 
Trapp, B.D. (1994). "Induction of nitric oxide synthase in demyelinating regions of 
multiple sclerosis." Ann Neurol 36 :778-786. 
Boccaccio, G.L., & Steinman, L. (1996). "Multiple sclerosis: from a myelin point of 
view."J Neurosci Res 45:647-54. 
Bonavia, R.,Bajetto, A.,Barbero, S.,Pirani, P.,Florio,& T.,Schettini, G. (2003). 
"Chemokines and their receptors in the CNS :expression of CXCL12/SDF-1 and CXCR4 
and their role in astrocyte proliferation." Toxicol Len 139:181-9 
Bongioanni, P.,Romano, M.R.,Boccardi, B.,Lombardo, F.,Moscato, F.,Mosti, C.,Baldini, 
r' 	 e 	 0. I' n....: fl flnnn\ "P 	 11 	 +... L.,i UL' i)., 1V1CUL4.d, LX. '.J.,1'Uaai, Li. 1 727). 
	 1 	 ts I 
	 u -5s'sw.sst,. necrocts 
factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects 
of interferon-beta-lb in treatment." Rev Neurol 29893-9. 
Borkakoti, N. (2004). "Matrix metalloproteinase inhibitors: design for structure." 
Biochem Soc Trans 32:17-20. 
Boylan, M.T.,Crockard, A.D.,Mc Donell, G.V.,Mc Millan, S.A.,& Hawkins, S.A. (2001). 
"Serum and cerebrospinal. fluid soluble Fas levels in clinical subgroups of multiple 
sclerosis." Immunol Letters 78 :183-187. 
Boz, C.,Ozmenoglu, M.,Velioglu, S.,Kilinc, K.,Orem, A.,Alioglu, Z.,& Altunayoglu, V. 
(2006). "Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix 
metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated 
with interferon beta." Clin Neurol Neurosurg 108:124-8. 
Brew, K., Dinakarpadian, D.,& Nasage, H. (2000). "Tissue inhibitors of 
metalloproteinases : evolution, structure and function."Biochim Biophys Acta 1477:267-
283 
Brochet, B. (1998). "Non-specific immunosuppression and multiple sclerosis." 
Rev Neurol 154:629-34. 
Brod, S.A.,Marshall, G.D. Jr,Henninger, E.M.,Sriram, S,Khan, M.,& Wolinsky, J.S. 
(1996). "Interferon-beta lb treatment decreases tumor necrosis factor-alpha and increases 
interleukin-6 production in multiple sclerosis."Neurology 46:1633-8 
Brod, S.A.,Nelson, L.D.,Khan, M.,& Wolinsky J.S. (1997). "Increased in vitro induced 
CD4+TcelI IL-10 production in stable relapsing multiple sclerosis."Int J Neurosci 
90:187-202. 
Brosnan, C.F., & Raine, C.S. (1996). "Mechanisms of immune injury in multiple 
sclerosis." Brain Pathol 6:243. 
Brosnan, C.F.,Selmaj, K.,& Raine, C.S. (1988). "Hypothesis: A role for tumor necrosis 
factor in immune-mediated demyelination and its relevance to multiple sclerosis."J 
Neuroimmunol 18:87-94. 
199 
Brundula,V.,Rewcastle,N.B.,Metz,L.M.,Bernard,C.c.,&Yongy.w. 	 (2002)."Targeting 
leucocyte MMPs and transmigration:minocycline as a potential therapy for multiple 
sclerosis" Brain 125: 1297-308. 
Buchanan, R.J.Schiffer, R.,Wang, S.,Stuifbergen, A.,Chalaavorty, B.,Zhu, L.,Suk Kim, 
M.,& James W. (2006). "Satisfaction with mental health among people with multiple 
sclerosis in urban and rural areas."PsyhiatrServ Aug.57: 1206-9. 
Buthix, M.,Stinissen, P.,Steels, P.,Ameloot,& M.,Raus, J. (2002). "Immune-mediated 
oligodendrocyte injury in multiple sclerosis:molecular mechanisms and therapeutic 
interventtions." Crit Rev Immunol 22:391-424. 
Calabresi, P.A.,Tranquill, L.R.,Dambrosia, J.M.,Stone, L.A.,Maloni, H.,Bash, 
C.N.,Frank, J.A.,& McFarland, H.F. (1997). "Increases in soluble VCAM-1 correlate 
with a decrease in MRI lesions in multiple sclerosis treated with interferon-beta-lb."Ann 
Neurol 41:669-674. 
Calabresi ,P.A.,Stöne, L.A.,Bash, C.N.,Frank, J.A.,& McFarland, H.F. (1997). 
"Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in 
multiple sclerosis patients followed by weekly MRI."Neurology 48:1446-8. 
Calabresi, P.A.,Pelfrey, C.M.,Tranquill, L.R.,Maloni, H.,& McFarland, H.F. (1997). 
"VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of 
multiple sclerosis with interferon beta."Neurology 49:1111-6. 
Calabresi, P.A.,Prat, A.,Biemacld, K.,Rollins, J.,& Antel, J.R. (2001). "T lymphocyes 
conditioned with interferon beta induce membrane and soluble VCAM on human brain 
endothelial cells."J Neuroimmunology 115: 161-7. 
Campell, I.L.,& Harrison, L.C. (1990). "Molecular pathology of type 1 diabetes." 
Mo] Biol Med 7:299-309. 
Cannella, B.,& Raine, C.S. (1995). "The adhesion molecule and cytokine profile of 
multiple sclerosis lesions." Ann Neurol 37: 419-2 1. 
Cannella, B.,& Raine, C.S. (2004). "Multiple sclerosis: cytokine receptors on 
oligodendrocytes predict innate regulation."Ann Neurol 55:46-57. 
Cartier, L.,Hartley, O.,Dubois Dophin, M.,& Krause, K.H. (2005). "Chemokine receptors 
in the central nervous system:role in brain inflammation and neurodegenerative 
diseases."Brain Res Brain Res Rev 48:16-42. 
Cascino, I.,Fiucci, G.,Rapoff, G.,& Ruberti,G. (1995). "Three tissue functional soluble 
forms of human apoptosis-inducing Fas molecules are produced from alternative 
splicing." J Immunol 154:2706-13. 
200 
Cebrian-Perez ,E.M.,Prieto, J.M.,Lema, M.,Amigo-Jorrin, M.C.,Iglesias Gomes, S.,& 
Noya Garcia, M. (2004). "Time evolution of TNF-alpha,VCAM-1,IL-4,IL-I0, neopterin 
and CD-30 in patients treated with interferon."Rev Neurol 39:213-2 17. 
Cevrovski, B.,Vitovic, T.,Petricek, I., Popovic-Suis, S., Kordvic, R.,Bojic, L.,Cevrovski, 
J.& Kovacevic, S. (2005). "Multiple sclerosis and neuro-opthalmologic manifestasions". 
Coil Anthropol 29 :1 53-8 
Chabot, S. & Yong, V.W. (2000). "Interferon beta-lb increases interleukin-iO in a model 
of T cell microglia interaction:relevance to MS." NeuroloRy 55:1497-505. 
Chandler, S., Miller, K.M., Clements, J.M., Lury, J., Corkill, D., Anthony, D.C., Adams, 
S.E.,& Gearing, A.J.H., (1997). "Matrix metalloproteinases, tumor necrosis factor and 
multiple sclerosis: an overview"J Neuroimmunology 72:155— 161. 
Chandler, S., Muller, K.M., Ciements, J.M., Lury, J., Corkill, D., Anthony, D.C., Adams, 
S.F., & Gearing, A.J. (1997). "Matrix mètalloproteinases, tUmor necrosis factor and 
implications to multiple sclerosis." J Neuroimniunol 131 :191-200. 
Chang, J.T.,Segal, B.M. & Shevach, F.M. (2000). "Role of costimulation in the induction 
of the IL-12/IL-12 receptor pathway and the development of autoimmunity." 
J Immunol 164:100-6. 
Charles, 	 P.D.,Esper, 	 G.J.,Davis, 	 T.L.,Maciunas, 	 R.J.& 	 Robertson, 	 D. 
(1999). "Classification of tremor and update of treatment". Am Fam Physic 59:1565-72. 
Charlton, B.,& Lafferty, K.J. (1995)."The Thl/Th2 balance in autoimmunity." Curr Opin 
Immunol 7:793-8. 
Chen, Q.,Carroll, FI.P.,& Cadina, M. (2006). "The newest interleukins: recent additions 
to the ever-growing cytokine family."Vitam Horm 74:207-28. 
Chesik, D.,De Keyser, J.,Glazenburg, L.,& Wilczak, N. (2006). "Insulin-like growth 
factor binding proteins:regulation in chronic active plaques in multiple sclerosis and 
functional analysis of glial cells." FurJNeurosci 24:1645-52. 
Chezzi,A. (2005)."Immunomodulatory treatment of early onset multiple sclerosis:results 
of an Italian co-operative study."Neurol Scie 26 :5183-6. 
Cho,C.,& Miller, R.J. (2002). "Chemokine receptors and neural function." J Neurobiol 
8:573-584. 
Choi, S.J.,Lee, K.H.,Park, H.S.,Kim, S.K.,Koch, S.M. & Park, J.Y. (2005). "Differential 
expression, shedding, cytokine regulation and function of TNFRI and TNFR2 in human 
fetal astrocytes."J Yonsei Med 46:818-26. 
201 
Christensen, T. (2006) "The role of EBV in MS pathogenesis." Tnt MS J 13:52-7. 
Classen-Linke, I., Muller-Newen, G.,Heinrich, P.C.,Beier, H.M. & von Rango, U. (2004). 
"The cytokine receptor gpl3O and its soluble form are under hormonal control in human 
endometrium and decidua."Mnl Hum Rei,rod 10:495-504. 
Cléments,J.M.,Cossins,J.A.,Wells,G.M.,Corkill,D.J.,Helfrich,K.,&Wood,L.M. 	 (1997). 
"Matrix metalloproteinase expression during experimental autoimmune 
encephalomyelitis and effects of combined matrix metallooproteinase and tumor necrosis 
factor-alpha inhibitor."J Neuroimmunol 74:85-94. 
Comabella, M.,Imitola, J.,Weiner, H.L.,& Khourg, S.J. (2002). "Interferon-beta treatment 
alters peripheral blood monocytes chemokine production in MS patients."J 
Neuroimmunol 126:205-12. 
Comi, C.,Leone, M.,Bonissoni, S.,De Franco, S.,Bottarel, F.,Mezzatesta, C.,Chioccetti, 
A.,Perla, F.,Monuco, F.,& Dianzani, U. (2000). "Defective T cell fas function in patients 
with multiple sclerosis." Neurol 33:921-7. 
Compston, A., Ebers, G.,& Lassmami, H. (1998) "McAlpines's multiple 
sclerosis."(Edited by: Churchill Livingstone) London. 
Compston, A. (2004). "The pathogenesis and basis for treatment of multiple 
sclerosis."Clin Neurol Neurosurg 106:246-248. 
Contasta, I.,Berghella, A.M.,Pellegrini, M., Del Beato, T., Casciani, T.A.,& Adorno, D. 
(1999). "Relationships between the activity of MMPIiTIMP1 enzymes and the TH1/TH2 
cytokine network."Cancer Biother Radionharm 14:465-75. 
Coppola, L.,Lanzillo, R., Florio, O.,Orefice, 0., Vivo, P.,Ascione, S.,Schiavone, 
V.,Pegano, A.,Vacca, F., De Michele,& F.,Morra, B. (2006). "Long-term clinical 
experience with weekly interferon beta-la in relapsing sclerosis."Eur J Immunol 
13:1014-21. 
Correale, J., & Bassani Molinas Mde, L. (2003). "Temporal variations of adhesion 
molecules and matrix metalloproteinases in 	 the course of MS."J Neuroimmunol 
140:198-209. 
Corsini, E.,Gelati, M.,Doufour, A.,Massa, G.,Nespolo, A.,Ciusani, E.,Milanese, C.,La 
Mantia, L.,& Salmaggi, A. (1997). "Effects of beta-IFN- lb treatment in MS patients on 
adhesion between PBMNCs, H1.JVECs and MS-HBECs:an in vivo and in vitro study." 
Neuroimmunol 79:76-83. 
Coughlan, C.M.,Mc Manus, C.M.,Sharron, M.,Gao, Z.,Murphy, D.,Jaffer, S.,Choe, 
W.,Hesselggesser, J., Caglord, H.,Kalyuzhny, A.,Lee, Y.M.,Wolf, B.,Doms R.W.,& 
202 
Kolson D.L. (2000). "Expression of multiple functional chemokine receptors and 
monocyte chemoattractant protein-i in human neurons." Neuroscience 97:591-600. 
Crayton, H.J.,& Rossman, H.S. (2006). "Managing the symptoms of multiple sclerosis: a 
multimodal approach."Clin Ther 28:445-60. 
Crucian, B.,Dunne, P.,Friedman, H.,Ragsdale,R.,Pross, S.,& Widen, R. (1995). 
"Alterations in peripheral blood mononuclear cell cytokine production in response to 
phytohemagglutinin in multiple sclerosis patients."Clin Diagn Lab Immunol 2:766-9. 
Crucian, B.,Dunne, P.,Friedman, H.,Rugsdale, R.,Pross, S.,& Widen, R. (1996). 
"Detection of altered T helperl and T helper 2 cytokine production by peripheral blood 
mononuclear cells in patients with multiple sclerosis utilizing intracellular cytokine 
detection by flow cytometry and surface markers analysis." Clin Diagn Lab Immunol 
3:411-16. 
Cuzncr, M.L.,Gveric, D.,Strand, C.,Loughlin, A.J.,Paemen, L.,Opdenakker, C., & 
Newcombe, J. (1996). "The expression of tissue plasminogen activator,matrix 
metalloproteinases and endogenous inhibitors in the central nervous system in multiple 
sclerosis:comparison of stages in lesion evolution."J Neuporathol Exp Neurol 55:1194-
1204. 
Czerkinsky, C., Moldoveanu, Z., Mestecky, J., Nilsson, LA.,& Ouchterlony, 0. (1988). 
"A novel two color ELISPOT assay. I. Similtaneous detection of distinct types of 
antibody-secreting cells." Journal of Immunological Methods 115:31-37. 
Dai, Y.,Masterman, T.,Huang, W.X.,Sandberg-Wollhein, M.,Laaksonen, M.,Harbo, 
Fl.F.,Oturai, A., Ryder, L.P.,Soelberg-Sorensen, P.,Svejgaard, A. & Hillert, J. (2001). 
"Analysis of an interferon-gamma gene dinucleotide-repeat polymorphism in Nordic 
multiple sclerosis patients."Mult Scler 7:157-63. 
D'Afldrca, A.,Aste-Amezaga, M.,& Klinman, D.M. (1993). "Interleukin- 10 (IL- 10) 
inhibits human lymphocyte interferon gamma-production by supressing natural killer cell 
stimulatory factor/IL-12 synthesis in accessory cells."J Exp Med 178:1041-8. 
Davey, F.,Hill, M.,Falk, J.,Sans, N. & Gunn-Moore, F.J. (2005). "Synapse associated 
protein 102 is a novel binding partner to the cytoplasmic terminus of neurone-glial 
related cell adhesion molecule."J Neurochem 94:1243-53. 
Davis, C.N.,Chen, S.,Boehme, S.A,Bakon, K.B.,& Harrison, J.K. (2003). "Chemokine 
receptor binding and signal transduction in native cells of the central nervous system." 
Methods 29:326-34. 
Dayer, J.M.,Molnarfi, N.,& Burger, D. (2005). "From cellular receptors to transduction-
transcription pathways for cytokines:at which level should the inhibition be targeted in 
inflammation?" Expert Opin Biol Ther 5: 83-96. 
203 
De Clerck, Y.A.,Yean, T.D.,Ratzkin, B.J.,Lu, H.S.,& Langley, K.E. (1989). "Purification 
and characterization of two revealed but distinct metalloproteinase inhibitors secreted by 
bovine aortic endothelial cells."J Biol Chem 264 :17445-17450 
Dc Groot CJ.,Montagne, L,,Barten, A.D.,Sminia, P.,& Van der Valk, P. (1999). 
"Expression of transforming growth factor (TGF)-betal,-beta2,and-beta3 isoforms and 
TOF-beta type I and type II receptors in multiple sclerosis lesions and human adult 
astrocyte cultures."J Neuropathol Ext Neurol 58:174-87. 
de Jong, B.A., Huizinga, T.W., Zanelli, E., Giphart, M.J., Bollen, E.L., Uidehaag, 
B.M., Polman, C.H.,& Westendorp,R.G. (2002). "Evidence for additional genetic risk 
indicators of relapse-onset MS within the HLA region." Neurology 59: 549-55. 
De Keyser, J. (1988). "Autoimmunity in multiple sclerosis." Neurology 38: 371-374. 
Delasnerie-Lupretre, N. & Alperovitch A. (1991). "Epidemiology of multiple sclerosis." 
Rev Prat 41:1884-7. 
Demicheli, V.,Rivetti, A.,Di Pietrantoni, C.,Clements, C.J.,& Jefferson, T. (2003). 
"Hepatitis B vaccination and multiple sclerosis: evidence from a systematic review." I 
Viral Hepat 10:343-4. 
De Seze, J., Calva-Dclsampre, V.,Fajardy, I.,Delalane, S.,Stoicovic, T.,Godet, E.,& 
Vermesch, P. (2005). "Autoimmune hepatitis and multiple sclerosis:a coincidential 
associatin?"Mult Scler 11:691-693. 
de Waal-Malefyt, R.,Haanen, J.,Spits, A.,Roncarolo, M.G.,te Velde, A.,Figdor, 
C.,Johnson, K.,Kastelein, R.,Yssel, H.,& de Vries, J.E. (1991). "Interleukin 10 (IL-b) 
and viral IL- 10 strongly reduce antigen specific human T cell proliferation by 
diminishing the antigen-presenting capacity of monocytes via dowi-regulation of class II 
major histocompatibility complex expression." J Ext Med 174:915-24. 
De Waal-Malefyt, R.,Abrams, J.,Benett, B.,Figdor, C.G.,& de Vries, J.E. (1991). 
"Interleukin- I 0(IL- 10) inhibits cytokine synthesis by human monocytes;an 
autoregulatory role for IL- 10 produced by monocytes."J Ext Med 174:1209-20. 
de Waal Malefyt, R., & Moore, K.W. (1998). "Interleukin-l0."(Edited by: Thomson A.) 
The cytokine handbook. London, UK: Academic Press, 333- 66. 
Dhein, J.,Walczak, H.,Baumler, C.,Debatin, K.,& Krammer, P. (1995). "Autocrine T-cell 
suicide mediated by Apo- 1 (Fas/CD95)."Nature 373:438-41. 
Dhib-Jalbut, S.,Jiang, H.,& Williams, G.J. (1996). "The effect of interferon beta-lb on 
lymphocyte-endothelial cell adhesion." J Neuroimmunol 71:215-22. 
204 
Dhib-Jalbut, S. (2002). "Mechanisms of actions of interferons and gelatimer acetate in 
multiple sclerosis." Neurol 58:53-59. 
Dijkstra, C.D., Polman, C.H.,& Berkenbosch, F. (1993). "Multiple sclerosis: some 
possible therapeutic opportunities." Trends Pharmacol Sci 14: 124-129. 
Docherty, A.J.,O'Connel, J.,Crabbe, T.,Angal, s. &Murphy, G. (1992). "The matrix 
metalloproteinases and their neutral inhibitors:prospects for treating degenerative tissue 
diseases."TIBTECJj 10:200-207. 
Dogan, R.N. & Karpus, W.J. (2004). "Chemokine and chemokine receptors in 
autoimmune encephalomyelitis as a model for central nervous system inflammatory, 
disease regulation". Front Biosci 9:1500-5. 
Dore-Duffy, P.,Newman, W.,Baladanov, R.,Lisak, R.P.,Mainolfi, E.,Rothlein, R.,& 
Peterson, M. (1995). "Circulating soluble adhesion proteins in cerebrospinal fluid and 
serum of patients with multiple sclerosis:correlation with clinical activity."Ann Neurol 
37:55-62. 
Dowling, P., Shang, G., Raval, S., Mennona, J., Cook, S.,& Husar, W. (1996). 
"Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis 
brain."J Exp Med 184:1513-18. 
Dowling, P., Husar, W.,Menomma, J.,Donnenfeld, H.,Cook, S.,& Sidhu, M. (1997)."Cell 
death and birth in multiple sclerosis brain." J Neurol Sci 149:1-11. 
Droogan, A.G., McMillan,S.A., Douglas,J.P.,& Hawkins,S.A. (1996). "Serum 
	 and 
cérebrospinal fluid levels of soluble adhesion moleàules in multiple sclerosis: 
predominant intrathecal release of vascular cell adhesion molecule-i ."J Neuroimmunol 
64:185-9 1. 
Druet, P.,Sheeta,R.,& Pelletir, L.(1995). "ml and Th2 cells in autoimmunity."Clin Exp 
Immunol 1:9-12. 
Drulovic, J., Mostarica-Stojkovic, M., Levic, Z., Stojsavljevic, N., Pravica, V., & 
Mesaros, S. (1997) "Interleukin-12 and tumor necrosis factor-alpha levels in 
cerebrospinal fluid of multiple sclerosis patients." J Neurol Sci 147: 145-150. 
Dubois, B.,Opdenakker, G.,& Carton, H. (1999). "Gelatinase B in multiple sclerosis and 
experimental autoimmune encephalomyelitis."Acta Neurol BeIg 99 :53-6. 
Duddy, M.E., Armstrong, M.A., Crockard, A.D.,& Hawkins, S.A. (1999). "Changes in 
plasma cytokines induced by interferon-l3la treatment in patients with multiple 
sclerosis."J Neuroimmunol 101 :98-109. 
205 
Durali, D.,de Goer de Herve, M.G.,Giron-Michel, J.,Azzarone, B.,Delfraissy, J.F. & 
Taoufik, Y. (2003). "In human B cells, JL-12 triggers a cascade of molecular events 
similar to ml commitment."Blood 102:4084-9. 
Durelli, L. (2004). " Is multiple sclerosis a disease that requires frequent beta interferon 
dosing?"J Neurol 251 IV/13—IV/24. 
Dutta, R.& Trapp, B.D. (2006). "Pathology, and definition of multiple sclerosis." 
Rev Prat 56:1293-8. 
Duvey, G.M.,Heath, W.R. & Starr, R. (2006). "SOCS 1 :a potent and multifaceted 
regulator of cytokines and cell-mediated inflammation". Tis Antig 67:1-9. 
Dziembowska, M.,Tham, T.N.,Lau, P.,Vitry, S.,Lazarini, E.,& Dubois Dulog, M. (2005). 
"A role for CXCR4 signalling in survival and migration of neural and oligodendrocyte 
"Glia 	 :258-269. 
•Dzenko, K.A.,Song, L.,Ge, S.,Kuziel, W.A., &Pacter, J.S. (2005). "CCR2 expression by 
brain microvascular endothelial cells is critical for macrophage transendothelial 
migration in response to CCL2."MicrovasO_Res70:53-64. 
Edan, G. (2001)."Treatment of progressive forms of multiple sclerosis."Rev Neurol 
157:1008-13. 
Edwards, L.J.,& Constantinescu, C.S. (2004). "A prospective study of conditions 
associated to multiple sclerosis in a cohort of 658 consecutive outpatients attending a 
multiple sclerosis clinic."Mult Scier 10:575-81. 
Eldstrem, F., Kallbery, S., Mizg, Y., Zheng, H.,& Unthake, B. (2004). "MHC class I, 
beta 2 microglobulin and the IFN-y receptor are upregulated in aged motorneurons." I 
Neuroscience Res 78 : 892-900. 
Elovaara, I.,Ukkonen, M.,Leppakynas, M.,Lehtinaki, T., Lasmala, M.,Peltola, J.,& 
Dastidar, P. (2000). "Adhesion molecules in multiple sclerosis:relation to subtype of 
disease and methylprednizolone therapy." Arch Neurol 57:546-551. 
Ennis, M.,Thain, J.,Boggild, M., Baker, G.A.,&Young, C.A. (2006). "A randomized 
controlled trial of health promotion education programme for people with multiple 
sclerosis."Clin Rehabil 20:783-792. 
Fainardi, E.,Castelazzi, M.,Bellini, T.,Manfrmnato, M.C.,Baldi, E.,Casetta, J.,Paolino, E., 
Granieri, E.,& Dalloccio, F. (2006). "Cerebrospinal fluid and serum levels and intrathecal 
production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity 
in patients with multiple sclerosis." Mult Scler 12: 294-301. 
206 
Fassbender, K., Ragoschke, A., Rossol, S., Schwartz, A., Mielke, 0., Paulig, A., 
Hennerici, M. (1998). "Increased release of interleukin-12p40 in MS: association with 
intracerebral inflammation." Neurology 51: 753-758. 
Feinstein, A. (2006). "Mood disorders in multiple sclerosis and the effects on 
cognition."J Neurol Sci 245:63-6. 
Feldman, M., Brennan, F.M.,& Maini, R.N. (1991). "Rheumatoid arthritis." QJi 85: 
3 07-10. 
Fellay, B.,Chofflon; M.,Juillard, C.,Pannier, A.M.,Landis, T.,Roth, S.,& Congeon, M.L. 
(2001). "Beneficial effect of copolymer I on cytokine production by CD4 T cells in 
multiple sclerosis." Immunology 104:383-9 1. 
Filllippi, M.,Wolinsky, J.S.,Sonnani, M.P.,& Comi, G. (2001). "Enhancment frequency 
decreases with increasing age in relapsing-remitting multiple sclerosis."Neurology 
56:422-423. 
Fillion, L.G.,Graziani-Bowering, G.,Matusevicious, D.,& Freedman, M.S. (2003). 
"Monocyte- derived cytokines in multiple sclerosis." din Exp Immunology 106:127-
138. 
Filipovic, R.,Jakovsevski, I.,& Zesevic, N. (2003). "GRO-alpha and CXCR2 in the 
human fetal brain and multiple sclerosis lesions"Dev Neurosci 25: 279-90. 
Fiorentino, D.F.,Bond, M.,& Mossman, T. (1989). "Two types of mouse T helper cell IV 
Th clones secrete a factor that inhibits cytokine production by Thl clones." J Exp Med 
170 :208 1-5. 
Fiorentino, D.F.,Zlotnik, A.,Vieira, P.,Mosmann,T.R.,Howard, M.,Moore,K.W.,& 
0 'Garra, A. (1991). "IL- 10 acts on the antigen presenting cell to inhibit cytokine 
production by ml cells."J Immunol 146:3444-51 
Fiorentino, D.F.,Zlotnik, A.,Mosman, T.R.,Howard, M.,& O'Garra, A. (1991). "IL-b 
inhibits cytokine production by activated macrophages."J Immunol 147:3815-22. 
Fishman, I.,Benedict, R.FL,Bakshi, R.,Priore, R.,& Weinstock-Guttman B. (2004). 
"Construct validity and frequency of euphoria sclerotica in multiple sclerosis." 
J Neuropsychiatry Clin Neurosci 16:350-6. 
Flachenecker, P. (2004). "Disease-modifying drugs for the early treatment of multiple 
sclerosis." Expert Rev Neurother 4:455-63. 
Flohe, S.,Ackerman,M.,Reuter, M.,Nast-Colb,B. & Schade, F.U. (2000)."Sublethal 
hemorrhagic shock reduces tumor necrosis factor-alpha-producing capacity in different 
cell compartments."Eur Cvtokine Netiv 11:420-6. 
207 
Fox, E.J. (2004). "Mechanism of action of mitoxantrone." Neurology. 63:S15-8 
Franciotta, D.,Zardini, E.,Bergamaschi, R.,Andreoni, L.,& Cosi, V. (2000). "Interferon-
gamma and interleukin-4-producing T cells in peripheral blood of multiple sclerosis 
patients." Fur Cytokine Netw 11:677-681. 
Freedman, M.S.,Thompson, E.J.,Deisenhammer, - F.,Giovanonni, G.,Grimsley, G.,Keir, 
G.,Ohman, S.,Racke, M.K.,Sharief, M.,Sindic, C.O.,Selleberg, F.,& Tourtelotte, 
W.W.(2005). "Recomended standard of cerebrospinal fluid analysis in the diagnosis of 
multiple sclerosis :a consensus statement," Arch. Neurol 62:865-70. 
Frei, K.,Fredrikson, S.,Fontana, A.,& Link, H. (1991). "Interleukin-6 is elevated in 
plasma in multiple sclerosis."J Neuroimmunol 31:147-153. 
Friedman, W.J. (2001). "Cytokines regulate expression of the type 1 interleukin-1 
receptor in rat hippocampal neurons and glia."Exr Neurol 168:23-31. 
Frohman, E.M.,Racke, M.K.,& Raine, C.S. (2006). "Multiple sclerosis-the plaque and it's 
pathogenesis."N EngI J Med 354:942-55. 
Froncillo, M.C.,Maffei, L.,Cantonetti, M.,Del Poeta, G.,Lentini, R.,Bruno, A.,Masi, 
M.,Tribalto, M. & Amadori, S. (1996). "FISH analysis for CML monitoring?". Ann 
Hematol 73:113-119. 
Furlan, R.,Bergami, A.,Lang, R.,Brambilla, E.,Franciotta, P.,Martinelli, V.,Comi, 
G.,Panina, P.,& Martino, G. (2000). "Interferon-beta treatment in multiple sclerosis 
patients decreases the number of circulating T cell producing interferon-gamma and 
interleukin-4."J Neuroimmunol 111:86-92. 
Galboiz, V. (2001). "Matrix metalloproteinases and their tissue inhibitors as markers of 
disease subtype and response to interferon-beta therapy in relapsing and secondary-
progressive multiple sclerosis patients." Ann Neurol 50:443-51. 
Galboiz, V.,Shapiro, S.,Lahat, N.,& Miller, A. (2002). "Modulation of monocytes matrix 
metalloproteinase-2, MTI-MMP and TIMP-2 by interferon-gamma and —beta: 
implication to multiple sclerosis."Neuroimmunology 131:191-200. 
Galetta, S.L.,Markowitz, C.,& Lee, A.G. (2002). "Immunomodulatory effects for the 
treatment of relapsing multiple sclerosis:a systematic review."Arch Int Med 162:2161-9. 
Gately, M.K.,Renzetti, L.M.,Magram, J., Stern, A.S.,Adorini, L.,Gulber, U., Presky, D.H. 
(1998). "The interleukin-12/interleukin-12-receptor system: role in normal and 
pathologic immune responses." Ann Rev Immunol 16:495-52 1. - 
PION 
Gayo, A.,Mozo, L.,Suarez, A.,Tunon, A.,Lahoz, C.,& Gutierrez, C. (1999). "Interferon-
beta-lb treatment modulates TNFalpha and IFNgamma spontaneus gene expression in 
MS."Neurology 52:1764-70. 
Gearing, A.J.,Beckett, P.,Christodulu, M.,Churchill, M.,Clements, J.M.,Grimmin, 
M,,Davidson, A.H,,Drummond, A.H.Galloway, W.A.,& Gilbert, R. (1995), "Matrix 
metalloproteinases and processing of pro-TNF-alpha." J Leucoc Biol 57:774-7. 
Gelati, M.,Corsini, E.,Dufour, A.,Massa, G.,La Mantia, L.,Milanese, C.,Nespolo, A.,& 
Salmaggi, A. (1999). "Immunological effects of in vivo interferon-betaib treatment in ten 
patients with multiple sclerosis: a 1-year follow-up." J Neurol 246:569-73. 
Gelati, M.,Corsini, E.,De Rossi, M.,Masini, L.,Bernardi, G.,Massa, G.,Boiardi, 
A.,Salmagi A.(2002): "Methyiprednizolone acts on peripheral blood mononuclear cells 
and endotheliumin inhibiting migration phenomena in patients with multiple 
sclerosis."Arch Neurol 59:774-80. 
Germenis,A. (2000). "Medical Immunology" (Edited by:Tourna K), Athens, Greek 
publications Papazisis.125-142. 
Gianelli, G.,De Marzo, E.,Scagnolari, C.,Bergamini, C.,Fransvea, E.,Bagnato, F.,Bellomi, 
F.,Millefiorini, E.,Gasperini, C.,Antonaci, C.,& Antonelli, G.(2002). "Proteolytic balance 
in patients with multiple sclerosis during interferon treatment." J Interferon Cytokine Res 
22 :689-692. 
Gijbels, K.,Masure, S.,Carton, H.,& Opdenakker, G.( 1992). "Gelatinase in cerebrospinal 
fluid of patients with multiple sclerosis and other inflammatory neurological disorders."J 
Neuroimmunol 41:29-34. 
Gijbels, K.,Proost, P.,Masure, S.,Carton, H.,Billiau, A.,& Opdenakker, G.(1993). 
"Gelatinase B is present in the cerebrospinal fluidduring experimental autoimmune 
encephalomyelitis and cleaves myelin basic protein."J Neurosci Res 36:432-440. 
Gijbels, K.,Galardy, R.E.,& Steinman, L.(1994). "Reversal of experimental autoimmune 
encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteinases."J Clin 
Invest 94:2177-2182. 
Gillespie, K.M.,Szeto, C.C.,Betin, V.M. & Mathieson, P.W.(2000). "Role of betal and 
beta2 subunits of the interleukin-12 receptor in determining T helper 1ff helper 2 
responses in vivo in the rat."Immunology 99:109-12. 
Gimenez, M.A.,Sim, G.,Archambault, C.S.,Klein, R.S.,& Russell, G.H.(2006). "A tumor 
necrosis factor receptor 1-dependent conversation between central nervous system-
specific I cells and the central nervous system is required for inflammatory infiltration of 
the spinal cord."Am J Pathol 168:1200-9. 
209 
Giubilei, F.,Antonini, G.,Di Legge, S,Sormani, M.P.,Pantano, P.,Antonini, R.,Sepe-
Monti, M.,& Pozzilli, C.(2002). "Blood cholesterol and MRI activity in first clinical 
episode suggestive of multiple sclerosis." Acta Neurol Scand 106 :109-12. 
Giusani,E.,Frigerio,S.,Gealti,M.,Corsini,EDufour,A.,Nespolo,A.,LaMantia,L.,Milanese, 
C.,Massa, G.,& Salmaggi, A.(1998). "Solublc Fas (Apo-1)lcvcls in ccrcbrospinal fluid of 
multiple sclerosis patients."J Neuroimmunol 86:151-4. 
Glabinsk, A.R.,& Ransohoff, R.M. (2001). "Targeting the chemokine system for multiple 
sclerosis treatment."Curr Opin Investig Drugs 2:1712-1719. 
Glass-Marmor, L.,Paperna, T.,Ben-Yosef, Y. & Miller, A.(2006). "Chronotherapy using 
Corticosteroids for Multiple Sclerosis Relapses."J Neurol Neurosurg Psychiatry 20. 
Oniadek, P.,Actas, O.,Wandiger, K.P., Bellman-Strobl, J.,Wengert, O.,Weber, A.,von 
Wussow, P.,Obert, H.J.,& Zipp, F. (2003). "Systemic IFN-beta treatment induces 
apoptosis of peripheral immune cells in MS patients."J Neuroimmunol 137:187-96. 
Goetzl, E.J.,Banda, M.J.,& Leppert, D.(1996). Matrix metalloproteinases in immunity. I 
Immunol 156:1-4. 
Gold, S.M.,& Irwin, M.R.(2006). "Depression and immunity: inflammation and 
depressive symptoms in multiple sclerosis."Neurol Clin Aug; 24(3):507-19. 
Gold, R.,Hartung, H.P.,&Lassmann, I-L(1997). 
	 "1-cell apoptosis in autoimmune 
specialized immunodefense mechanisms."Trends Neurosci 20:399-404. 
Gomes, A.C.,Jonsson, G.,Mjomheim, S.,Olsson, T.,Hillert, J.,& Grandienn, A. (2003). 
"Upregulation of the apoptosis regulation c FLIP, CD95, and CD95 ligand in peripheral 
blood mononuclear cells in relapsing-remitting multiple sclerosis." J Neuroimmunol 
135:126-34. 
Gomes, A.C., Morris, M., Stawiarz, L.,Jonsson, G., Putheti, P., Bronge, L.,Lin, K.H., & 
Hillert J.(2003). "Decreased levels of CD95 and caspase-8 in RNA in multiple sclerosis 
patients with gladolinium-enhancing lesions on MRI." Neurosci Left 352:101-4. 
Goodin, D.S.(2006). "IM interferon beta-la delays definite multiple sclerosis 5 years 
after a first demyelinating event."Neurology 67:1104-5. 
Gosselin, R.O., Varela, C.,Banisdar, G.,Mechighel, P.,Rostene, W.,Kitabji, P.,& Melik-
Pursaniatz, S. (2005). "Constitututive expression of CCR2 chemokine receptor and 
inhibition by MCP-l/CCL2 of GABA-induced currents in spinal cord neurones."J 
Neurochem 95: 1023-34. 
Gottberg, K., Einarsson, U.,Fredrikson, S.,von Koch, L.,& Widen Holkmqwist, L.(2006). 
"A population-based study of depressing symptoms in multiple sclerosis in Stocholm 
210 
Country. Association with functioning and sense of coherence."J Neurol Neurosurg 
Psychiatry 17. 
Greek National Drugs Organization,(2000). " National Formulary of 2000."(Edited by: 
Greek National Drugs Organization.). 438-440. 
Grigoriadis,N.,Grigoriadis,S.,Polyzoidou,E. ,Milonas,I.,&Karussis,D.(2006). 
"Neuroinflammation in multiple sclerois:evidence for autoimmune dysregulation,not 
simple autoimmune reaction." Clin Neurol Neurosurg 108:241-4. 
Guthrie, T.C.,Nelson, D.A.(1995): "Influence of temperature changes on multiple 
sclerosis: critical review of mechanisms and research potential."J Neurol Sci 129:1-8. 
Gytten, N., & Masede, P.(2006). " "When I'm together with them I feel more ill".The 
stigma of multiple sclerosis patients in social relationships." Chronic illn 2:195-208. 
Haahr, S.,& Hollsberg, P.(2006). "Multiple sclerosis is linked to Epstein-Barr virus 
infection." Rev Med Virol 16:297-3 10. 
Haase, C.G.,& Faustmann, P.M. (2004). "Benign multiple sclerosis is characterized by a 
stable neuroimmunology network." Neuroimmunomodulation 11:273-7. 
	 - 
Hadjilambreva, G., Mix, E.,Rolfs, A.,Muller, J. & Strauss U.(2005). "Neuromodulation 
by a cytokine: interferon-beta differentially augments neocortical neuronal activity and 
excitability."J Neurophysiol 93:843-52. 
Han, H.S. & Suk, K.(2005). "The function and integrity of the neurovascular unit rests 
upon the integration of the vascular and inflammatory cell systems." 
Curr Neurovasc Res 2:409-23. 
Hansen, T., Skytthe, A.,Stenager, E.,Petersen, H.C.,Bronnum-Hansen, H.& Kyvik, 
K.O.(2005). "Concordance for multiple sclerosis in Danish twins: an update of a 
nationwide study." 
Mult Scler 11:504-10. 
Hartrich, L.,Weinstock-Guttman, B .,Hall, D.,Badgett, P.,Baier, M.,Patrick, K.,Feichter, 
J.,Hong, J.,& Rananathan, M.(2003). "Dynamics of immune cell traficcing in interferon-
beta treated multiple sclerosis patients."J Neuroimmunol 139 :84-92. 
Hartung, H.P.,& Kieseier, B.C.(2000). "The role of matrix metlloproteinases in 
autoimmune damage to the central and peripheral nervous system."J Neuroimmunol 107 
:140-7. 
Hecht, O.,Dingley, A.J.,Schwanter, A.,Ozbek, S.,Rose-Jone, S. & Crotzinger, J.(2006). 
"The solution structure of the membrane-proximal cytokine receptor domain of the 
human interleukin-6 receptor."Biol Chem 387:1255-9. 
211 
Heesen, C.,Hadji, 8.,Gbramosi, J.,& Kunze, K.,(1998). "CSF inflammatory parameters 
decline in gelatimer acetate treated multiple sclerosis patients." Multiple sclerosis 4:336. 
Heesen, C., Sieverding, F., Schoser, BC., Hadji, B.,& Kunze, K.(1999). "Interleukin- 12 
J. detectable in sera of patients with multiple sclêrois association with chronic 
progressive disease course?" Eur J Neurol 6: 591-96. 
Heesen, C.,Georghin, S.,Gbadamosi, J.,& Schoser, B.G.(2000). "CD95-mediated 
apoptosis and DNA fragmentation in MS." Acta Neurol Scand 102:333-6. 
Hem, J.,Schellenberg, U.,Bein, G. & Hackstein, H. (2001). "Quantification of murine 
IFN-gamma mRNA and protein expression: impact of real-time kinetic RT-PCR using 
SYBR green I dye."Scand J Immunol 54:285-91. 
Helms, T.,Bohem, B.O.,Asaad R.J.,Trezza, R.P.,Lehman, P.V.& Targ-Lehman 
M.(2000)."Direct visualization of cytokine producing recall antigen-specific CD4 
memory I cells in healthy individuals and HIV patients". J Immunol 164:3723-32. 
Hemmer, B.,Archelos, J.J,& Hartung, H.P.(2002). "New concepts in the 
immunnopathogenesis of multiple sclerosis."Nat Rev Neurosci 3:291-301. 
Hemmer, B.,Cepok, S.,Zhou, D. & Sommer, N. (2004). "Multiple sclerosis -- a 
coordinated immune attack across the blood brain barrier." 
CurrNeurovasc Res 1:141-50. 
Hemmer, B.,Nessler, 	 S.,Zhou, D.,Kieseier, B.,& Hartung, H.P. (2006). 
"Immunopathogenesis and immunotherapy of multiple sclerosis." NatI Clin Pract Neurol 
2:201-11. 
Hermans, G.,Stinissen, P.,Hauben, L.,Van der Berg-Loonen, E.M.,Raus, J.,& Zhang, J. 
(1997). "Cytokine profile of myelin basic protein-reactive T cells in multiple sclerosis 
and healthy individuals." Ann Neurol 42:18-27. 
Heman, M.A., Olek, M.J., & Ascherio, A. (2001). "Cigarette smoking and incidence of 
multiple sclerosis." Am J Epidemiol 154:69-74. 
Heman, M.A.,A}onso, A.,& Hemandez-Diaz, S.(2006). "Tetanus vaccination and risk of 
multiple sclerosis: a systematic review." Neurology 67:212-5. 
Hewson, A.K.,Smith, T.,Leonard, J.P.,& Cuzner, M.L.(1995). "Supression of 
experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase 
inhibitor Ro31-9790."Inflamm Res 44 :345-349. 
212 
Hindiger, C., Gonzalez, J.M.,Bergmann, C.C., Fuss, B., FEnton, D.R., Atkinson, 
R.D.,Macklin, W.B.,& Stohlman, S.A.(2005). "Astrocyte expression of a dominant-
negative interferon-gamma receptor." J Neurosc Res 82:20-31. 
Hintzen, R.Q.,& Polman, C.H.( 1 997)."Th-cell modulation in multiple sclerosis."Immunol 
Today 18:507-8. 
Hirano, T.(1998). "Interleukin 6 and its receptor: ten years later." mt Rev Immunol 16: 
249-284. 
Hisaoka, T., Morikawa, N.,Kitamura, T.,& Senda, E. (2003). "Expression of a member of 
tumor necrosis factor receptor superfamily, TROY, in the developing mouse brain." 
Brain ResDev Brain Res 143:105-9. 
Ho, AS., Liu, Y., Khan, T.A., Hsu, D.H.,Bazan, J.F.,& Moore, K.W. (1993). "A receptor 
for interleukjn 10 is related to interferon receptors." Proc NatI Acad Sci USA 90: 11267-
11271. 
Hofinan, F.M., Hinton, DR., Johnson, K., & Merrill, J.E. (1989). "Tumor necrosis factor 
identified in multiple sclerosis brain." J Exp Med 170 : 607-6 12. 
Hoganchamp, WE., Rodriguez, M., & Weinshenker, B.G. (1997). "The epidemiology of 
multiple sclerosis." Mayo Clin Proc 72: 87 1-878. 
Hohnoki, K.,Inoue, A.,& Koh, C.S. (1998). "Elevated serum levels of IFN-y, IL-4 and 
TNF-alunelevated serum levels of IL-lO in patients with demyelinating diseases during 
the acute stage." J Neuroimmunol 87:27-32. 
Holliffield, R.D.,Harbige, L.S.,Dham-Din, D.,& Sharief, M.K. (2003). "Evidence for 
cytokine dysregulation in multiple sclerosis:peripheral blood mononuclear cell 
production of pro-inflammatory and anti-inflammatory cytokines during relapse and 
remission." Autoimmunity 36:133-41. 
Holmes, S.,Siebold, C.,Jones E.Y.,Friese, M.A.,Fugger, L. & Bell, J.(2605). "Multiple 
sclerosis: MHC associations and Iherapeutic implications."Exyert Rev Mol Med 7:1-17. 
Hong (2004). "CD95 polymorhisms are associated with suspectibility to to MS in 
women. A population based study of CD95 and CD95L in MS." Eur J Immunol 34:870-
871. 
Hope, R.A., Longmore, J.M., Moss, P.A.H., & Warrens A.N.(1993). "Oxford Manual of 
Clinical Medicine" 2 nd edition. (Edited by: Oxthrd University Press). New York. 
Howard, M.,& O'Garra, A.(1992). "Biological properties of interleukin 10."Immunol 
Today 13:198-200. 
213 
Hua, L.L.,Kim, M.D.,Brosnan, C.F.,& Lee, S.C.(2002). "Modulation of astrocyte 
inducible nitric oxide synthetase and cytokine expression by interferon beta is associated 
with induction and inhibition of interferon-gamma activated sequence binding activity."L 
Neurochem 83:1120-8. 
Huang, W.X., Huang, P.,Link, H.,& Hillert, J. (1999). "Cytokine analysis in multiple 
sclerosis by competitive RT-PCR: A decreased expression of IL-10 and an increased 
expression of TNF-alpha in chronicprogression." Mult Scler 5 :342-8. 
Hughes,R.A.(1994)."Immunotherapy for multiple sclerosis." J Neurol Neurosurg 
Psychiatr 57:3-6. 
Huishof, S., Montagne, L., De Groot, C.J.,& van der Valk, P.(2002). "Cellular 
localization and expression patterns of interleukin-lO, interleukin-4, and their receptors in 
multiple sclerosis lesions."Qi.La 38:24-35. 
Hunter, M.I.S., Nlemadim, B.C.,& Davidson, D.L.W. (1985). "Lipid peroxidation 
products and antioxidant proteins in plasma and cerebrospinal fluid from multiple 
sclerosis patients."J Neurochem Res 10 :1645-1652. 
Huynh, H.K.,Oger, J.,& Dorovini-Zis, K.(1995). "Interferon-n downregulates interferon-
y-induced class II MHC molecule expression and morphological changes in primary 
cultures of human brain microvascular endothelial cells."J Neuroimmunol 60:63-73. 
Ichikawa, H.,Ota, K.,& Iwata, M.,(1996). Increased Fas antigen on T cells in multiple 
sclerosisj Neuroimmunol 71:125-9. 
Ichiyama, T.,Kajimoto, M.,Suenaga, N.,Maebu, S.,Matsubara, I.,& Furukawa, S.(2006). 
"Serum levels of matrix metalloproteinase-9 and its tissue inhibitor(TIMP-l) in acute 
disseminated encephalomyelitis."J Neuroimmunol. 172:182-6. 
Inoges, S.,Merino, J.,Bandres, E.,De Castro, E.,Subira, M.L.,& Sanchez-Ibarrola, 
A.(1999). "Cytokine flow cytometry differentiates the clinical subtypes of MS patients." 
Clin Exp Immunol 115:521-5. 
Inoue, A.,Koh, C.S.,Sakai, T.,Yamazaki, M.,Yangisawa, N.,Osuku, K.,& Osame, 
M.(1997). "Detection of soluble form of the Fas molecule in patients with multiple 
sclerosis and human T-lymphotropic virus type-I associated myelopathy." J 
Neuroimmunol 75 :141-6. 
loppoli, C., Meucci, G., Mariotti, S.,Martino, E.,Lippi, A.,Gironelli, L.,Pinchera, A.,& 
Muratorio, A.(1990). "Circulating thyroid and gastric parietal cell autoantibodies in 
patients with multiple sclerosis." Ital J Neurol Sci 11: 3 1-36. 
214 
Isomaki, P., Luukkainen, R., Saario, R., Toivanen, P.,& Punnonen, J.(1996). 
"Interleukin-lO functions as an antiinflammatory cytokine in rheumatoid synovium." 
Arthritis Rheum 39: 386- 95. 
Iwasaki, Y.,& Kinoshita, M.(1988) "Thyroid function in patients with multiple sclerosis." 
/%cut INeurol Scand ii: zo. 
Jansson, A., Ernerudh, J., Kvarnstrom, M., Ekerfelt, C.,& Vrethem, M. (2003). "Elispot 
assay detection of cytokine secretion in multiple sclerosis patients treated with interferon-
betala or glatiramer acetate compared with untreated patients." Mult Scler 9: 440-5. 
Jensen, J.,Krakauer, M.,& Sellebjerg, F. (2005). "Cytokines and adhesion molecules in 
multiple sclerosis patients treated with interferon-n lb." Cytokine 29: 24-30. 
Jia, G.O.,Gonzalo, J.A.,Hindalgo, A.,Wagner, D.,Cybulsky, M.,& Gutierrez-Ramos, 
J.C.(1999). "Selective eosinophil transendothelial migration triggered by eotaxin via 
modulation of Mac- 1/ICAM- 1 and VLA-4/VCAM- I interactions."Int Immunol 11:1-10. 
Jiang, H., Williams, G.J.,& Labat, S.(1997). "The effect of interferon beta-lb on cytokine 
induced adhesion molecule expression." Neurochem Tnt 30:449-453. 
Kailman, B.A.,Hummel, V.,Lindenlaub, T.,& Toyka, K.Y. (2000). "Cytokine-induced 
modulation of cellular adhesion to human cerebelar endothelial cells is mediated by 
soluble vascular cell adhesion molecule-I "Brain 123:687-697. 
Kanesaka, T., Mori, M., Hattori, T., Oh, T.,& Kuwabara, S. (2006). "Serum matrix 
metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple 
sclerosis."J Neurol Neurosurg Psych 77:185-8. 
Kang, B.Y.,& Kim, T.S.(2006). "Targeting cytokines of the interleukin-12 family in 
autoimmunity."Curr Med Chem 13:1149-56. 
Kappos, L.,Trabulsee, A.,Constantinescu, C., Fraling, G.P.,Forrestal, F.,Jongen, 
P.,Pollard, J., Sandberg-Wollheim,M., Sindic, C.,Stubinski, B.,Uitdehaag, B.,& Li, 
D.(2006). "Long-term clinical experience with weekly interferon beta-la in relapsing 
sclerosis."Eur J Neurol 13:1014-21. 
Karabudak, R.,Kame, A.,Guc, D.,Sengelen, M.,Canpinar, H.,& Kansu, E. (2004). 
"Effect of interferon beta-la on serum matrix metalloproteinase-9 (MMP-9) and tissue 
inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis 
patients. One year follow-up results."J Neurol 251 :279-283. 
Karandikar, N.J.,Crawford, M.P.,Yun, X.,Rutts, R.B.,Brenchley, J.M.,Ambrozak, 
D.R.,Lovvet-Racke,A.E.,Frohman,E.M.,Stastung, P.,Donek,D.C.,Koup,R.A.,&Racke, 
M.K.(2002). "Glatimer acetate (Copaxone) therapy induces CD8(+) T cell responses in 
patients with multiple sclrosis."J Clin Invest 109:641-9. 
215 
Karandikar, N.J.,& Racke, M.K.(2005)."Glatimer acetate therapy:the plot thickens."A rch  
Neurol 62:858-9. 
Kami, A., Koladzic, D.N., Bharanidliaran, P., Khoury, S.J.,& Weiner, H.L. (2002). "IL-
18 is linked to raised 1FN-gamma in multiple sclerosis aid is induced by activated 
CD4(+) cells via CD40-CD40 ligand interactions." J Neuroimmunol 125: 134-140. 
Karni, A.,Abraham, M.,Monsonego, A.,Cai, G.,Freeman, G.J.,Hafler, D.,Klioury, S.J.,& 
Weiner, H.L.(2006). "Innate immunity in multiple sclerosis: myeloid dendritic cells in 
secondary progressive multiple sclerosis are activated and drive a proinflammatory 
immuneresponse."J Immunol 177:4196-202. 
Karulin, A.Y., Hesse, M.D., Tary-Lehmann, M.,& Lehmaiin, P.V.(2000). "Single 
cytokine- producing CD4 memory cells predominate in type 1 and type 2 immunity." I 
Immunol 164: 1862-72. 
Kassiotis, G.,& Kollias, 0(2001). "Uncoupling the proinflammatory from the 
immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor 
level: implications for pathogenesis and therapy of autoimmune demyelination." J Exp 
Med 193:427-34. 
Keegan, B.M., & Noseworthy, J.H. (2002). "Multiple sclerosis." Ann Rev Med 53:285-
302. 
Kennedy, M.,Torrance, D.S.,Picha, K.S.,& Mohler, K.M.(1992). "Analysis of cytokine m 
RNA expression in the central nervous system of mice with experimental autoimmune 
encephalomyelitis reveals that IL-10 m RNA expression correlates with recovery."J 
Immunol 149:2496-505. 
Kermode, A.G.,Thompson, A.J.,Tofts, P.,McManus, D.0.,Kendall, B.E.,Kingsley, 
D.P.,Moseley, I.F.,Rudge, P.,& McDonald, W.I.(1990). "Breakdown of the blood-brain 
bather preceedes symptoms and other MRI signs of new lesions in multiple 
sclerosis.Pathogenetic and clinical implications."Brain_113:1477-1489. 
Khademi, M.,Waldestrom, E.,Andersson, M.,Piehl, F.,Di Marco, R.,& Olsson, T.(2000). 
"Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon 
beta-I a treatment of multiple sclerosis."Neuroimmunol 103:202-10. 
Khalili, K.,& White, M.K.(2006)."Human demyelinating disease and the polyomavirus 
JCV." Mult Scler 12:133-42. 
Khan, M.Z.,Brandimarti, R.,Musser, B.J.,Ressue, D.M.,Fatatis, A.,&Meucci, 0.(2003). 
"The chemokine receptor CXCR4 regulates cell-cycle proteins in neurons." J Neurovirol 
9:300-314. 
216 
Khan, O.A.,Xia, Q.,Bever, C.T. Jr,Johnson, K.P.,Panitch, H.S., & Dhib-Jalbut, S.S. 
(1996). "Interferon betaib serum levels in multiple sclerosis patients following 
subcutaneous administration."Neurology 46:1639-1643. 
Khan, O.A.,Tselis, A.C.,Kamholtz, J.A.,Garbern, J.Y.,Lewis, R.A.,& Lisak, R.P.(2001). 
"A p4ospeetive  open-lebel treatment trial to compare the effect of IFN beta-IA 
(Avonex),IFN beta-lb (Betaferon), and gelatimer acetate (copaxone) on the relapse rate 
in relapsing-remitting multiple sclerosis."Eur J Neurol 8:141-8. 
Khrestchatisky, M.,Jourganin, J.,Ogier, C.,Charton, G.,Bemard, A., Trembley, E.,& 
Rivera, 5(2003). "Matrix metalloproteinases and their inhibitors, modulate of neuro-
immune interactions and of pathophysiological processes in the nervous system."J Soc 
Biol 197:133-44. 
Kieseier, B.C.,Kiefer, R.,Clements, J.M.,Miller, K.,Wells, G.M.,Schweitzer, T.,Gearing, 
A.J.,& Hartung, H.P.(1998). "Matrix metalloproteinase-9 and —7 are regulated in 
experimental autoimmune encephalomyelitis."Brain_121:159-166. 
Kieseier, B.C.,Seifer, T.,Giovvanoni, G.,& Hartung, 	 H.P. 	 (1999)."Matrix 
metalloproteinases in inflanmmatory demyelination:targets for treatment." Neurology 53, 
20-25. 
Kiessling, W.R., Pflughaupt, K.W, Haubitz, I.,& Mertens, H.G.(1980). "Thyrciid function 
in multiple sclerosis." Acta Neurol Scand 62: 255-258. 
Kiessling, W.R., & Pflughaupt, K.W.(1980). " Antithyroid antibodies in multiple 
sclerosis." Lancet 1: 41. 
Kilinc, M., Saatci-Cekirge, I.,& Karabudak, R.(2003). "Serial analysis of soluble 
intercellular adhesion molecule-i level in relapsing-remitting multiple sclerosis patients 
during IFN-betaib treatment." J Interferon Cytokine Res 23:127-33. 
Kim, J.M.,Brannan, S.I.,Copeland, N.G.,Jekins, N.A.,Khan, T.A.,& Moore, K.W.(1992). 
"Structure of the mouse IL- 10 gene and chromosomal localization of the mouse and 
human genes."J Immunol 148:3618-23. 
Kin N.W. & Sanders, W.M.(2006). "It takes nerve to tell T and B cells what to do." 
J Leukoc Biol 79:1093-104. 
Kiapps, P., Seyfert, S., Fischer, T.,& Scherbaum, W.A.(1992). "Endocrine function in 
multiple sclerosis." Acta Neurol Scand 85: 353-357. 
Kohji, T.,& Matsumoto, Y. (2000). "Coexpression of Fas/FasL and Bax on brain and 
infiltrating T cells in the central nervous system is closely associated with apoptotic cell 
death during autoimmune encephalomyelitis."J Neuroimmunol 106:165-71. 
217 
Kotilainen, P.,Airas, L.,Kojo, T., Kurki, T.,Kataja, K.,Minn, H.,& Nuutila, P.(2005). 
"Riedel thyroiditis in a patient with multiple sclerosis." Neuro Endocrinol Left 26:67-68. 
Kowenhoven, M., Ozenki, V.,Gomes, A.,Yarilin, D.,Giedraitis, V., Press, R.,& Link, H. 
(2001). " Multiple sclerosis: elevated expression of matrix metalloproteinases in blood 
monocytes." J Neuroimmunul 16:463-70. 
Kouwenhoven, M.,Ozenki, V.,Tjemlund, A.,Pashenkov, M.,Homrnan, M.,Press, R.,& 
Link, H. (2002). "Monocyte derived dendritic cells express and secrete matrix-degrating 
metalloproteinases and their inhibitors and are imbalanced in multiple sclerosis."J 
Neuroimmunol 126 :161-171. 
Kraus, J.,Bauer, R.,Chatzimanolis, N.,Engelhardt, B.,Tofighi, E.,Bregenzer, T.,Kuehne, 
B.S.,Stolz, E.,Blaes, F.,Morgan, K.,Traupe, H.,Kaps, M. & Oschmann, P.(2004). 
"Interferon-beta lb leads to a short-term increase of soluble but long-term stabilisation of 
cell surface bound adhesion molecules in multiple sclerosis." 
J Neurol 251:464-72. 
Kreher, C.R.,Dittrich, M.T.,Guerkov, R.,Boehm, B .O.,Herrera, M .T.& Targ-Lehman, M. 
(2003)."Detection of low-frequency antigen-specific IL-lO producing CD4 (+) I cells via 
ELISPOT in PBMC: cognate vs non specific production of the cytokinc.J Neurol 
Methods 278: 79-93. 
Krumbholtz,M.,Theil,D.,Cepok,S.,Hemmer,B.,Kivisakk,P.,Ransohoff,R.M.,Hofbauer, 
M.,Farina, C.,Derfuss, T., Hartle, C.,Newcombe, J.,Hohfeld, R.,& Meinl, E.(2006). 
"Chemokines in multiple sclerosis:CXCL12 and CXCL13 up-regulation is differentialy 
linked to CNS immune cell recruitment."Brain 129:200-11. 
Kuchroo, V.K.,Anderson, A.C.,Waldner, H.,Munder, M.,Bettelli, E.& Nicholson, 
L.B.(2002). "T cell response in experimental autoimmune encephalomyelitis (EAE): role 
of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic I 
cell repertoire." Annu Rev Tmmuno120: 101-23. 
Kudinov, Y., Wiseman, C.L.,& Kharazi, A.I.(2003). "Phorbol myristate acetate and 
Bryostatin I rescue IFN-gamma inducibility of MHC class II molecules in LS1034 
colorectal carcinoma cell line."Cancer Cell Tnt 3:4. 
Kumar, P.,& Clark, M.(2002) "Clinical Medicine." (Edited by: Kumar P and Clark M). 
UK, W.B.Saunders. 1189-1191. 
Kurowska, M.,Rudinska, W.,Maslinska, D.,& Maslinski, W. (2002). "Expression of IL-
15 and IL-IS receptor isofonns in select structures of human and fetal brain."Ann NY 
Acad Sci 966 :441-5. 
Kuitke, J.F.(1975). "A reassessment of the distribution of multiple sclerosis." 
Acta Neurol Scand 51:137-57 
218 
Kurzepa, J.,Bartosik-Psujek, H.,Suchozebreska-Jesionek, D.,Rejdak, K.,Styjeku-Zimmer, 
M.,& Stelmasiak, Z.(2005). Role of matrix metalloproteinases in the pathogenesis of 
multiple sclerosis. Neurol Neurochim Pol 39:63-67. 
T,.,... TI 
	 V..L,.,t. A 
	 P_ 	 I (lflflfl\ LSLL'L11L1, Ii., Itaus,.a¼,ss, fl.U' I 
	 WtUIL1UL j• 1274.). 1VI¼,U1I.#LIL.#ILL UI •uw - lILulc.A,uIaI 
weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from 
patients with multiple sclerosis." Eur Neurol 32 :248-252. 
Laplaud, D.A.,& Confavreux, C.(2006). "Etiology of multiple sclerosis."Rev Prat 
56:1306-12. 
Lassmann, H. (1998). "Neuropathology in multiple sclerosis: new concepts." Mult Scler 
4:93-100. 
Lassmann, H. (2004). "Recent neuropathological findings in MS-indications for 
diagnosis and therapy."J Neurol 251 :2-5. 
Learn, C.A.,Boger, M.S.,Li,L. & McCall, C.E. (2001). "The phosphatidylinositol 3-
kinase pathway selectively controls sIL-1RA not interleukin-ibeta production in the 
septic leukocytes."J Biol Chem 276:20234-9. 
Ledeboer, A., Breve, J.J.P., Poole, S., Tilders, F.J.H. ,& Van Dam, A.M.(2000). 
"Interleukin-lO, interleukin-4 and transforming growth factor-n differentially regulate 
lipopolysaccharide-induced production of pro-inflammatory cytokines and nitric oxide in 
co-cultures of rat astroglial and microglial cells." Glia 30 :134-142. 
Ledeboer, A., Wierinoch, A.,Boz, J.G., Floris, S.,Renardel de Layette, C.,de Vries, A.E., 
van der Berg, T.K., Dijkstra, C.D., Tilders, F.J.,& van Dam A.M.(2003). "Regional and 
temporal expression patterns of interleukin-lO, interleukin-lO receptor and adhesion 
molecules in the rat spinal cord during chronic relapsing EAE." J Neuroimmunol 136: 
94-103. 
Lee, M.A., Palace, J., Stabler, F., Ford, J., Gearing, A.,& Miller K.(1999). "Serum 
gelatinase B, TIMP- 1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and 
MRI study." Brain 122 : 191-7. 
Lee, Y.B.,Nagai, A.,& Kim, S.U. (2002). "Cytokines, chemokines and cytokine receptors 
in human microglia."J Neurosc Res 69(1):94-103. 
Leonard, J.P.,Waldburger, K.E.,& Goldman, S.J.( 1995). "Prevention of experimental 
autoimmune encephalomyelitis by antibodies against interleukin-12."J Exp Med 
181:381-385. 
219 
Leoni, V.,Masterman, T.,Diczfalusy, U.,De Luca, G.,Hillert, J.,& Bjorkhem, I.(2002). 
"Changes in the human plasma levels of the brain specific oxysterol 24S 
hydoxycholesterol during progression of multiple sclerosis."Neurosci Let 331:163-166. 
Leppert, D.,Waubant, E.,Galardy, R.,Bunnett, N.W.,& Hauser, S.L.(1995). "T cell 
geiatinases mediate basement membrane wansthigration in vitro." J immiinoi 154: 4379- 
4389 -
Leppert, D.,Waubant, A.,Burk, M.R.,Oksenberg, G.R.,& Hauser, S.L. (1996). "Interferon 
beta-lb inhibits gelatinase secretion and in vitro migration of human T cells: a possible 
mechanism for treatment efficiacy in multiple sclerosis."Ann Neurol 40:846-52. 
Leppert, D.,Ford, J.,Stabler, G.,Grygar, C.,Lienert, C.,Huber, S.,Miller, K.,Hauser, 
S.L.,& Kappos, L.(1998). "Matrix metalloproteinase-9 (gelatinase B) is selectively 
elevated in CSF during relapses and stable phases of multiple sclerosis."Brain_121 :2327-
23 34. 
Leppert, 	 D., Lindberg, 	 R.L., Kappos, 	 L., & Leib 	 S.L. (2001). "Matrix 
metalloproteinase's: multifunctional effectors of inflammation in multiple sclerosis and 
bacterial meningitis." Brain Res Rev 36 :249-257. 
Leussink, V.1., Jung, S.,Merschadorf, U.,Toykak, V.,& Gold, R.(2001). "High-
dosemethylprednizolone therapy in multiple sclerosis induces apoptosis in peripheral 
blood leucocytes."Acrh Neurol 58:91-97. 
Leyhe, T.,Laske, C.,Buchkremer G.,Wormstall, H.& Wiendl, H. (2005). "Dementia as a 
primary symptom in late onset multiple sclerosis. Case series and review of the literature" 
Nervenarzt 76:748-55. 
Li, J., Gran, B., Zhang, F.X, Ventura, E.S., Siglienti, I., Rostami, A.,& Kamoun, M. 
(2003). "Differential expression and regulation of IL-23 and IL-12 subnuits and receptors 
in adult mouse microglia." J Neurol Scie 15:95-103. 
Li, J. ,Yang, L.,Lindholm, K.,Konishi, Y.,Yue, X.,Humpel, H.,Zhang, G.,& Shen, 
Y.(2004). "Tumor necrosis factor death receptor signaling cascade is required for 
amyloid-beta protein-induced neuron death." J Neurosc 18 : 1760-7 1. 
Lichtinqhagen, R.,Seifert, T.,Krucke, A.,Marhmann, S.,Wurster, U.,& Heindenreich, F. 
(1999). "Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear 
blood cells of patients with multiple sclerosis." J Neuroimmunol 99:19-26. 
Liedtke, W.,Cannella, B.,Mazzaccaro, R.J.,Clements, J.M.,Miller, K.M.,Wucherpfenning, 
K.W.,Gearing, A.J.H.,& Raine, C.S.(1998). "Effective treatment of models of multiple 
sclerosis by matrix metalloproteinase inhibitors."Ann Neurol 44:35-46. 
220 
Limaota, C.,Di Bartolomeo, S.,Tretter, G.,Lauro, C.,Giotti, M.T.,Mercandi, 
D.,Castellani,& L.,Ensebi, F. (2003). "Expression of AMPA-type glutamate receptors in 
HEK cells and cerebellar grannule neurons impairs CXCL2-mediated chemotaxis." J 
Neuroimmunol 134:61-71. 
Limburg, LU4I950)Slne geograpmcal clistnbution of multiple scierosis and its 
estimated prevalence in the United States". Res PubI Assoc Res Neur Ment Dis 28 :15-
24. 
Lindberg, R.L., De Groot, C.J., Montagne, L., Freitag, P.,van der Valk, P., Kappos, 
L.,& Leppert, D.(2001). "The expression profile of matrix metalloproteinase's 
(MMP's and their inhibitors (TIMP's) in lesions and normal appearing white 
matter of multiple sclerosis." Brain 124: 1743-1753. 
Lindia, J.A.,McGowan, E.,Jochnowitz, N.& Abbadie, C.(2005). "Induction of CX3CLI 
expression in astrocytes and CX3CRI in microglia in the spinal cord of a rat model of 
neuropathetic pain."J Pain 6 :434-8. - 
Link, H.(1998). "The cytokine storm in multiple sclerosis."Mult Scler 4: 12-15. 
Link, J.,Soderstrom, M.,Ljungdahl, A.,Hojeberg, B.,Olsson, T.,Fredrikson, S.,Wang, 
Z.Y.,& Link, H.(1994). "Organ-specific autoantigens induce interferon-y and interleukin-
4 in RNA expression in mononuclear cells in multiple sclerosis and myasthenia 
gravis."Neurology 44: 728-734. 
Link, J., Soderstrom, M., Kostulas, V., Olsson, T., Hojeberg, B., Ljungdahl, A.,& Link, 
H. (1994). "Optic neuritis is associated with myelin basic protein and proteolysis protein 
reactive cells producing interferon-y, interleukin-4, and transforming growth factor-D." I 
Neuroimmunol 49:9-18. 
Link, J.(1994). "Interferon-gamma, interleukin-4 and transfonning growth factor —beta m 
RNA expression in multiple sclerosis and myasthenia gravis." Acta Neurol Scand 158:1 - 
58. 
Link, J.,Soderstrom, M.,Olsson, T.,Hojeberg, B.,Ljungdahl, A.,& Link, H.( 1994). 
"Increased transforming growth factor-(3, interleukin-4 and interferon-gamma in multiple 
sclerosis."Ann Neurol 36 :379-386. 
Liu, L.,Callahan, M.K.,Huang, D.,& Ransohoff, R.M.(2005). "Chemokine receptor 
CXCR3: an unexpected enigma."Curr Top Dev Biol 68:149-181. 
Liu, Y., Wei, S.H., Ho, A.S.,de Waa! Malefyt, R.,& Moore, K.W.(1994). "Expression of 
cloning and characterization of a human IL- 10 receptor." J Immunol 152: 1821-1929. 
221 
Liu, Z., Pelfrey, C.M., Cotleur, A., Lee, J.C.,& 	 Rudick, RA. (2001). 
"Immunomodulatory effects of interferon beta-la in multiple sclerosis." J Neuroimmuol 
112(1-2): 153-162. 
Liuzzi, G.M.,Trojano, M.,Fanelli, M.,Avolio, C.,Fasano, A.,Livrea, P.,& Riccio, P. 
(2002). "inirathecal synthesis of matrix metafloproteinase-9 in patients with multiple 
sclerosis: implication for pathogenesis." Mult Scler 8 :222-8. - 
Losy, J.,& Michalowska-Wender, G.(2002). "In vivo effect of interferon-betala on 
interleukin-12 and TGF-beta 1 cytokines in patients with relapsing-remitting multiple 
sclerosis. "ActaNeurol Scand 106:44-46. 
Lou, J.,Gasche, Y.,Zheng, L.,Giroud, C.,Morel, P.,Clements, J.,Ythier, A.,& Grau, 
G.E.(1999). "Interferon-beta inhibits activated leucocyte migration through human brain 
microvascular endothelial cell monolayer."Lab Invest 79:1015-22. 
Louis, E.(2001). "The immuno-inflammatory reaction in Crohn's disease and ulcerative 
colitis: characterisation, genetics and clinical application. Focus on TNF alpha."A cta 
 
Gastroenterol BeIg 2001 64:1-5. 
Lovvet-Racke, A.E.,& Rucke, M.K.(2006). "Epstein-Barr virus and multiple 
scerosis."Arch Neurol 63:810-11. 
Lu, H.T.,Riley, J.L.,Badcock, G.T.,Huston, M.,Stark, G.R.,Boss, J.M.,& Ransohoff, 
R.M.(1995). "Interferon (IFN) 13 acts downstream of IFN-y-induced class II transactivator 
messanger RNA accumulation to block major histocompatibility complex class II gene 
expression and requires the 48-kd DNA-binding protein,ISGF3-y."J Exp Med 182:1517-
1525. 
Lublin, F.D.,& Reingold, S.C. (1996). "Defining the clinical course of multiple sclerosis: 
results of an international survey." Neurology 46:907-915. 
Lucchinetti, C.,Bruck, W.,Parisi, J.,Scheithauer, B.,Rodriguez, M.,& Lassmann, 
H.(2000). "Heterogeneity of multiple sclerosis lesions:implications for the pathogenesis 
of demyelination."Ann Neurol 47,707-717. 
Lukes, A.,Mun-Bryce, S.,Lukes,M.& M.,Rosenberg, G.A. (1999). "Extracellular matrix 
degradation by metalloproteinases and central nervous system diseases." Mol Neurobiol 
19:267-84. 
Luscinskas, F.W.,Kansas, G.S.,Ding, H.,Pizcueta, P.,Schleiffenbaum B.E.,Tedder,T.F.& 
Gimbrone, M.A. Jr(1994). "Monocyte rolling, arrest and spreading on IL-4-activated 
vascular endothelium under flow is mediated yia sequential action of L-selectin, beta 1-
integrins, and beta 2-integrins."J Cell Biol 125:1417-27. 
222 
Ma, M.,Wei, T.,Boringo, L.,Charo, I.F.,Ransohoff, R.M.,& Jakeman, L.B.,(2002). 
"Monocyte recriment and myelin removal are delayed following spinal cord injury in 
mice with CCR chemokine receptor deletion." J Neurosc Res 68:691-702. 
Ma, Z.,Qin, H.,& Benveniste, E.N.(2001). "Transcriptional supression of matrix 
meiafloproteinase-9 gene expression by JFN-gamma and iFN-beta:criticai role of STAT-
1 alpha."J Immunol 167:5150-9. - 
Macchi, B .,Mateucci, C.,Nocentini, U.,Caltagirone, C.,& Mastino, A.( 1999). "Impaired 
apoptosis in mitogen-stimulated lymphocytes of patients with multiple 
sclerosis."Neuroreport 10:399-402. 
Maeda, A.,& Sobel, R.A.(1996). "Matrix metiloproteinases in the normal human central 
nervous system,microglial nodules, and multiple sclerosis lesions."J Neuropathol Exn 
Neurol 55(3)300-9. 
Mahad, D.,& Ransohoff, R.M. (2003). "The role of MCP-1 (CCL2) and CCR2 in 
multiple sclerosis and experimental autoimmune encephalomyelitis (EAE)."Semin 
Immunol 15:23-32. 
Mahovic, P.,Petrovic, D.,Petelin, Z.,Zurak, N.,Horvart,& F.,Hajnsek, S. (2004). "Level of 
s Fas/APO I in serum and cerebrospinal fluid in multiple sclerosis." Clinical Neurol and 
Neurosurg 106: 230-232. 
Mair, E.M.,Adcock, K.H.,Morgenstern, D.A.,Clayton, R.,von Stillfried, N.,Rhoder, 
K.,Ellis, C.,Fawcett, J.W.,& Rogers, J.H.(2002). "Matrix metalloproteinases and their 
inhibitors are produced by overlapping populations of activated astrocytes".Brain Res 
Mol Brain Res 100:103-7. 
Marckmann, S., Wiessermann, E.,Hilse, R.,Trebst, C.,Stangel, M.,& Windhagen, 
A.(2004). "Interferon-beta upregulates the expression of co-stmulatory molecules 
CD80,CD86 and CD40 on monocytes:significance for treatment of multiple 
sclerosis."Clin Exp Immunol 138:499-506. 
Martin, R.,McFarland, 1-LF.,& McFarlin, D.E.( 1 992)."Immunological aspects of 
demyelinating diseases."Annu Rev Immunol 10:153-187. 
Martino, 0., Grohovaz, F., Brambilla, E., Codazzi, F.,Consiqlio, A.,Clementi, E.,Filippi, 
M.,Comi, 0., & Grimaldi, L.M.(1998)."Proinflammatory cytokines regulate antigen-
independent T-cell activation by two separate calcium-signaling pathways in multiple 
sclerosis patients." Ann Neurol 43: 340- 49. 
Masiukiewisz, U.S.,Mitnick, M.,Gulanski, B.I. & Insogna, K.L.(2002). "Evidence that 
the IL-6/IL-6 soluble receptor cytokine system plays a role in the increased sceletal 
sensitivity to PTH in estrogen-deficient women".J Clin Endocrinol Metabol 87:2892-8. 
223 
Masse, T., & Gray, C.M. (2002). "The ELISPOT assay: an easily transferable method 
for measuring cellular responses and identifying T cell epitopes." Clin Chem Lab Med 
40(9): 903-910. 
Matusevicious, D., Navikas, V., Soderstrom, M., Xiao, B.G., Hauglund, M., Fredrikson, 
S.,& Link, H.. (1996). "Multiple sclerosis: the pruinfiamiratory cytokines iymphotoxin-a 
and tumor necrosis factor-a are upregulated in cerebrospinal fluid mononuclear cells." J 
Neuroimmunol 66:115-123. 
Matusevióius, D., Kivisakk, P., Navikas, V., Soderstrom, M., Fredrikson, S.,& Link, H. 
(1998). "Interleukin-12 and perforin mRNA expression is augmented in blood 
mononuclear cells in multiple sclerosis." Scand J Immunol 47: 582- 90. 
Matusevicius, D.,Kivisakk, P.,Navikas, V.,Tian, W.Z.,Soderstrom, M.,Fredrikson, S.,& 
Link, H.( 1998). "Influence of IFN-P lb (Betaferon) on cytokine m RNA profiles in blood 
mononuclear cells and plasma levels of soluble VCAM-1 in multiple sclerosis." Eur J 
Neurol 5:265-75. 
McDermott, (2001). "TNF and TNFR biology in health and disease." 
Cell Mol Biol 47:619-35. 
McDonald, W.I.& Ron, M.A.(1999). "Multiple sclerosis: the disease and its 
manifestations."Philos Trans R Soc Lond B Biol Sci 354:1615-22. 
McDonell, G.V.,McMillan, S.A.,Douglas, J.P.,Droogan, A.G.,& Hawkins, S.A. (1998). 
"Raised CSF levels of soluble adhesion molecules across the clinical spectrum of 
multiple sclerosis."J Neuroimmunol 85:186-192. 
McDonell, G.V.,McMillan, S.A.,Douglas, J.P.,Droogan, A.G.,& Hawkins S.A.(1999). 
"Serum soluble adhesion molecules in multiple sclerosis raised s VCAM- 1, s ICAM- I 
and s E-selectin in primary progressive disease."J Neuroimmunol 246:87-92. 
McCutcheon, M., Wehner, N., Wensky, A., Kushner, M., Doan, S., Hsiao, L., Calabresi, 
P., Ha, T., Tran, T.V., Tate, K.M., Winkelhake, J.,& Spack, E.G.. (1997). "A sensitive 
ELI SPOT assay to detect low-frequency human T-lymphocytes." J Immunol Meth 
210:149-166. 
Meier, D.S.& Guttmann, C.R.(2006). "MRI time series modeling of MS lesion 
development."Neuroimage 32:531-7. 
Mekala, D.J.,Alli, R.S.,& Geiger, T.L.(2005)."IL-10 dependent supression of 
experimental allergic encephalomyelitis by Th-2 differentiated,anti-TCR redirected T-
Iymphocytes.J_Immunoll74:3789-97. 
224 
Mennicken, F.,Maki, R., de Souza, E.B.,& Quirion, R.(1999). "Chemokines and 
chemokine receptors in the CNS :a possible role in iieuroinflammation and 
patterning."Trends Pharmacol Sci 20:73-78. 
Merill, J.E.,Ignarro, L.J.,Shermann, M.P,Melinek, J.,& Lane, T.E.(1993). "Microglial cell 
cytotoxicity of oiigodendrocytes is mediated through nitric oxide." J Immunol 151:2132-
41: 
Merle, H., Smadja, D., Merle, S.,Olindo, S.,Signate A.,Donnio, A.,Richer, R.,Bonnan, 
M.& Cabre, P. (2005). "Visual phenotype of multiple sclerosis in the Afro-Caribbean 
population and the influence of migration to metropolitan France." 
Eur J Ophthalmol 15:392-9. 
Miller, D.,Barkhof, F.,Montalban, X.,Thompson, A.&Filippi, M.(2005). "Clinically 
isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, 
diagnosis, and prognosis."Lancet Neurol 4:281-8. 
Mills, R.J.,Young, C.A.,& Smith, A.P.(2006). "31) MRI in multiple sclerosis:a study of 
three sequences at 3T." Br J Radiol 27. 
Minagar, A.,& Alexander, J.S.(2003). "Blood-brain disrruption in multiple 
sclerosis."Mult Scler 9:540-9. 
Miosec, P. (1995). "Pro- and antiinflammatory cytokine balance in rheumatoid arthritis." 
Clin Exp Rheumatol 13:13-6 
Misu, T.,Fujihara, K.,& Itoyama, V. (2003). "Chemokines and chemokine receptors in 
multiple sclerosis."Nipyon Rinsho 61:1422-7. 
Moller, B.,& Villinger, P.M. (2006). "Inhibition of IL-i, IL-6, and TNF-alpha in 
immune-mediated inflammatory diseases." Spring Semin Immunopathol 27:391-408. 
Montalban, X.,& Rio J.(2006). "Interferons and cognition." J Neurol Sci 245:137-40. 
Moore,K.W.,O 'Garra,A.,deWaalMalefyt,R.,Vieira,P.,&Mossman,T.R.( 1993). 
"Interleukin-10."Ann Rev Immunol 11:165-90. 
Moore, K.W.,de Waal Malefyt, R., Coffman, R.L.,& OGarra, A.(2001). "Interleukin-lO 
and the interleukin-lO receptor." Annu Rev Immunol 19: 683-765. 
Moreland, L.W., Baumgartner, S.W., Schiff, M.H., Tindall, E.A.,Fleishmann, 
R.M.,Weaver, A.L.,Ettlinger, R.E.,Cohen, S.,Koopman, W.J.,Mohler, K. ,Widmer, 
M.B.,& Blosch, S.M.(1997). "Treatment of rheumatoid arthritis with a recombinant 
human tumor necrosis factor receptor (p75)- Fc fusion protein." N EngI J Med 337: 141-
47. 
225 
Mossman, T.R.,& Moor; K.W.(1991). "The role of IL-10 in crossregulaion of Thi and 
Th2 responses."Immunol Today 12:49-53. 
Mossman, T.R.(1994)."Properties and functions of interleukin-10."Adv Immunol 56:1-
26. 
Mostert, S.,& Kesseiring, J. (2002). "Effects of a short-term exercise training program on 
aerobic fitness, fatigue, health perception and activity level of subjects with multiple 
sclerosis." Mult Scler8:161-168. 
Muller, D.M.,Pender, M.P.,& Greer, J.M.(2004). "Chemokines and chemokine 
receptors:potential therapeutic targets in multiple sclerosis." Curr Drug Targets Inflamm 
Allergy 3:279-290. 
Mun-Bryce, S.& Rosenberg, G.A.(1998). "Matrix metalloproteinases in cerebrovascular 
disease."J Cereb Blood Flow Metabl8: 1163-72. 
Muraro, P.A.,Leist, T.,Bielkova, B.,& 
downregulated on primed T lymphocytes 
sclerosis."J Neuroimmunol 111:186-94. 
McFarland, H.F.(2000). "VL-4/CD49d 
during interferon-beta therapy in multiple 
Musette, P.,Benveniste, O.,Lim, A.,Beguet, D.,Kourilsky, P.,Dorniont, P.,& Gachelin, 
G.(1996). "The pattern of production of cytokine m RNAs is markedly altered in the 
onset of multiple sclerosis." Res Immunol 147: 435-41. 
Nagase,H.,&Woessner Jr, J.F.(1999). "Matrix metalloproteinases."J Biol Chem 274: 
2 1491-4. 
Nardocci N.,Zorzi G.,Savoldelli M.,Rumi V.,& Angelini L.(1995). Paroxysmal dystonia 
and paroxysmal tremor in a young patient with multiple sclerosis. 
Ital JNeurol Sci 16:315-9. 
Nakajima, H., Fukuda, K., Doe, Y., Sugino, M., Kimura, F., Hanafusa, T., Ikemoto, 
T., & Shimizu, A . (2004). "Expression of TH1/TH2-related chemokine receptors on 
peripheral T-cells and correlation with clinical disease activity in patients with 
multiple sclerosis." EurNeurol. 52:162-8. 
Navikas, V., Link, J., Palasik, W., Soderstrom, M., Fredrikson, S., Olsson, T., & Link, H. 
(1995). "Increased m-RNA expression of IL-lO in mononuclear cells in multiple sclerosis 
and optic neuritis." Scand JImmuol 41:171-178. 
Navikas, V.,& Link, H.(1996). "Cytokines and the pathogenesis of multiple sclerosis."J 
Neurosci Res 45:322-33. 
Navikas, V.,Matusevicious, D.,Soldestrom, M.,Fredrikson, S.,Kivisakk, P.,Ljundahl, 
226 
A.,Hojeberg, B.,& Link, H.(1996). "Increased interleukin-6 m RNA expression in blood 
and cerebrospinal fluid mononuclear cells in multiple sclerosis."J Neuroimmunol 64:63-
69. 
Navikas, V., He, B., Link, J., Haglund, M.,Soderstrom, M.,Fredrikson, S.,Ljugdahl, 
A.,1-lojeberg, i.,yuiao, J.,Ulsson, 1.,& Link, 1-141990). 'Augmented expression 01 
tumour necrosis factor-alpha and lymphotoxin in mononuclear cells in multiple sclerosis 
and optic neuritis." Brain 119: 213- 23. 
Nelissen, I.,Dubois, B.,Goris, A.,Ronsse, I.,Carton, H.,& Oppdenakker, G.(2002). 
"Regulation of gelatinase B in human monocytic and endothelial cells by PECAM-1 
ligation and its modulation by interferon-beta." J Leucoc Biology 71:89-98. 
Nelissen, I.,Martens, E.,Van der Steen, P.E.,Broost, P.,Ronsse, J.,& Opdenakker, G. 
(2003). "Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target 
for immunotherapy." Brain 126:1371-81. 
Neuhaus, O.,Farina, C.,Wekerle, H.,& Holfield, R.(2001). "Mechanism of action of 
gelatimer acetate in multiple sclerosis."Neurology 56:702-708. 
Newman, T.A.,Wolley, S.T.,Hughes, P.M.,Sibson, N.R.,Anthony, D.C.,& Perry, 
V.H.(2001). "T-cell and macrophage-mediated axon damage in the absence of UNS-
specific immune response:involvement of metalloproteinases."Brain_124: 2203-22 14. 
Nguyen, L.T., Ramanathan, M., Munschauer, F., Brownscheidle, C.,Krantz, S.,Umhauer, 
M.,MiIler,C.,DeNardin,E.,& Jakobs,L.D.(1999) "Flow cytometric analysis of in vitro 
proinflammatory cytokine secretion in peripheral blood from multiple sclerosis patients." 
J din Immunol 19: 179-85. 
Nguyen, D.,& Stangel, M.(2001). "Expression of the chemokine receptors CXCR1 and 
CXCR2 in rat oligodendroglial cclls."Brain Res Dev Brain Res 128:77-81. 
Nicoletti, F., Di Marco, R., Patti, F.,Zaccone, P., L' Episkopo, M.R.,& Reggio, E. (2000). 
"Short-term treatment of relapsing remitting multiple sclerosis patients with interferon 
(IFN)-beta lB transiently increase the blood levels of interleukin (IL)-6, IL-10 and IFN-
gamma without significantly modifying those of IL-I beta, IL-2, IL-4 and tumor necrosis 
factor alpha." Cytokine 12: 682-7. 
Noronha, A., Toscas, A.,& Jensen, M.A. (1993). "Interferon - P decreases T cell 
activation and interferon - y production in multiple sclerosis." J Neuroimmunol 46:145-
154. 
Nortvedt, M.W.,Riise, T. & Maeland, J.G.(2005). "Multiple sclerosis and lifestyle 
factors:The Hordaland Health Study".Neuro Sci 26:334-9. 
227 
Nouza, K. & Krejkova, H.(1997). "Pathogenesis and therapy of multiple sclerosis". 
Bratisl Lek Listy 98:199-203. 
Nyquist, P.A.,Cascino, G.D.,& Rodriguez M.(2001). "Seizures in patients with multiple 
sclerosis seen at Mayo Clinic, Rochester, Minn, 1990-1998."Mayo Clin Proc 76:983-6. 
Obonyo, M.,Cole, S.P.,Data, S.K.,& Guiney, D.G.(2006). "Evidence for interleukin-1-
independent stimulation of interleukin-12 and down-regulation by interleukin-lO in 
Helicobacter pylori-infected murine dendritic cells deficient in the interleukin-1 
receptor."FEMS Immunol Med Microbiol 47:414-9. 
Ochi, H., Feng-Jun, M., Osoegawa, M., Minohara, M.,Murai, H.,Taniwaki, T.,& Kiva, J. 
(2004). "Time-depedent cytokine deviation toward the Th2 side in Japanese multiple 
sclerosis patients with interferon beta-lb." J Neurol Sci 222:65-73. 
Ogata, Y., Itoh, Y.,& Nagase, H., (1995). "Steps involved in activation of promatrix 
metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinase- 1 complex by 
4-aminophenylmercuric acetate and proteinases." J Biol Chem 270:18506— 18511. 
Oh, L.Y.,Larsen, P.H.,Krekoski, C.A.,Edwards, D.R.,Donovan, F.,Werb, Z., & Yong, 
V.W.(1999). "Matrix metalloproteinase-9/gelatinase B is required for process outgrowth 
by oligodendrocytes".J Neurosci 19:8464-75. 
Oksenberg, J.R.,Barazini, S.E.,Barcellos, L.F.,& Hauser, S.L. (2001)."Multiple sclerosis 
genomic rewards." J Neuroimmunol 113:171-184. 
Okuda, V.,Apatoff, B.R.,& Posnett, D.N. (2006). "Apoptosis of T cells in peripheral 
blood and cerebrospinal fluid is associated with disease activity of multiple sclerosis." I 
Neuroimmunol 171:163-70. 
Olsson, T.,Zhi, W.W.,Hojeberg, B.,Kostulas, V.,Yu Ping, J.,Anderson, G.,Ekre, H.P.,& 
Link H.((1990). "Autoreactive T lymphocytes in multiple sclerosis determined by 
antigen-induced secretion of interferon-y."J Clin Invest 86:981-5. 
Oman, K.M., John, G.,Lango, R.,& Raine C.S. (2006). "Role for CXCR2 and CXCL1 on 
glia in multiple sclerosis." Qjj 53:24-31. 
Opdenakker, G.,Van der Steen, P.E.,Debois, B.,Nelissen, I.,van Coillie, E.,Masure, 
S.,Proost, P.,van Damme, J.(2001). "Gelatinase B functions as regulator and effector in 
leucocyte biology." J Leucocyte Biol 69:851-859. 
Opdenakker, G.,Nelissen, I.,& Van Damme, J.(2003). "Functional roles and therapeutic 
targeting of gelatinase B and chemokines in multiple sclerosis."Lanc Neurol 2:747-56. 
Oswald, I.P.,Wynn,T.A.,Sher, A.,& James, S.L.(1992). "Interleukin-lO inhibits 
macrophage microbial activity by blocking the endogenous production of tumor necrosis 
Flo 
factor a required as a costimulatory factor for interferon y induced activation."Proc NatI 
Acad Sci USA 89:8676-80. 
Ozenci, V.,Rinaldi, L.,Teleshova, N.,Matusevicious, P.,Kivisakk, P.,Kouvenhoven, M.,& 
Link H. (1999). "Metalloproteinases and their tissue inhibitors in multiple sclerosis." I 
Autoimmun 12:297-303. 
Ozenci, V., Kouwenhoven, M., Huang, Y.M., Xiao, B.G., Kivisakk, P., Fredrikson, S.,& 
Link, H. (1999). "Multiple sclerosis: Levels of interleukin-lO secreting blood 
mononuclear cells are low in untreated patients but augmented during interferon-D-lb 
treatment."Scand J Immunol 49:554-56 1. 
Ozenci, V.,Kouwenhoven,M.,Press, R.,Link,H.& Huang, Y.M.(2000). "IL- 12 elispot 
assays to detect and enumerate IL- 12 secreting cells".Cvtokine 12:1218-24. 
Ozenci, V., Kouwenhoven, M., Teleshova, N., Pashenkov, M., Fredrikson, S.,& Link, H. 
(2000). "Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases 
are affected differentially by treatment with IFN-J3." J Neuroimmunol 108 :236-243. 
Ozenci, V.,Kowenhoven, M.,Huang, Y.M., Kivisakk, P.,& Link, H. (2000). "Multiple 
sclerosis is associated with an imbalance between tumor necrosis factor-alpha (TNF-
alpha) and IL-10 secreting blood cells that is corrected by interferon-beta (IFN-beta) 
treatment." Clin Exp Immunol12: 1218 -24. 
Ozenci, V.,Pashenkov, M.,Kouwenhoven, M.,Rinaldi, L.,& Link, H. (2001). "IL-12/IL-
12R system in multiple sclerosis." J Neuroimmunol 114:242-252. 
Ozenci, V., Kouwenhoven, M. & Link, H.(2002). "Cytokines in multiple sclerosis: 
methodological aspects and pathogenic implications."Mult Scler 8:396-404. 
Pahan, K.,Khan, M. & Singh, I.(2000). "Interleukin-lO and interleukin-13 inhibit 
proinflammatory cytokine-induced ceramide production through the activation of 
phosphatidylinositol 3-kinase."J Neurochem 75:576-82. 
Pannitsch, H.S.(1 994). "Influence of infection on excarbations of multiple sclerosis."Ann 
 
Neurol 36:25-28. 
Panitch, H.S.,Hirsh, L. Schindler, J.,& Johnson, K.P.(1987). "Treatment of multiple 
sclerosis with gamma interferon:excarbations associated with activation of the immune 
system."Neurology 37:1097-102. 
Papageorgiou, K.,Zis, V.,Sfaggos,K.,Tsakanikas K.,Sgouropoulos P.,Davaki, P.,Chioni, 
A.,Kalfanis, N.,Vasilopoulos, D.,Ilias, A.,Siafakas, A.,Madouvalos, V.,Robos, 
A.,Staboulis, E.,Karandreas, N. & Manta, P.( 1993). "Neurology"(Edited by:Parisianou 
M.), Athens, Greek publications "Gregorios Parisianos". 
229 
Papoff, G.,Cascino, I.,Eramo, A.,Starace, G.,Lynch, D.,& Ruberti, G.(1996). "An N-
terminal domain shared by Fas/Apo-l(CD95) soluble variants prevents cell death in 
vitro."J Immunol 156:4622-30. 
Paty, D.W.,& Li, D.K.(1993). "Interferon-beta lb is effective in relapsing-remitting 
multiple sclerosis.I1.MRI analysis results of a multicenter,randomizêd,double-blind, 
placebo-controlled trial.UBC MS/MRI Study Group."Neurology 43:662-667. 
Paty, D.W.,Hartung, H.P.,Ebers, G.C.,Soelberg-Sorensen, P.,Abramsky, O.,Kesserling, J. 
(1999). "Management of relapsing-remitting multiple sclerosis:diagnosis and treatment 
guidelines." EurJNeurol 6:1-35. 
Pender, M.P.(l998)."Genetically determined failure of activatirni-induced apoptosis of 
autoreactive T cells as a cause of multiple sclerosis."Lancet 351:978-8 1. 
Pennline, K.J.,Roque-Gaffney, E.,& Monahan, M. (1994). "Recombinant human IL-b 
prevents the onset of diabetes in the non-obese diabetic mouse." Clin Immunol 
Immunopathol 71:169-175. 
Perrella, O.,Sbreglia, C.,Perella, M.,Spetrini, G.,Gorga, F.,Perella, M.,Atripuldi, L.,& 
Carried, P. (2006). "Interleukin-lO and tumor necrosis factor-alpha :model of 
immunomodulation in multiple sclerosis." Neuro Res 28 :193-5. 
Persson H.E.& Sachs C.(1978). "Provoked visual impairment in multiple sclerosis 
studied by visual evoked responses." Electroencephalogr Clin Neurophysiol 44:664-8. 
Petajan, J.H., Gappmaier, E., White, A.T., Spencer, M.K., Mino, L.,& Hicks, R.W. 
(1996). "Impact of aerobic training on fitness and quality of life in multiple sclerosis." 
Ann Neurol 39:432-441, 
Petek-Balci, B.,Yayla, V.,& Ozer, F.(2005)."Multiple sclerosis and Hashimoto 
thyroiditis:two cases."Neurologist 11:301-304. 
Petelin, Z.,Binar, V.,Petrovic, D.,Zurak, N.,Dubrarcic, K.,& Batinic, D. (2004). 
"CD95/Fas expression in peripheral blood T lymphocytes in patients with multiple 
sclerosis:effect of high-dose methylprednizolone therapy." Clin Neurol Neurosurg 
106:259-62. 
Peters, W.,Dupuis, M.,& Charo, I.F.(2000). "A mechanism for the impaired IFN-gamma 
production in C-C chemokine receptor 2 (CCR2) knockout mice:role for CCR2 in linking 
the innate and adaptive immune responses." J Immunol 165 :7072-7. 
Peterson, C.(2001). "Exercise in 94 degrees F water for a patient with multiple sclerosis." 
Phys Ther8l:1049-58. 
230 
Petrovic-Rackov, L.(2005)."Cytokines in rheumatoid arthritis and osteoarthrosis." 
Med Pregl 58:245-5 1. 
Phadke, J.G. (1990). "Clinical aspects of multiple sclerosis in north-east Scotland with 
particular reference to its course and prognosis."Brain 113 :1597-628. 
Pietropaolo, V.,Fioriti, D.,Miscitelli, M.,Anzavino, E;,Santini, M.,Millefiorini, E., Di 
Rezze, S.,& Degener, A.M.(2005). "Detection of herpesviruses and polyomaviruses DNA 
in a group of patients with relapsing-remitting multiple sclerosis."New Microbiol 
28:199-203. 
Planas, A.M.,Gorina, R. & Chamorro, A. (2006). "Signalling pathways mediating 
inflammatory responses in brain ischaemia."Biochem Soc Trans 34:1267-1270. 
Porrini, A.M.,Gampi, D.,& Reder, A.T.(1995). "Interferon effects on interleukin-lO 
secretion-Mononuclear cell response to interleukin-lO is normal in multiple sclerosis 
patients." J Neuroimmunol 61:27-34. 
Porrini, A.M.,Luca, G.,Gambi, D.,& Reder, A.T.(1998). "Effects of an anti-IL-b 
monoclonal antibody on rIFN-13-mediated immune modulation. Relevance to multiple 
sclerosis."J Neuroimmunol 81:109-15. 
Poser, C.M.(1993). "The pathogenesis of multiple sclerosis: additional considerations." I 
Neurol Sci 115 :3-15. 
Poser, C.M.& Brinar V.V. (2003). "Epilepsy and multiple sclerosis."E,ilepsy Behav 4:6-
12. 
Poser, C.M.(2006). "The multiple sclerosis trait and the development of multiple 
sclerosis: genetic vulnerability and environmental effect."Clin Neurol Neurosurg 
108:227-33 
Poskanzer, D.C.,Prenney, L.B.,Sheridan, J.L.& Kondy, J.Y.(1980). "Multiple sclerosis in 
the Orkney and Shetland Islands. I: Epidemiology, clinical factors, and methodology." 
J Epidemiol Community Health 34:229-39. 
Pouly, S.,& Antel, J.P. (1999)."Multiple sclerosis and central nervous system 
demyelination." J Autoimmun 13 :297-306. 
Pozzilli, E.,Prosperini, E.,Sbardella, E. & Paolillo, A.(2006). "Interferon after 10 years in 
patients with multiple sclerosis."Neurol Sci 27 :369-372. 
Prange, A.J.,Lauer, K.,Poser, S.,Palffy, G.,Minderbound, J.M.,Firnhaber, W.,Dassel, H.& 
Bauer, H.(1986)."Epidemiological aspects of multiple sclerosis:a comparative study of 
four centers in Europe."Neuroepidemiol 5:71-79. 
231 
Prat, A.,Biemacki, K.,Lavoie, J.F.,Poirtier, J.,Duquette, P., & Ante!, J.P.(2002). 
"Migration of mu!tiple sclerosis lymphocytes through brain endothelium."Arch Neurol 
59:391-7. 
Prat, A.,&Antë!, J. (2005). "Pathogenesis of mu!tiple sclerosis."Curr Opin Neurol 
io:zzj-ju. 	 - 
Putzki, N.,Knipp, S.,Ramczykovski, T.,Vago, S.,Germing, U.,Diener, H.C. & Limmroth, 
V.(2006). "Secondary myelodysp!astic syndrome fol!owing long-term treatment with 
azathioprine in patients with multiple sc!erosis."Mult Sc!er 12:363-6. 
Pugliatti, M.,Rosuti, G.,Carton, I-J.,Riise, J.,Drulovic, J.,Vessei, L.,& Milanov, I.(2006). 
"The epidemiology of multiple sclerosis in Europe." Eur J Neurol 13:700-22. 
Qin, Y.& Duguette, P.(2003). B-ce!l immunity in MS.Int MS J 10:11 0-20. 
Quintana, A.,Ciru!t, M.,Rojas, S.,Penkowa, M.,Campe!!, I.L.,Hinda!go, J.,& Mo!inero, A. 
(2005). "Differential role of tumor necrosis factor receptors in mouse brain inflammatory 
responses in cryolesion brain injury." J Neurosc Res 82: 701-16. 
Racke, M.K., Bonomo, A., Scott, D.E, Cane!!a, B., Levine, A., Raine, C.S., Schevan, 
E.M.,& Rocken, M.. (1994). "Cytokine-induced immune deviation as a therapy for 
inflammatory autoimmune disease." J Exp Med 180: 1961-1966. 
Racke, M.K.,Hawker, K.,& Frohman, E.M.(2001). "Multiple sclerosis and magnetic 
resonance imaging:advancement in linking the pictures with the progression."Arch 
Neurol 58:35-36. 
Racke, M.K.,Hawker, K.,& Frohman, E.M.(2004). "Fatigue in mu!tip!e sclerosis:is the 
picture getting simpler or more complex?"Arch Neurol 61:176-7. 
Rahaman, S.O., Sharma, P., Harbor, PC., Aman, MJ., Vogelbaum, MA.,& Haque, 
S.J.(2002). "IL-13Ra2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent 
signal transduction in glioblastoma ce!ls." Cancer Res 62:1103-1109. 
Raine, C.(1991)."Multiple. sclerosis:a pivotal role for the T cell in lesion 
development. "N europathol AnpI Neurobiol 17:265-74. 
Ragozzino, D.(2002). "CXC chemokine receptors in the central nervous system: Role in 
cerebellar neuromodulation and development." J Neurovirol 8:559-72. 
Ramsaransing, G.S.& de Keyser, J.(2006). "Benign course in mu!tiple sclerosis: a 
review."Acta Neurol Scand 113:359-69. 
232 
Rasley, A.,Tranguch, S.L.,Rati, D.M. & Mariott, I.(2006). "Murine glia express the 
immunosuppressive cytokine, interleukin- 10, following exposure to Borrelia burgdorferi 
or Neisseria meningitidis."Glia 53:583-92. 
Rails, RB., Karandicar, N.J.,Hussain, R.Z.,Choy, J.,Northrop, S.C.,Lovett-Racke, A.E.,& 
icacKe, lvlac.(2000). - Trienotype cnaractenzation 01 autoreactive I cells in multiple 
sclerosis."JNeuroimmunol 178:100-10. 
Ratts, R.B .,Lovet-Racke, A.E.,Choy, J.,Northrop, S .C.,Hussain, R.Z .,Karandikar, N.J.,& 
Racke, M.K.(2006). "CD28(-),CD57(+) T cells predominate in CD8 responses to 
gelatimer acetate."J Neuroimmunol 178 :117-29. 
Rauer, S.,Euler, B.,Reindl, M.& Berger, T.(2006). Antimyelin antibodies and the risk of 
relapse in patients with a primary demyelinating event.J Neurol Neurosurg Psychiatry 
77: 739-42. 
Ravizza, T.& Vezzani, A. (2006). "Status epilepticus induces time-dependent neuronal 
and astrocytic expression of interleukin-1 receptor type I in the rat limpic system." 
Neuroscience 137:301-8. 
Reder, A.T.,& Amason, B.G.W.(1985). "Immunoly of multiple sclerosis".Handbook of 
Clinical Neurology.Vol 3. (Edited by: Vinken PJ, Bruyn 0 and Koetsier JC) 
Amsterdam,Elsevier, 337-395. 
Rep, M. HG, Hintzen, R.Q., Polman, C.H.,& Van Lier, R.A.W. (1996). "Recombinant 
interferon-n blocks proliferation but enhances interleukin-lO secretion by activated 
human T-cells." J Neuroimmunol 67:111-118. 
Rep, M.H., Schrijver, H.M.,van Lopic, T., Hitzen, R.Q., Roots, M.T.,Ader, H.J.,Polman, 
van Kier, R.A. (1999). "Interferon (IFN)-beta treatment enhances CD95 and 
interleukin 10 expression but reduces interferon-gamma producing T cells in MS 
patients."J Neuroimmunol 96:92-100. 
Revel, M.,Chebath, J., Mangelous, H.,Horrosch, S.,& Moviglia, G.A.(1995). 
"Antagonism of interferon beta on interferon gamma:inhibition of signal transduction in 
vitro and reduction of serum levels in multiple sclerosis patients." Mult Scler 1:5-11. 
Rezaie, P.,Trillo-Pazos, G.,Everall, I.P.,& Male, D.K.(2002). "Expressionof beta-
chemokines and chemokine receptors in human fetal astrocytes and microglial 
cultures:potential role of chemokines in the developing CNS." QJj 37:64-75. 
Rich, R. R., Fleisher, T.A., Shearer, W.T., Kotzin, B. L.,& Schroeder, H. W. (2001). 
"Clinical Immunology: Principles and Practice."(Edited by:.Mosby).UK,Mosby 
International Limited. 
233 
Rieckmann, P.,Albrecht, M.,Kitze, B.,Weber, T.,Tumani, H.,Brooks, A.,Luer, W.,& 
Poser, S.(1994)."Cytokine m RNA levels in mononuclear blood cells from patients with 
multiple sclerosis."Neurology 44:1523-1526. 
Rieckmann, P.,Martin, S.,Weichselbraun, I.,Albrecht, M.,Kitze, B.,Weber, T.,Tumani, 
H.,Broock,S.E.,Luei, W., Heiwig, A.,& ai.(1994). "Serial analysis of circulating adhesion 
molecules and TNF receptor in serum of patients with multiple sclerosis:s ICAM is an 
indicator for relapse." Neurology 44:2367-72. 
Rieckmann, P.,Albrecht, M.,Kitze, B.,Weber, T.,Tumani, I-L,Broocks, A.,Luer, 
W.,Helwig, A.,& Poser, S.(1995). "Tumor necrosis factor-alpha messanger RNA 
expression in patients with relapsing-remitting multiple sclerosis is associated with 
disease activity."Ann Neurol 37:82-87. 
Rieckmann, P.,Altenhofen, B.,Riegel, A.,Kallman, B.,& Felgenhauer, K.(1998). 
"Correlattion of soluble adhesion molecules in blood and cerebrospinal fluid with 
magnetic resonance imaging activity in patients with multiple sclerosis." Mult Scler 
4: 178-182. 
Ries, C.,& Petrides, P.E.(1995). "Cytokine regulation of matrix metalloproteinase activity 
and its regulatory dysfunction in disease."Biol Chem 376:345-355. 
Rizvi, S.A.,& Agius, M.A,(2004). "Current approved options for treating patients with 
multiple sclerosis." Neurology 63:8-14. 
Ru, T., Nortvedt, M.W.,& Ascherio, A. (2003). "Smoking is a riskfactor for multiple 
sclerosis." Neurology 61:1122-1124. 
Ru, T., Moen, B.,& Nortvedt, M.W. (2003). "Occupation, lifestyle factors and health-
related quality of life: the Hordaland Health Study."J Occup Environ Med 45:324-332. 
Rio, J.,Tintore, M.,Nos, C.,TeIIez, N.,GalIan, A.,& Montalban, X. (2005). "Interferon 
beta in relapsing remitting multiple sclerosis. An eight year experience in a specialist 
thultiple sclerosis centre." J Neurol 252:795-800. 
Ristori, G.,Montesperelli, C.,Gasperini, C.,Battistini, L.,Borsellino, G.,Butinelli, 
C.,Cannoni, S.,Perna, A.,Pozzilli C.,&Salvetti, M. (1999). "T cell response to myelin 
basic protein before and after treatment with interferon beta in multiple sclerosis."J 
Neuroimmunol 99:91-96. 
Rizvi, S.A.,& Agius, M.A,(2004). "Current approved options for treating patients with 
multiple sclerosis." Neurology 63:8-14. 
Rizzi, M.,Perego C.,Aliprandi, M.,Richichi, C.,Ravizza, T.,Colella, D.,Veliskova, 
J.,Moshe, S.L.,De Simoni, M.G. & Vezzani, A.(2003). "Glia activation and cytokine 
234 
increase in rat hippocampus by kainic acid-induced status epilepticus during postnatal 
development." Neurobiol Dis 14:494-503. 
Robinson Agramonte, M.A.,Reiber, H.,Pohl, D.,Lange, P.,Ohlenbush, A.,Eiffert, 
H.,Maass, M. & Hanefeld, M.(2001). "Intrathecal oligoclonal and polyspecific immune 
response in multiple scierosis."Rev Newel 33:809-11. 
Robinson, S.C.,Scott, K.A.,&Balkwill, F.R.(2002)."Chemókine stimulation of monocyte 
matrix metalloproteinase-9 requires endogenous TNF-a."Eur J Immunol 23:404-12. 
Rogge, L.,Barberis-Maino, L.,Biffi, M.,Passini, M.,Presky, D.H.,Gulber, U.,& Sinigaglia, 
F.(1997). "Selective expression of an interleukin-12 receptor component by human T 
helper I cells." J Exp Med 185:825 -31. 
Rogge, L., Papi, A., Presky, D.H., Biffi, M.,Minetti, L.G.,Miotto, D.,Agostini, 
C.,Semenzato, G.,Fabbri, L.M.,& Sinigaglia, F.(1999). "Antibodies to the IL-12 receptor 
beta 2 chain mark human ThI but not Th2 cells in vitro and in vivo." J Immunol 162: 
3926- 32. 
Rohowsky-Kochan, C.,Molinaro, D.,Choondry, A.,Kahn, M.,& Cook, S.D. (1999). 
"Impaired IL-12 secretion in multiple sclerosis patients." Mult scler 3:327-34. 
Roitt, I.,Brostoff, J.,&Male, D.( 1998). "Immunology."(Edited by:Crowe L).London, 
Mosby International Ltd. 
Rose-John, S.,Scheller, J.,Elson, G. & Jones, S.A.(2006). "Interleukin-6 biology is 
coordinated by membrane-bound and soluble receptors: role in inflammation and 
cancer."J Leukoc Biol 80:227-36. 
Rosenberg, 0 .A. ,Kornfeld, M.,Estrada, E.,Kelley, R.O.,Liotta, L.A.,& Stetler-Stevenson, 
W.G.(1992). "TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV 
collagenase." Brain Res 576:203-7. 
Rosenberg, G .A.,Kornfeld, M.,Estrada, E.,Kelley, R.O.,Liotta, L.A.,& Stetler-Stevenson, 
W.G.(1996). "Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: 
relation to blood-brain barrier injury." Neurology :1626-1632. 
Rosenberg, 0.A.(2001). "Matrix metalloproteinase in multiple sclerosis:it is time for a 
treatment trial?" Ann Neurol 50:43 1-433. 
Rosenberg, G.A.(2002). "Matrix metalloproteinases and neuroinflammation in multiple 
sclerosis." Neuroscientist 8:586-95. 
Rothuizen, L.E.,Buchlin, T.,Spentini, F.,Trichard, I.,Munafo, A.,Buchwalder, 
P.A.,Ythier, A.,& Biollaz, J.(1999). "Influence of interferon beta-la dose frequency on 
PBMC cytokine secretion and biological effect markers."J Neuroimmunol 99:131-141. 
235 
Rot, O.,Fleischer, B.,& Cash, E.(1994) "Interleukin-lO prevents experimental allergic 
encephalomyelitis in rats ."Eur J Immunol 24:1434-40. 
Ruddle, N.H.,Bergam, S.M.,Mc Grath, K.M.,Lingenheld, E.G,Grunnet, M.L.,Padula, 
S.J.,& Clark L.B.(i990). "An antibody to lympholoxin and tumor necrosis factor 
prevents transfer of experimental autoimmune enephalomyelitis."J Exp Med 172:1193-
200. 
Rudge, P.(1998). Cyclosporine and multiple sclerosis: the cons.Neurologv 38:29-30. 
Rudick, R. .,Ransohoff, R.M.,Peppler, R.,Van der Brug Mendendorp,S.,Lehman, P.,& 
Adam, J.(1996). "Interferon beta induces interleukin-lO expression:relevance to multiple 
sclerosis."Ann Neurol 40:618-27. 
Rudick, R.A.,Ran A.,Carpenter, C.S.,Cookfair, D.L.,Tuohy, V.K.,& Ransohoff, 
R.M.(1993). "In vitro and in vivo inhibition of mitogen-driven-Tcell activation by 
recombinant interferon beta." Neurology 43,2080-2087. 
Rudick,R.A.,Ransohoff, R.M,Lee, J.C.,Peppler, R.,Ya, M.,Mathisen, P.M.,& Tuohg, 
V.K.(1998). "In vivo effects of interferon b-la on immunosupressive cytokines at 
multiple sclerosis." Neurology 50:1294-300. 
Ruiz-Vazquez, E.,De Castro, P. (2003). "2-6-11" motif in heat shock protein 60 and 
central nervous system antigens: a preliminary study in multiple sclerosis patients." 
J Physiol Biochem 59:1-9. 
Runkel, L.,Meier, W.,Pepinsky, B.B.,Karpusas. M.,Whitty, A.,Kimball, K.,Brickelmeier, 
M.,Muldoney, V.,Jones, W.,& Goelz, S.E. (1998). "Structural and functional differences 
between glycosylated and non-glycosylated forms of human interferon-beta(IFN-
beta)."Pharm Res 15:641-9. 
Rutchmann, O.T.,McCrory, D.C.,Matchar, D.B.,& Immunization Panel of the Multiple 
Sclerosis Council for Clinical Practice Guidelines(2002). "Immunization and MS: a 
summary of published evidence and recommendations." Neurology 59:1837-43. 
Ryffel, B.,& Mihatsch, M.J. (1993). "TNF receptor distribution in human tissues." 
mt Rev Exp Pathol 34 :149-56. 
Sakai, T.,Inoue, A.,Koh, C.S.,& Osame, M. (1999). "Serum levels of apoptosis related 
molecules in patients with multiple sclerosis and human T-lymphotropic virus Type I-
associated myelopathy." J InterfCyt Res 19:999-1004. 
Sabelko-Downes, K.A., Rushel, J.H.,& Cross, A.H. (1999). "Role of Fas-Fas interactions 
in the pathogenesis and regulation of autoimmune demyelinating disease." 
Neuroimmunol 100:45-52. 
236 
Salgado, C.G., Nakamura, K., Sugaya, M., Tada, Y.,Ashasina, A.,Fukuda, S.,Koyama, 
Y.,Iri, S.,& Tamaki, K.(1999). "Differential effects of cytokines and immunosuppressive 
drugs on CD40, B7- 1, and B7-2 expression on purified epidermal Langerhans celisi ." j 
Invest Derniatol 113: 1021 -27. 
Salleras, L.,Brugucra, M.,& Prat, A.(2006)."Hepatitis B vaccine zind multiple scierosis:an 
uriproved association."Med Gun 126 :581-588. 
Salmaggi, A., Dufour, A., EoIi, M., Corsini, E.,La Mantia, L.,Massa, G.,Nespolo, A.,& 
Milanese, C.(1996). "Low serum interleukin-1 0 levels in multiple sclerosis: further 
evidence for decreased systemic immunosuppression?"J Neurol 243: 13- 17. 
Sarchielli, P.,Orlaccio, A.,Vicinanza, F.,Pelliccioli, G.P.,Toynoloni, M.,Saccardi, C.,& 
Gallai, V. (1997). "Cytokine secretion and nitric oxide production by mononuclear cells 
of patients with multiple sclerosis."J Neuroimmunol 80:76-78. 
Sastre-Carriga, J.,Comabella, M.,Brieva, L., Rovira, A., Tintore, M.,& Montalban, X. 
(2004). "Decreased MMP-9 production in primary progressive multiple sclerosis 
patients." Mutt Scler Aug 10 (4): 367-80. 
Schmidt, S.(1999). "Candidate autoantigens in multiple sclerosis."Mult Scler 5:147-60. 
Schrijcver, H.M., Hooper-van Veen, T., van Belzen, M.J., Crusus, J.B., Pena, A.S., 
Barkhof, F., Polman, C.H.,& Uitdehaag, B.M. (2004). "Polymorphisms in the gene 
encoding interferon-gamma and interferon-gamma receptors in multiple sclerosis." 
Eur J Immunogenet 31:133-40. 
Schwarz, S.& Leweling H.(2005). "Multiple sclerosis and nutrition."Mult Scler 11:24-32 
Seder, R.A.,Grazzinelli, R.,Sher, A.,& Paul W.E.(1993). "IL-12 acts directly on CD4+ 
cells to enhance priming for IFN-y production and diminishes IL-4 inhibition of such 
priming."Proc NatI Acad Sci USA 90:10188-92. 
Sedwick, J.D.,& 1-Jolt, P.G. (1983). "A solid-phase immunoenzymatic technique for the 
enumeration of specific antibody-secreting cells." J Immunol Meth 57: 301-309. 
Segal, J.G., Lee, N.C.,Tsung, Y.L.,Norton, J.A. & Tsung, K.(2002). "The role of IFN-
gamma in rejection of established tumors by IL-12 : source of production and target." 
Cancer Res 62:4696-703. 
Sellebjerg, F.,Madsen, H.O.,Jensen, C.V.,Jensen, J.,& Caned P.(2000). "CCRS,delta32, 
matrix metalloproteinase-9 and disease activity in multiple sclerosis."J Neuroimmunol 
102:98-106. 
Sellebjerg, F., & Sorensen, T.L. (2003). "Chemokines and matrix-metalloproteinase-9 
in leukocyte recruitment to the central nervous system." Brain Res Bull 61:347-55. 
237 
Seliner J.& Leib S.L.(2006). "hi bacterial meningitis cortical brain damage is associated 
with changes in parenchymal MMP-9/TIMP-1 ratio and increased collagen type IV 
degradation."Neurobiol Dis 21:647-56. 
C' 	 0 	 TT--J 	 fl IflflflA\ 	 fl 
'V 	 nALuu't). niotogicat agents in rheumatoid arthritis." 
J Postgrad Med 50:293-9. 
Shapiro, S.D., Fliszar, C.J., Broekelmann, T.J., Mecham, R.P., Senior, R.M., Welgus, 
H.G., (1995). "Activation of the 92-kDa gelatinase by stromelysin and 4-
aminophenylmercuric acetate. Differential processing and stabilization of the carboxyl-
terminal domain by tissue inhibitor of metalloproteinases (TIMP)." J Biol Chem 
270:6351-6356. 
Sharief, M.K.,& Hentges R.(1991). "Association between tumor necrosis factor-alpha 
and disease progression in patients with multiple sclerosis."N EngI J Med 325:467-472. 
Sharief, M.K.,& Semra, Y.K.(2001). "Upregulation of the inhibitor of apoptosis proteins 
in activated T lymphocytes from patients with multiple sclerosis."J Neuroimmunol 
119:350-7. 
Sharief, M.K., Semra, Y.K., Seydi, O.A.,& Zoukos, Y. (2001). "Interferon-beta therapy 
downregulates the anti-apoptosis protein FLIP in T cells from patients with multiple 
sclerosis." J Neuroimmunol 120: 199-207. 
Sharief, M.K.,Noori, M.A.,Douglas, M.R.,& Semra, Y.K.(2002). "Reduced expression of 
the inhibitor of apoptosis proteins in T cells from patients with multiple sclerosis 
following interferon-beta therapy."J Neuroimmunol 129:224-231. 
Sharief, M.K.(2004). "MS patient management: The Analog Model."J Neurol 251:74-78. 
Shibagaki, N.,Hanada, K.,Yamashita, H.,Shimada, S. & Hamada, H. (1999). 
"Overexpression of CD82 on human T cells enhances LFA-1 / ICAM-l-mediated cell-
cell adhesion: functional association between CD82 and LFA-1 in T cell activation." 
EurJ Immunol 29:4081-91. 
Shideman, CR., Hu, S.,Peterson, P.K.,& Thayer, S.A.(2006). "CCLS evokes calcium 
signalling in microglia through a kinase-phosphoinositole and nucleotide dependent 
mechanism." J Neurosci Res 83:1471-8. 
Shimizu, Y.,Newman, W.,Gopal, T.V.,Horgan, K.J.,Graber, N.,Beall, L.D.,van Seventer, 
G.A.,& Shaw S.(1991). "Four molecular pathways of I cell adhesion to endothelial cells: 
roles of LFA- 1, VCAM- 1, and ELAM- 1 and changes in pathway hierarchy under 
different activation conditions."J Cell Biol 113:1203-12. 
238 
Shrikant, P.,Chang, I.V.,Ballestas, M.E.,& Beneviste, E.N. (1994). "Regulation of 
intracellular adhesion molecule- 1 gene expression by tumor necrosis factor-
alpha,interleukin-lb and interferon-gamma in astrocytes."J Neuroimmunol 51:209-20. 
Sibley, W.A.,Bantord, C.R.,& Clark, K.(1985). "Clinical and viral infections and 
n,1,1t,n1c. on1c.ree,.e , 'l nnnt I . t 11 1 1 21 C 
'ttIFIo._#A._fl,L. 	 LIt#%LS.S_)1_JL_/1J. 
Sieling, P.A.,Wang, X.FL,Gately, M.K.,Oliveros, J.L.,McHugh, T.,Bames, P.F.,Wolf, 
S.F.,Golkar, L.,Yamamura, M.,Yogi, Y. & al.(1994). "IL-12 regulates T helper type 
cytokine responses in human infectious disease."J Immunol 153:3639-47. 
Sisto, D.,Trojano, M.,Wertugno, M.,Trabucco, T.,Iliceto, J.,& Sborgia, C.(2005). 
"Subclinical visual involvement in multiple sclerosis: a study by MRI, VEPs,frequency 
doubling perimetry, standard perimetry and contrast sesitivity." Invest Onthalmol Vis Sci 
46: 1264-8. 
Skarsvik, S.,Luclvigsson, J. &Vaarala, 0.(2005). "Aberrant regulation of interleukin-12 
receptor beta2 chain on type 1 cytokine-stimulated T lymphocytes in type 1 diabetes." 
Immunology 114:287-93. 
Smith, M.E.,Eller, N.F.,McFarland, H.F.,Racke, M.K.,& Raine, C.S.(1999). "Age 
dependence of of clinical and pathological manifestations of autoimmune 
demyelination.Implications for multiple sclerosis."Am J Pathol 155:1147-1161. 
Soderstrom, M.,Link, H.,Xu, Z.,& Fredrikson, S.(1993). "Optic neuritis and multiple 
sclerosis:Anti-MBP and anti-MBP peptide antoibody-secreting cells are accumulated in 
CSF."Scand J Immunol 43:12 15-22. 
Sodestrom, M.,Hillert, J.,Link, J.,Navikas, V.,Fredrikson, S.,& Link, H.(1995). 
"Expression of IFN-gamma, IL-4, and TGF-beta in multiple sclerosis in relation to HLA-
Dw2 phenotype and stage of disease."Mult Scler 1:173-80. 
Soilu-Hanninen, M.,Salmi, A.,& Salonen, R.(1995). "Interferon-n therapy downregulates 
expression of VLA-4 antigen and antagonizes interferon-y-induced expression of HLA 
DQ on human peripheral blood monocytes."J Neuroimmunol 60:99-106. 
Solaro, C.(2006). Epidemiology and treatment of pain in multiple sclerosis subjects. 
Neurol Sci 27:291-3. 
Sorensen, T.L.,Tani, M., Jensen, J.,Pierce, V.,Lucchinetti, C.,Folcik, V.A.,Qin, 
S.,Rottman, J.,Selleberg, F.,Strieter, R.M.,Fredriksen, J.L.,Ransohoff, R.M. (1999). 
"Expression of specific chemokines and chemokine receptors in the central nervous 
system of multiple sclerosis patients." J Clin Investig 103:807-15. 
239 
Sorensen, T.L., Roed, H., & Sellebjerg, F. (2002). "Chemokine receptor expression on 
B cells and effect of interferon-beta in multiple sclerosis." J Neuroimmunol 122 
:125-131. 
Sorensen, T.L., Trebst, C.,Kivisakk, P.,Klaege, P.L.Majmudur, A.,Ravid, R.,Lassman, 
H.,Olscnd, D.B.,Striter, R.M.,Ranshofç- R.rvt,& Seiieberg, F. (2002). "Multiple 
sclerdsis:a study of CXCL1O and CXCR3 co-localizatioii in the inflammed nervous 
system." J Neuroimmunol 127:59-68. 
Sorensen, T.L. (2004). "Targeting the chemokine receptor CXCR3 and its ligand 
CXCL1O in the central nervous system: potential therapy for inflammatory demyelinating 
disease?" Cun Neurovacjsc Res 1:183-90. 
Steinman, L.(1996). "Multiple sclerosis;a coordinated immunological attact against 
myelin in the central nervous system."j 85:299-302. 
Stone, L.A,Frank, J.A.,Albert, P.S.,Bash, C.,Smith, M.E.,Maloni, H.,& McFarland, 
H.F.(1995). "The effect of interferon-beta on blood-brain barrier disruptions 
demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting 
multiple sclerosis."Ann Neurol 37:611-19. 
Storkus, W.J., Tahara, H., & Lotze, M.T.(1998. "Interleukin-12."The cytokine 
handbook.(Edited by: Thomson A). San Diego, Academic Press, 390 -425. 
Stott, D.I. (2000). "Immunoblotting, Dot-Blotting, and ELISPOT assays: methods and 
applications." J Immunoas. 21:273-290. 
Stuve, O.,Chabot, S.,Jung, S.S.,Williams, G.,& Yong, V.W.(1997). "Chemokine-
enhanced migration of human peripheral blood mononuclear cells is antagonized by 
interferon beta-lb through an effect on matrix metalloproteinase-9." J Neuroimmunol 
80:38-46. 
Stuve, O.,Dooley, N.P.,Uhm, J.H.,Antel, J.P.,Francis, G.S.,Williams, G.,& Yong, V.W. 
(1996). "Interferon beta-lb decreases the migration of T lymphocytes in vitro:effects on 
matrix metalloproteinase-9."Ann Neurol 40:853-863. 
Sun, J.B.,Olsson, T.,Wang, W.Z.,Xiao, B.G.,Kostulas, V.,Fredrikson, S.,Ekre, 
H.P.,&Link, H.(1991). "Autoreactive T and B cells responding to myelin proteolipid 
protein in multiple sclerosis and controls."Eur J Immunol 21:1461-8. 
Suppiah, V.G.,Govis, A.,Alloza, J.,Heggarty, S., Dubois, B., Carton, H.,Antiguedad, 
A.,Mendibe, M.,Mc Donnel, G., Droogan, A., Hawkins, S.,Graham, C.,& Vanderbroek, 
K. (2005). "Polymorphisms in the interleukin-4 and IL-4 receptor genes and multiple 
sclerosis: a study in Spanish-Basque, Northern Irish and Belgian populations."Int J 
Immunogenet 32: 3 83-8. 
240 
Swanton, J.K.,Fernando K.,Dalton, C.M.,Miszkiel K.A.,Thompson A.J.,Plant G.T.& 
Miller D.H. (2006). "Is the frequency of abnormalities on magnetic resonance imaging in 
isolated optic neuritis related to the prevalence of multiple sclerosis? A global 
comparison."J Neurol Neurosurg Psychiatry 77:1070-2. 
Szelenyi, J. (2001). "Cytokincs and the central nervous system." Br Res Bull 54:329-338. 
Taceuchi, H.,Wang, J.,Kawanocuchi, J.,Mitsuma, N.Mizuno, T. & Suzumura A.(2006) 
"Interferon-gamma induces microglial-activation-induded cell death: a hypothetical 
mechanism of relapse and remission in multiple sclerosis." 
Neurobiol Dis 22:33-9. 
Takaoka, A. & Yanai, H.(2006). "Interferon signalling network in innate defence." 
Cell Microbiol 8:907-22. 
Tenakoon, D.K.,Mehta, R.S.,Ortega, S .B.,Bhoj, V.,Racke, M.K.,Karandikar, N.J.(2006). 
"Therapeutic induction of regulatory cytotoxic CD8+ cells in multiple sclerosis." J 
Immunol 176:7119-29. 
Thacker, E.L.,Mirzaei, F.,& Ascherio, A.(2006). "Infectious mononucleosis and risk for 
multiple sclerosis: a meta-analysis.".Aim Neurol 59:499-503. 
The IFNB Multiple Sclerosis Study Group (1995). "Interferon beta-lb in the treatment of 
multiple sclerosis:final outcome of the randomized controlled trial." Neurology 45:1277-
85. 
The Lenercept Multiple Sclerosis Study Group and The University of British Columbia 
MS/MRI Analysis Group (1999). "TNF neutralization in MS: results of a randomized, 
placebocontrolled multicenter study." Neurology 53: 457-65. 
The Multiple sclerosis Collaborative Research Groop(MSCRG) (1996). "Intramuscular 
interferon-beta-la for disease progression in relapsing multiple sclerosis." Ann Neurol 
39:285-294. 
Tishler, M.,& Shoenfeld, Y.(2004). "Vaccination may be associated with autoimmune 
diseases." Isr Med Assoc J 6:430-2. 
Tissir, F.,Wang, C.E.,& Caffient, A.M.(2004). "Expression of the chemokine receptor 
CXCr4 m RNA during mouse brain development." Brain Res Dev Brain Res 149:63-71. 
Tran, E.H.,Azuma, Y.T.,Chen, M.,Weston, C.,Davis, R.J. & Flavell, R.A.(2006). 
"Inactivation of JNKI enhances innate rL-10 production and dampens autoimmune 
inflammation in the brain."Proc NatI Acad Sci US A 103:13451-6. 
Traugott, U., & Lebon, P.,(1988). "Multiple sclerosis:involvement of interferons in 
lesions pathogenesis."Ann Neurol 24:243-251. 
241 
Traugott, U.(1990). "Evidence of immunopathogenesis."Handbook of Multiple 
sclerosis.(Edited by:Cook 5, New York), Marcel Dekker, 101-128. 
Trebst, C.,& Ransohoff, R.M., (2001). "Investigating chemokines and chemokine 
receptors in patients with multiple sclerosis:opportunitics and chaiienges."Arch Neurol 
58:1975-80. 
Trebst, C.& Stangel, M. (2006). Promotion of remyelination by immunoglobulins: 
implications for the treatment of multiple sclerosis.Curr Pharm Des 12:241-9. 
Tremlett, I-L,& Devonshire, V.(2006). "Is late-onset multiple sclerosis associated with a 
worst outcome?"Neurology 67:954-5. 
Trinchieri,G.( 1 995)."Interleukin- I 2:a proinflammatory cytokine with immunoregulatory 
functions that bridge innate resistance and antigen-specific adaptive immunity." Annu 
Rev Immunol 13: 251-76. 
Trinchieri, G. (2003). "Interleukin-12 and the regulation of innate resistance and 
addaptive immunity." Nat Rev Immunol 3:133-46. 
Trojano, M.,Avolio, C.,Liuzzi, G.M.,Ruggieri, M.,Defagio, G.,Liguori, M.,Santacroce, 
M.P.,Paolicelli, D., Giuliani, F., Riccio, P.,& Livrea, P.(1999). "Changes of serum s 
ICAM-1 and MMP-9 induced by r IFNb-lb treatment in relapsing-remitting MS." Neurol 
53:1402-1408. 
Tsai, H.H.,Frost, E.,To, V.,Robinson, S.,Efrench-Constant, S.,Geertman, R.,Ransohoff, 
R.M.,& Miller, R.H. (2002). "The chemokine receptor CXCR2 controls posisioning of 
oligodendrocyte precursors in developing spinal cord by arresting their migration. cfl 
Aug 110: 378-83. 
Tsukada, N.,Matsuda, M.,Miyagi, K.,& Yanagisawa, N.(1993). "Cytotoxicity of T cells 
for cerebral endothelium in multiple sclerosis."J Neurol Sci 117:140-7. 
Uhm, J.H.,Dooley, N.P.,Stuve, O.,Francis, G.S.,Duquette, P.,Antel J.P.,& Yong, 
V.W.(1999). "Migratory behavior of lymphocytes isolated from multiple sclerosis 
patients:effects of interferon beta-lb therapy."Ann Neurol 46:319-324. 
Urcelay, E.,Santiago, T.L.,Mas, A.,Martinez, A.,de Las Heras, V.Arroyo, R.& de Ia 
Concha, E.G.(2005). "Role of interleukin-4 in Spanish multiple sclerosis patients". I 
Neuroimmunol 168:164-7. 
Valles,A.,Crijpink-Ongering,L.,deBree,G.M.,Tuinsta,T.,&Ronken,E.(2006). "Differential 
regulation of the CxCR2 chemokine network in rat brain trauma:implications for 
neuroimmune interactions and neuronal survival." Neurobiol Dis 22:312-22. 
242 
van Boxel-Dezaire, A.H., Hoff, S.C., van Oosten, B.W., Verweij, C.L.,Drager, 
A.M.,Ader, H.J.,van Houweligen, J.C.,Bakhof, F.,Polman, C.H.,Nagelkerken, L.( 1999). 
"Decreased interleukin-lO and increased interleukin-12p40 mRNA are associated with 
disease activity and characterize different disease stages in multiple sclerosis." Ann 
Neurol 45:695- 703. 
van Boxel-Dezaire, A.H., Smits, M.,van Trigt-Hoff, S.C., Killenstein, J., van 
FIo*ellingen, .J.C., Polimen, C.H., Nageekerken, L. (2001). "Cytokine and IL-12 receptor 
rnRNA discriminate between different clinical subtypes in multiple sclerosis."L 
Neuroimmunol 120:152-160. 
Vandenbark, A.A., Finn, T., Barnes, D. , Culbertson, N. , Chou,Y.K. , Hicks, K. 
Bakke, A. ,Mass, M., Whitham, R. , Ofther, H.,& Bourdette,D.(2001). "Diminished 
frequency of interleukin-10-secreting,T-cell receptor peptide-reactive T cells in multiple 
sclerosis patients might allow expansion of activated memory I cells bearing the cognate 
BY gene."J Neurosci Res 66:171-176. 
Van der Veen, R.C.,& Stohlman, S.A.,(1993). "Encephalitogenic Thl cells are inhibited 
by Th2 cells with related peptide specificity:Relative roles of interleukin(IL)-4 and IL-
lO."J Neuroimmunol 48:213-20. 
Van Meeteren, M.E.,Teunissen, C.E.,Dijkstra, C.D. & van Tol, E.A.(2005). 
"Antioxidants and polyunsaturated fatty acids in multiple sclerosis."Eur J Clin Nutr 
59: 1347-61. 
Van Weyenbergh, J.,Lipinski, P.,Abadie, A.,Chabas, D.,Blank, U.,Liblau, R.,& 
Wietzerbin, J.(1998). "Antagonistic action of IFN-J3 and IFN-y on high affinity Fcy 
receptor expression in healthy controls and multiple sclerosis patients.". J Immunol 
161:1568-1574. 
Vaneckova, M.(2001). "Distribution of plaques in multiple sclerosis using magnetic 
resonance imaging"Sb Lek 102:511-7. 
Vartarian, T.,Li, Y.,Zhao, M.,& Stefanson, K.( 1995). "Interferon-y-induced 
oligodendrocyte cell death:implications for the pathogenesis of multiple sclerosis."MQ 
Med 1:732-43. 
Vial, T.,& Descotes, J. (2004). "Autoimmune diseases and vaccinations." Eur J Dermatol 
14:86-90. 
Vieira, P.,de Waal-Malefyt, R.,Dang, M.N., & al.(1991). "Isolation and expression of 
human cytokine synthesis inhibitory factor (CSIF/IL-10) c DNA clones:homology to 
Epstein-Barr virus open reading frame BCRFI ." Proc Natl Acad Sci USA 88:1172-6. 
243 
Von Bundigen, H.C.,Tanuma, S.,Villoslada, P.,Ouallet, J.C.,Hauser, S.L. & and Genain, 
S.P.(2001). "Immune responses against the myelinloligodendrocyte glycoprotein in 
experimental autoimmune demyelination."J Clin Immunol 21:155-70. 
Vos, C.M., van Haastert, E.S.,de Groot, C.J., van der Valk, P.& de Vries, H.E. (2003). 
"Matrix metalloproteinase-12 is expressed in phagocytic macrophages in actiye muilipie 
sclerosis lesions."J Neuroimmunol 138:106-14. - 
Wallin, M.T.,Wilken, J.A.,Tui-ner, A.P.,Williams, R.M.,& Kane, R.(2006). "Depression 
and multiple sclerosis: Review of a lethal combination." J Rehabil Res Dev 43:45-62. 
Wang, X., Chen, M., Wandiger, K.M., Williams, G.,& Dhib-Jalbut, 5(2000). "IFN-B-lb 
inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10 dependent 
mechanism: Relevance to IFN-J3-lb."J Immunol 165 (1):548-57. 
Wang, Z.Y.,Yang, D.,Chen, Q.,Leifer, C.A.,Segal, D.M.,Su, S.B.,Caspi, R.R.,Howard, 
Z.O.,& Oppenheim, J.J.(2006). "Induction of dendritic cell maturation by pertussis toxin 
and its B subunit differentially initiate Toll-like receptor 4-dependent signal transduction 
pathways."Exp Hematol 34:1115-24. 
Wamick, G.R.& Wood, P.D. (1995). "National Cholesterol Education Program 
recommendations for tthe measurment of high density lipoprotein cholesterol:excecutive 
summary.The National Cholesterol Education Program Working Group on Lipoprotein 
Measaurment." Clin Chem 41: 1427-33. 
Waubant, E.,Goodkin, D.E.,Gee, L.,Baccetti, P.,Sloan, R.,Stewart, T.,Anderson, 
P.B.,Stabler, G.,& Miller, K.(1999). "Serum MMP-9 and TIMP-1 levels are related to 
?vfRI activity in relapsing multiple sclerosis."Neurology 53:1397-1401. 
Waubant, E.,Gee, L.,Miller, K.,Stabler, G.,& Goodkin, D. (2001). "IFN-betala may 
increase serum levels of TIMP-1 in patients with relapsing remitting multiple sclerosis." J 
Interferon Cytokine Res 21:181-5. 
Waubant, E.,Goddkin, D.,Bostram, A.,Bachetti, P.,Hietpas, J.,Lindberg, R.,& Leppert, D. 
(2003). "IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in 
patients with SPMS." Neurology 60:52-57. 
Weber, F.,Janoskaja, J.,Polak, T.,Poser, S. & Rieckmann, P.(1999). "Effect of interferon 
beta on human myelin basic protein-specific T-cell lines: comparison of IFNbeta-la and 
IFNbeta-lb."Neurology 52:1069-71. 
Wegner, C.,Esiri, M.M.,Chance, S.A., Palace, J.,& Mathews, P.M.(2006). "Neocortical 
neuronal, synaptic and glial cells in multiple sclerosis." Neurology 67:960-7. 
Wenning, G.K.,Wietholter, H.,Schnauder, G.,Muller, P.H.,Kanduth, S. & Renn, 
W.(1994). "Recovery of the hypothalamic-pituitary-adrenal axis from suppression by 
244 
short-term, high-dose intravenous prednisolone therapy in patients with MS." 
Acta Neurol Scand 89:270-3. 
Weinstock-Guttman, B.,Budgett, D.,Patrick, K.,Hatrich, L.,Santos, R.,Hall, D.,Baier, 
M.,Feichter, M.& Ramanathan, M. (2003). "Genomic effects of IFN-beta in multiple 
"1 Tn,.,,,,,,.-.1 Ill .flCA lAn 
JSI*LIILaIItJI I II ...u , r I 
Weinshenker, B.G., Bass, R.,& Rice, G.P. (1989): "The natural history of multiple 
sclerosis: a geographically based study. I. clinical course and disability." Brain 112:133-
140. 
Wheeler, T.T.,& Ford, H..C.(1988). "A search for protein abnormalities in erythrocyte 
membranes and platelets from patients with multiple sclerosis using double-label two-
dimensional electrophoresis."J Neurol Sci 88:151 -9. 
Wieseman, E.,Sonmez, D.,Heidenreich,& F.,Windhagen, A.(2002). "Interferon-beta 
increases the stimulatory capacity of monocyte-derived dendritic cells to induce IL-13, 
IL-S and IL- 10 in autologous T-cells." J Neuroimmunol 123:160-9. 
Wjtowicz-Praya,S.M.,Dickson,R.B.,&Hawkins,N.J. (1 997)."Matrix metalloproteinase 
inhibitors."Invest New Drugs 15:61-75. 
Wolinsky,J.S.(2004)."Gelatimer acetate for the treatment of multiple sclerosis."Exp Opin 
Pharmacother 5:875-91. 
Xiao, B.G., Bai, X.F., Zhang, G.X.,& Link, H. (1998). "Suppression of acute and 
protracted-relapsing experimental allergic encephalomyelitis by nasal administration of 
low-dose IL-10 in rats." J Neuroimmunol 84:230-237. 
Yang, L.,Lindholm, K.,Konishi, Y.,Li, R.,& Shen, Y.(2002). "Target depletion of distinct 
tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival 
through different transduction pathways." J Neuroscie 21:6617-25. 
Yasuda, C.L.,AI Sabbagh, A.,Oliveira, E.C.,Diaz-Bardales, B.M.,Garcia, A.A.,& Santos, 
L.M. (1999)."Interferon beta modulates experimental autoimmune encephalomyelitis by 
altering the pattern of cytokine secretion."Immunol Invest 28:115-26. 
Yenari, M., Xu, L.,Tang, X.N.,Qiao, Y.&Giffard, R.G.(2006). Microglia potentiate 
damage to blood-brain barrier constituents: improvement by minocycline in yivo and in 
vitro.Stroke 37:1087-93. 
Yong, V.W.,Chabot, S.,Stuve, O.,& Williams, G.(1998)."Interferon beta in the treatment 
of multiple sclerosis:mechanisms of action." Neurology 51:682-9. 
Yong, V.W. ,Power, C.,Forsyth, P.,& Edwards, D.R.(200 1). "Metalloproteinases in 
biology and pathology of the nervous system."Nat Rev Neurosci 2:502-11. 
245 
Yong, V.W. (2002)."Differential mechanisms of action of interferon-beta and gelatimer 
acetate in MS."Neurology 59:802-8. 
Young, H.A,& Hardy, K.J.(1995). "Role of interferon-y in immune cell regulation." 
Leucocyte 	 58:373-381. 
Yushchenko, M.,Mader, M.,Elitok, E.,Bitsch, A.,Dressel, A.,Tuftiani, H.,Bogumil, 
T.,Kitee, B., Poser, S.& Weber, F. (2003). "Interferon-beta-lb decreased matrix 
metalloproteinase-9 serum levels in primary progressive multiple sclerosis." J Neurol 
250:1224-8. 
Zabaleta, L., Marino, R., Borges, J.,Camargo, B.,Ordaz, P.,De Sanctis, J.B. & Bianco, 
N.E.(2002). "Activity profile in multiple sclerosis: an integrative approach. A preliminary 
report."Mult Scler 8:343-9. 
Zang,Y.C.Q.,Halder,J.B.,Samanta,A.K.,Hong,J.,Rivera,V.M.,&Zhang,J.Z.(2001 )."Regula 
tion of chemokine receptor CCR5 and production of RANTES and MIP-la by interferon-
13." J Neuroimmunol 112:174-180. 
Zdanov, A. (2004). "Structural features of the interleukin-lO family of cytokines." Qj.g 
Pharm Des 10(31): 3873-84. 
Zhang, G.X., Baker, C.M., Kolson, D.L., Rostami, A.M. (2000). "Chemokines and 
chemokine receptors in the pathogenessis of multiple sclerosis."Mult Scler 6:3-13. 
Zhang,J.,MarkovicPlese,S.,Lucet,B.,Raus,J.,Weiner,H.L.,&Haffer,D.A.(1 994)."Increased 
frequency of interleukin-2 responsive T cells specific for myelin basic protein in 
peripheral blood and cerebrospinal fluid of patients with multiple sclerosis." J Exp Med 
179:973-984. 
Ziaber, J., Pasnik, J., Baj, Z., Pokoca, L., Chmielewski, H.,& Tchorzewski, H.(2000). 
"Tumor necrosis factor-alpha binding by peripheral blood lymphocytes and 
polymorphonuclear neutrophils in patients with multiple sclerosis." J Investig Allergol 
din Immunol 10:98-101. 
Zingg, W.(2005)."Does vaccination cause disease?" Therm Umsch 62 :665-674. 
Zipp, F., Webber, F., Huber, S., Sotgiu, S., Czlonkowska, A., Holler, E., Albert, E., 
Weiss, E.H., Wekerle, I-i.,& Hohlfeld, R. (1995). "Genetic control of multiple 
sclerosis: increased production of lymphotoxin and tumor necrosis factor-alpha by 
HLA-DR2+ T cells." Ann Neurol 38:723-30. 
Zipp, F., Faber, E.,Sommer, N., Muler, C., Dichgans, J.,Krammer, P.H.,Martin, R., & 
Weller, M.(1998a). "CD95 expression and CD95- mediated apoptosis of T cells in 
246 
multiple sclerosis. No differences from normal individuals and no relation to HLA-DR2." 
J Neuroimmunol 81: 168-72. 
Zipp, F. ,Weller, M.,Calabresi, P.A.,Frank, J.A.,Bash, C.N.,Dichgans, J.,McFarland, 
H.F.,& Martin, R.(1998b). "Increased levels of soluble CD95 (APO-1/Fas) in relapsing-
remitting multiple sclerosis." Ann Neurol 43: ll 6-20. 
Zipp, F., Otzelberger, K.,Dichgans, J.,Martin, R.,& Weller, M. (1998c). "Serum CD95 of 
relapsing-remitting multiple sclerosis patients protects from CD-95 mediated apoptosis."J 
Neuroimmunol 86:151. 
Zipp, F.j&ammer, P.H.,& Weller M.(1999). "Immune dysregulation in multiple sclerosis 
:role of the CD95-CD95 ligand system."ImmunolToday 520:550-4. 
Zipp F.(2000). "Apoptosis in multiple sclerosis." Cell Tissue Res 301:163-171. 
Zurak, N.(1997). "Programmed cell death,apoptosis and central nervous system." Neurol 
Croat 46:3-18. 
247 
